{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "8d4a3cc5",
   "metadata": {},
   "source": [
    "# Part I: Automation 8pts.\n",
    "### 1.\tCreate a function that defines an object, via bioservices or biopython, that will run a query and return a file of fasta sequences using the search term 'ErbB-1 AND EGFR AND FGFR1' . All sequences must be human. If this is not designed as a function, but successfully carried out manually 1 points will be deducted.\n",
    "### 2.\tCreate a function that will run the clustal MSA program and produce an alignment.  If this is not designed as a function, but successfully carried out manually 1 points will be deducted.\n",
    "### 3.\tThe first function that should accept the search term as a parameter. The output is to be automatically fed into the clustal msa function. Run a multiple sequence alignment (MSA).\n",
    "### 4.\tIf there is no alignment alignment file, then that is a deduction of 1 points."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "f15ac633",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Multiple sequence alignment performed and saved to /Users/Kaitlyn/Desktop/alignment.aln\n",
      "580 fasta seqs found and written to /Users/Kaitlyn/Desktop/protein_sequences.fasta\n"
     ]
    }
   ],
   "source": [
    "from Bio import Entrez\n",
    "from Bio import SeqIO\n",
    "import os\n",
    "\n",
    "#hash out code for alignment and make a function pipeline for both alignment and search functions.\n",
    "#os.system('/Users/Kaitlyn/PS/clustal-omega-1.2.2-win64/clustalo -i /Users/Kaitlyn/Desktop/protein_sequences.fasta -o /Users/Kaitlyn/Desktop/alignment.aln --resno --outfmt=clu')\n",
    "\n",
    "def Align(File, Output): #Function for Clustal Omega alignment adapted from line of code above. Runs as a pipeline, will output alignment file.\n",
    "    clustal = '/Users/Kaitlyn/PS/clustal-omega-1.2.2-win64/clustalo' #clustal omega can't be found in windows unless a direct file path is established. This format works for windows.\n",
    "    arguments = ['-i', File, '-o', Output, '--resno', '--outfmt=clu'] #put elements of command line for alignment individually in list\n",
    "    command = [clustal] + arguments #get full command line here by concatinating the individually created lists, everything will be individual elements\n",
    "        #make clustal file path into a list (same data type as arguments) to concatinate together to form full command line\n",
    "    os.system(\" \".join(command)) #joins all elements in the command list to make into a string that will run the command for the alignment\n",
    "    #if you do: print(\" \".join(command)) the output will be the same as: os.system('/Users/Kaitlyn/PS/clustal-omega-1.2.2-win64/clustalo -i /Users/Kaitlyn/Desktop/protein_sequences.fasta -o /Users/Kaitlyn/Desktop/alignment.aln --resno --outfmt=clu')\n",
    "    \n",
    "File = '/Users/Kaitlyn/Desktop/protein_sequences.fasta'  #file path for input fasta file, variable in Align function\n",
    "Output = '/Users/Kaitlyn/Desktop/alignment.aln'  #file path for output alignment file, variable in Align function\n",
    "print('Multiple sequence alignment performed and saved to', Output)\n",
    "    \n",
    "def FastaSearch(query): #search function nested in pipeline will produce fasta file for protein sequences from search\n",
    "    file = '/Users/Kaitlyn/Desktop/protein_sequences.fasta'  #enter file path for output file to write fasta seqs to\n",
    "    Entrez.email = 'knt2039@nyu.edu'  # Replace with your email address\n",
    "    search = Entrez.esearch(db='protein', term=query, retmax=600) #perform search with entrez using term \"query\" as filler term, use search terms as function variable later will fill in here.\n",
    "    record = Entrez.read(search) #read the search before getting ID list below\n",
    "    IDList = record['IdList'] #get a list of search titles, checking this length helps to know what to set the retmax at (580, set at 600)\n",
    "\n",
    "    fetch = Entrez.efetch(db='protein', id=IDList, rettype='fasta', retmode='text') #use entrez to fetch the fasta seq's from search terms\n",
    "    records = SeqIO.parse(fetch, 'fasta') #use seqio to parse the fetch data and then write it out to output file in later step\n",
    "    #fasta = fetch.read() #read the fetch to visualize the fasta seqs\n",
    "    #print(fasta) #visualize the fetch of fasta seqs (this is what will write to output file)\n",
    "    \n",
    "    SeqIO.write(records, file, 'fasta') #use seqio to write the fasta sequences from search to output file\n",
    "    print(len(IDList), 'fasta seqs found and written to', file) #print number of searches to confirm search and save to file done\n",
    "    \n",
    "FastaSearch('Human[ORGN]ErbB-1' and 'Human[ORGN]EGFR' and 'Human[ORGN]FGFR1') #recall function name with search terms to run the search\n",
    "\n",
    "Align(File, Output) #recall function name to close the pipeline and run the alignment\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7e8aad58",
   "metadata": {},
   "source": [
    "# Part II: Uniprot 4pts.\n",
    "### 1.\tCreate a uniprot object and perform a search based on the protein_names ErbB-1, EGFR, FGFR1 and organism being human. 1 point\n",
    "### 2.\tPost output in jupyter notebook as a dataframe. 1 point"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "b768a6ae",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Entry</th>\n",
       "      <th>Entry Name</th>\n",
       "      <th>Reviewed</th>\n",
       "      <th>Protein names</th>\n",
       "      <th>Gene Names</th>\n",
       "      <th>Organism</th>\n",
       "      <th>Length</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>P00533</td>\n",
       "      <td>EGFR_HUMAN</td>\n",
       "      <td>reviewed</td>\n",
       "      <td>Epidermal growth factor receptor (EC 2.7.10.1)...</td>\n",
       "      <td>EGFR ERBB ERBB1 HER1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>1210</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>P50616</td>\n",
       "      <td>TOB1_HUMAN</td>\n",
       "      <td>reviewed</td>\n",
       "      <td>Protein Tob1 (Transducer of erbB-2 1)</td>\n",
       "      <td>TOB1 TOB TROB1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>345</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Q9UJM3</td>\n",
       "      <td>ERRFI_HUMAN</td>\n",
       "      <td>reviewed</td>\n",
       "      <td>ERBB receptor feedback inhibitor 1 (Mitogen-in...</td>\n",
       "      <td>ERRFI1 MIG6</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>462</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>O14511</td>\n",
       "      <td>NRG2_HUMAN</td>\n",
       "      <td>reviewed</td>\n",
       "      <td>Pro-neuregulin-2, membrane-bound isoform (Pro-...</td>\n",
       "      <td>NRG2 NTAK</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>850</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>I6S2Y9</td>\n",
       "      <td>I6S2Y9_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>ERBB receptor feedback inhibitor 1 (ERBB recep...</td>\n",
       "      <td>ERRFI1 hCG_21818</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>462</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>K7EMD2</td>\n",
       "      <td>K7EMD2_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>ERBB receptor feedback inhibitor 1</td>\n",
       "      <td>ERRFI1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>74</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>K7ENN7</td>\n",
       "      <td>K7ENN7_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>ERBB receptor feedback inhibitor 1</td>\n",
       "      <td>ERRFI1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>52</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>K7EJB4</td>\n",
       "      <td>K7EJB4_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>ERBB receptor feedback inhibitor 1</td>\n",
       "      <td>ERRFI1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>79</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>K7ENI4</td>\n",
       "      <td>K7ENI4_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>ERBB receptor feedback inhibitor 1</td>\n",
       "      <td>ERRFI1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>53</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Q86T13</td>\n",
       "      <td>CLC14_HUMAN</td>\n",
       "      <td>reviewed</td>\n",
       "      <td>C-type lectin domain family 14 member A (Epide...</td>\n",
       "      <td>CLEC14A C14orf27 EGFR5 UNQ236/PRO269</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>490</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Q96AW1</td>\n",
       "      <td>VOPP1_HUMAN</td>\n",
       "      <td>reviewed</td>\n",
       "      <td>Vesicular, overexpressed in cancer, prosurviva...</td>\n",
       "      <td>VOPP1 ECOP GASP</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>172</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Q8IYD2</td>\n",
       "      <td>KLD8A_HUMAN</td>\n",
       "      <td>reviewed</td>\n",
       "      <td>Kelch domain-containing protein 8A (Substitute...</td>\n",
       "      <td>KLHDC8A</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>350</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>A0A2D3C337</td>\n",
       "      <td>A0A2D3C337_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>SEC61G-EGFR fusion protein</td>\n",
       "      <td>SEC61G-EGFR fusion</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>598</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>A0A2D3C335</td>\n",
       "      <td>A0A2D3C335_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>SEC61G-EGFR fusion protein</td>\n",
       "      <td>SEC61G-EGFR fusion</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>631</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>C9JVH1</td>\n",
       "      <td>C9JVH1_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>Vesicular, overexpressed in cancer, prosurviva...</td>\n",
       "      <td>VOPP1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>170</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>C9JTY8</td>\n",
       "      <td>C9JTY8_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>Vesicular, overexpressed in cancer, prosurviva...</td>\n",
       "      <td>VOPP1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>96</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>C9J548</td>\n",
       "      <td>C9J548_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>Vesicular, overexpressed in cancer, prosurviva...</td>\n",
       "      <td>VOPP1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>52</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>C9J827</td>\n",
       "      <td>C9J827_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>Vesicular, overexpressed in cancer, prosurviva...</td>\n",
       "      <td>VOPP1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>109</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>C9JF99</td>\n",
       "      <td>C9JF99_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>Vesicular, overexpressed in cancer, prosurviva...</td>\n",
       "      <td>VOPP1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>85</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>C9JIM1</td>\n",
       "      <td>C9JIM1_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>Vesicular, overexpressed in cancer, prosurviva...</td>\n",
       "      <td>VOPP1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>105</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>L0R6G1</td>\n",
       "      <td>L0R6G1_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>Alternative protein EGFR</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>49</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Q75MF2</td>\n",
       "      <td>Q75MF2_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>Uncharacterized protein EGFR</td>\n",
       "      <td>EGFR</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>387</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>O95684</td>\n",
       "      <td>CEP43_HUMAN</td>\n",
       "      <td>reviewed</td>\n",
       "      <td>Centrosomal protein 43 (FGFR1 oncogene partner)</td>\n",
       "      <td>CEP43 FGFR1OP FOP</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>399</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Q9NVK5</td>\n",
       "      <td>FGOP2_HUMAN</td>\n",
       "      <td>reviewed</td>\n",
       "      <td>FGFR1 oncogene partner 2</td>\n",
       "      <td>FGFR1OP2 HSPC123</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>253</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>B5A959</td>\n",
       "      <td>B5A959_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>Soluble FGFR1 variant 2</td>\n",
       "      <td>FGFR1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>320</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>J7M832</td>\n",
       "      <td>J7M832_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>BCR/FGFR1 chimera protein</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>197</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>F5GX47</td>\n",
       "      <td>F5GX47_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>FGFR1 oncogene partner 2</td>\n",
       "      <td>FGFR1OP2</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>60</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>J7M5B9</td>\n",
       "      <td>J7M5B9_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>FGFR1/BCR chimera protein</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>92</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>A9XLN4</td>\n",
       "      <td>A9XLN4_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>FGFR1/PLAG1 fusion variant 3</td>\n",
       "      <td>FGFR1/PLAG1 fusion</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>52</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>B4DH64</td>\n",
       "      <td>B4DH64_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>cDNA FLJ52986, highly similar to FGFR1 oncogen...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>365</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>B5A958</td>\n",
       "      <td>B5A958_HUMAN</td>\n",
       "      <td>unreviewed</td>\n",
       "      <td>Fibroblast growth factor receptor 1 (Soluble F...</td>\n",
       "      <td>FGFR1</td>\n",
       "      <td>Homo sapiens (Human)</td>\n",
       "      <td>228</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         Entry        Entry Name    Reviewed  \\\n",
       "0       P00533        EGFR_HUMAN    reviewed   \n",
       "1       P50616        TOB1_HUMAN    reviewed   \n",
       "2       Q9UJM3       ERRFI_HUMAN    reviewed   \n",
       "3       O14511        NRG2_HUMAN    reviewed   \n",
       "4       I6S2Y9      I6S2Y9_HUMAN  unreviewed   \n",
       "5       K7EMD2      K7EMD2_HUMAN  unreviewed   \n",
       "6       K7ENN7      K7ENN7_HUMAN  unreviewed   \n",
       "7       K7EJB4      K7EJB4_HUMAN  unreviewed   \n",
       "8       K7ENI4      K7ENI4_HUMAN  unreviewed   \n",
       "9       Q86T13       CLC14_HUMAN    reviewed   \n",
       "10      Q96AW1       VOPP1_HUMAN    reviewed   \n",
       "11      Q8IYD2       KLD8A_HUMAN    reviewed   \n",
       "12  A0A2D3C337  A0A2D3C337_HUMAN  unreviewed   \n",
       "13  A0A2D3C335  A0A2D3C335_HUMAN  unreviewed   \n",
       "14      C9JVH1      C9JVH1_HUMAN  unreviewed   \n",
       "15      C9JTY8      C9JTY8_HUMAN  unreviewed   \n",
       "16      C9J548      C9J548_HUMAN  unreviewed   \n",
       "17      C9J827      C9J827_HUMAN  unreviewed   \n",
       "18      C9JF99      C9JF99_HUMAN  unreviewed   \n",
       "19      C9JIM1      C9JIM1_HUMAN  unreviewed   \n",
       "20      L0R6G1      L0R6G1_HUMAN  unreviewed   \n",
       "21      Q75MF2      Q75MF2_HUMAN  unreviewed   \n",
       "22      O95684       CEP43_HUMAN    reviewed   \n",
       "23      Q9NVK5       FGOP2_HUMAN    reviewed   \n",
       "24      B5A959      B5A959_HUMAN  unreviewed   \n",
       "25      J7M832      J7M832_HUMAN  unreviewed   \n",
       "26      F5GX47      F5GX47_HUMAN  unreviewed   \n",
       "27      J7M5B9      J7M5B9_HUMAN  unreviewed   \n",
       "28      A9XLN4      A9XLN4_HUMAN  unreviewed   \n",
       "29      B4DH64      B4DH64_HUMAN  unreviewed   \n",
       "30      B5A958      B5A958_HUMAN  unreviewed   \n",
       "\n",
       "                                        Protein names  \\\n",
       "0   Epidermal growth factor receptor (EC 2.7.10.1)...   \n",
       "1               Protein Tob1 (Transducer of erbB-2 1)   \n",
       "2   ERBB receptor feedback inhibitor 1 (Mitogen-in...   \n",
       "3   Pro-neuregulin-2, membrane-bound isoform (Pro-...   \n",
       "4   ERBB receptor feedback inhibitor 1 (ERBB recep...   \n",
       "5                  ERBB receptor feedback inhibitor 1   \n",
       "6                  ERBB receptor feedback inhibitor 1   \n",
       "7                  ERBB receptor feedback inhibitor 1   \n",
       "8                  ERBB receptor feedback inhibitor 1   \n",
       "9   C-type lectin domain family 14 member A (Epide...   \n",
       "10  Vesicular, overexpressed in cancer, prosurviva...   \n",
       "11  Kelch domain-containing protein 8A (Substitute...   \n",
       "12                         SEC61G-EGFR fusion protein   \n",
       "13                         SEC61G-EGFR fusion protein   \n",
       "14  Vesicular, overexpressed in cancer, prosurviva...   \n",
       "15  Vesicular, overexpressed in cancer, prosurviva...   \n",
       "16  Vesicular, overexpressed in cancer, prosurviva...   \n",
       "17  Vesicular, overexpressed in cancer, prosurviva...   \n",
       "18  Vesicular, overexpressed in cancer, prosurviva...   \n",
       "19  Vesicular, overexpressed in cancer, prosurviva...   \n",
       "20                           Alternative protein EGFR   \n",
       "21                       Uncharacterized protein EGFR   \n",
       "22    Centrosomal protein 43 (FGFR1 oncogene partner)   \n",
       "23                           FGFR1 oncogene partner 2   \n",
       "24                            Soluble FGFR1 variant 2   \n",
       "25                          BCR/FGFR1 chimera protein   \n",
       "26                           FGFR1 oncogene partner 2   \n",
       "27                          FGFR1/BCR chimera protein   \n",
       "28                       FGFR1/PLAG1 fusion variant 3   \n",
       "29  cDNA FLJ52986, highly similar to FGFR1 oncogen...   \n",
       "30  Fibroblast growth factor receptor 1 (Soluble F...   \n",
       "\n",
       "                              Gene Names              Organism  Length  \n",
       "0                   EGFR ERBB ERBB1 HER1  Homo sapiens (Human)    1210  \n",
       "1                         TOB1 TOB TROB1  Homo sapiens (Human)     345  \n",
       "2                            ERRFI1 MIG6  Homo sapiens (Human)     462  \n",
       "3                              NRG2 NTAK  Homo sapiens (Human)     850  \n",
       "4                       ERRFI1 hCG_21818  Homo sapiens (Human)     462  \n",
       "5                                 ERRFI1  Homo sapiens (Human)      74  \n",
       "6                                 ERRFI1  Homo sapiens (Human)      52  \n",
       "7                                 ERRFI1  Homo sapiens (Human)      79  \n",
       "8                                 ERRFI1  Homo sapiens (Human)      53  \n",
       "9   CLEC14A C14orf27 EGFR5 UNQ236/PRO269  Homo sapiens (Human)     490  \n",
       "10                       VOPP1 ECOP GASP  Homo sapiens (Human)     172  \n",
       "11                               KLHDC8A  Homo sapiens (Human)     350  \n",
       "12                    SEC61G-EGFR fusion  Homo sapiens (Human)     598  \n",
       "13                    SEC61G-EGFR fusion  Homo sapiens (Human)     631  \n",
       "14                                 VOPP1  Homo sapiens (Human)     170  \n",
       "15                                 VOPP1  Homo sapiens (Human)      96  \n",
       "16                                 VOPP1  Homo sapiens (Human)      52  \n",
       "17                                 VOPP1  Homo sapiens (Human)     109  \n",
       "18                                 VOPP1  Homo sapiens (Human)      85  \n",
       "19                                 VOPP1  Homo sapiens (Human)     105  \n",
       "20                                  EGFR  Homo sapiens (Human)      49  \n",
       "21                                  EGFR  Homo sapiens (Human)     387  \n",
       "22                     CEP43 FGFR1OP FOP  Homo sapiens (Human)     399  \n",
       "23                      FGFR1OP2 HSPC123  Homo sapiens (Human)     253  \n",
       "24                                 FGFR1  Homo sapiens (Human)     320  \n",
       "25                                   NaN  Homo sapiens (Human)     197  \n",
       "26                              FGFR1OP2  Homo sapiens (Human)      60  \n",
       "27                                   NaN  Homo sapiens (Human)      92  \n",
       "28                    FGFR1/PLAG1 fusion  Homo sapiens (Human)      52  \n",
       "29                                   NaN  Homo sapiens (Human)     365  \n",
       "30                                 FGFR1  Homo sapiens (Human)     228  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import matplotlib \n",
    "import pandas as pd\n",
    "import io\n",
    "from Bio import SeqIO\n",
    "from bioservices import UniProt\n",
    "\n",
    "\n",
    "u = UniProt(verbose=False)\n",
    "result1 = u.search(\"Protein_name: ErbB-1  AND organism_name:human\", frmt=\"tsv\") #search for ErbB-1\n",
    "result2 = u.search(\"Protein_name: EGFR  AND organism_name:human\", frmt=\"tsv\") #search for EGFR\n",
    "result3 = u.search(\"Protein_name: FGFR1  AND organism_name:human\", frmt=\"tsv\") #search for FGFR1\n",
    "result = result1+result2+result3 #concatinate 3 searches to visualize in one dataframe\n",
    "\n",
    "searchout = open('/Users/Kaitlyn/Desktop/Proteins_uniprot.txt','w')\n",
    "#for line in result:\n",
    "    #column = line.rstrip('\\n').split('\\t')\n",
    "    #file_out.write(line)\n",
    "searchout.write(result) #writes the same as above code\n",
    "searchout.close()\n",
    "\n",
    "df = pd.read_table(io.StringIO(result), on_bad_lines = 'skip')  \n",
    "df\n",
    "\n",
    "#on_bad_lines removes error from lines with missing values\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "62ad50fa",
   "metadata": {},
   "source": [
    "### 3.\tCreate a query that returns a list of fasta sequences. 1 point"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "2f659d3f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      ">sp|P00533|EGFR_HUMAN Epidermal growth factor receptor OS=Homo sapiens OX=9606 GN=EGFR PE=1 SV=2\n",
      "MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV\n",
      "VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA\n",
      "VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF\n",
      "QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC\n",
      "TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV\n",
      "VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK\n",
      "NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF\n",
      "ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL\n",
      "FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN\n",
      "LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM\n",
      "GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV\n",
      "ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS\n",
      "GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI\n",
      "CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA\n",
      "RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY\n",
      "GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK\n",
      "FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ\n",
      "QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED\n",
      "SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN\n",
      "TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV\n",
      "APQSSEFIGA\n",
      ">sp|P50616|TOB1_HUMAN Protein Tob1 OS=Homo sapiens OX=9606 GN=TOB1 PE=1 SV=1\n",
      "MQLEIQVALNFIISYLYNKLPRRRVNIFGEELERLLKKKYEGHWYPEKPYKGSGFRCIHI\n",
      "GEKVDPVIEQASKESGLDIDDVRGNLPQDLSVWIDPFEVSYQIGEKGPVKVLYVDDNNEN\n",
      "GCELDKEIKNSFNPEAQVFMPISDPASSVSSSPSPPFGHSAAVSPTFMPRSTQPLTFTTA\n",
      "TFAATKFGSTKMKNSGRSNKVARTSPINLGLNVNDLLKQKAISSSMHSLYGLGLGSQQQP\n",
      "QQQQQPAQPPPPPPPPQQQQQQKTSALSPNAKEFIFPNMQGQGSSTNGMFPGDSPLNLSP\n",
      "LQYSNAFDVFAAYGGLNEKSFVDGLNFSLNNMQYSNQQFQPVMAN\n",
      ">sp|Q9UJM3|ERRFI_HUMAN ERBB receptor feedback inhibitor 1 OS=Homo sapiens OX=9606 GN=ERRFI1 PE=1 SV=1\n",
      "MSIAGVAAQEIRVPLKTGFLHNGRAMGNMRKTYWSSRSEFKNNFLNIDPITMAYSLNSSA\n",
      "QERLIPLGHASKSAPMNGHCFAENGPSQKSSLPPLLIPPSENLGPHEEDQVVCGFKKLTV\n",
      "NGVCASTPPLTPIKNSPSLFPCAPLCERGSRPLPPLPISEALSLDDTDCEVEFLTSSDTD\n",
      "FLLEDSTLSDFKYDVPGRRSFRGCGQINYAYFDTPAVSAADLSYVSDQNGGVPDPNPPPP\n",
      "QTHRRLRRSHSGPAGSFNKPAIRISNCCIHRASPNSDEDKPEVPPRVPIPPRPVKPDYRR\n",
      "WSAEVTSSTYSDEDRPPKVPPREPLSPSNSRTPSPKSLPSYLNGVMPPTQSFAPDPKYVS\n",
      "SKALQRQNSEGSASKVPCILPIIENGKKVSSTHYYLLPERPPYLDKYEKFFREAEETNGG\n",
      "AQIQPLPADCGISSATEKPDSKTKMDLGGHVKRKHLSYVVSP\n",
      ">sp|O14511|NRG2_HUMAN Pro-neuregulin-2, membrane-bound isoform OS=Homo sapiens OX=9606 GN=NRG2 PE=1 SV=1\n",
      "MRQVCCSALPPPPLEKGRCSSYSDSSSSSSERSSSSSSSSSESGSSSRSSSNNSSISRPA\n",
      "APPEPRPQQQPQPRSPAARRAAARSRAAAAGGMRRDPAPGFSMLLFGVSLACYSPSLKSV\n",
      "QDQAYKAPVVVEGKVQGLVPAGGSSSNSTREPPASGRVALVKVLDKWPLRSGGLQREQVI\n",
      "SVGSCVPLERNQRYIFFLEPTEQPLVFKTAFAPLDTNGKNLKKEVGKILCTDCATRPKLK\n",
      "KMKSQTGQVGEKQSLKCEAAAGNPQPSYRWFKDGKELNRSRDIRIKYGNGRKNSRLQFNK\n",
      "VKVEDAGEYVCEAENILGKDTVRGRLYVNSVSTTLSSWSGHARKCNETAKSYCVNGGVCY\n",
      "YIEGINQLSCKCPNGFFGQRCLEKLPLRLYMPDPKQKAEELYQKRVLTITGICVALLVVG\n",
      "IVCVVAYCKTKKQRKQMHNHLRQNMCPAHQNRSLANGPSHPRLDPEEIQMADYISKNVPA\n",
      "TDHVIRRETETTFSGSHSCSPSHHCSTATPTSSHRHESHTWSLERSESLTSDSQSGIMLS\n",
      "SVGTSKCNSPACVEARARRAAAYNLEERRRATAPPYHDSVDSLRDSPHSERYVSALTTPA\n",
      "RLSPVDFHYSLATQVPTFEITSPNSAHAVSLPPAAPISYRLAEQQPLLRHPAPPGPGPGP\n",
      "GPGPGPGADMQRSYDSYYYPAAGPGPRRGTCALGGSLGSLPASPFRIPEDDEYETTQECA\n",
      "PPPPPRPRARGASRRTSAGPRRWRRSRLNGLAAQRARAARDSLSLSSGSGGGSASASDDD\n",
      "ADDADGALAAESTPFLGLRGAHDALRSDSPPLCPAADSRTYYSLDSHSTRASSRHSRGPP\n",
      "PRAKQDSAPL\n",
      ">tr|I6S2Y9|I6S2Y9_HUMAN ERBB receptor feedback inhibitor 1 OS=Homo sapiens OX=9606 GN=ERRFI1 PE=4 SV=1\n",
      "MSIAGVAAQEIRVPLKTGFLHNGRAMGNMRKTYWSSRSEFKNNFLNIDPITMAYSLNSSA\n",
      "QERLIPLGHASKSAPMNGHCFAENGPSQKSSLPPLLIPPSENLGPHEEDQVVCGFKKLTV\n",
      "NGVCASTPPLTPIKNSPSLFPCAPLCERGSRPLPPLPISEALSLDDTDCEVEFLTSSDTD\n",
      "FLLEDSTLSDFKYDVPGRRSFRGCGQINYAYFDTPAVSAADLSYVSDQNGGVPDPNPPPP\n",
      "QTHRRLRRSHSGPAGSFNKPAIRISNCCIHRASPNSDEDKPEVPPRVPIPPRPVKPDYRR\n",
      "WSAEVTSSTYSDEDRPPKVPPREPLSPSNSRTPSPKSLPSYLNGVMPPTQSFAPDPKYVS\n",
      "SKALQRQNSEGSASKVPCILPIIENGKKVSSTHYYLLPERPPYLDKYEKFFREAEETNGG\n",
      "AQIQPLPADCGISSATEKPDSKTKMDLGGHVKRKHLSYVVSP\n",
      ">tr|K7EMD2|K7EMD2_HUMAN ERBB receptor feedback inhibitor 1 OS=Homo sapiens OX=9606 GN=ERRFI1 PE=1 SV=1\n",
      "MSIAGVAAQEIRVPLKTGFLHNGRAMGNMRKTYWSSRSEFKKACFQICSDEWPLLCRKWS\n",
      "ISKVQLAPSSYSPK\n",
      ">tr|K7ENN7|K7ENN7_HUMAN ERBB receptor feedback inhibitor 1 OS=Homo sapiens OX=9606 GN=ERRFI1 PE=1 SV=1\n",
      "MSIAGVAAQEIRVPLKTGFLHNGRAMGNMRKTYWSSRSEFKNFLSFQQLFKY\n",
      ">tr|K7EJB4|K7EJB4_HUMAN ERBB receptor feedback inhibitor 1 OS=Homo sapiens OX=9606 GN=ERRFI1 PE=1 SV=1\n",
      "MSIAGVAAQEIRVPLKTGFLHNGRAMGNMRKTYWSSRSEFKNNFLNIDPITMAYSLNSSA\n",
      "QERLIPLGMYSENLITVSI\n",
      ">tr|K7ENI4|K7ENI4_HUMAN ERBB receptor feedback inhibitor 1 OS=Homo sapiens OX=9606 GN=ERRFI1 PE=1 SV=1\n",
      "MSIAGVAAQEIRVPLKTGFLHNGRAMGNMRKTYWSSRSEFKNTGRKLPGTVGD\n",
      ">tr|B3KTV8|B3KTV8_HUMAN cDNA FLJ38830 fis, clone MESAN1000080, highly similar to ERBB receptor feedback inhibitor 1 OS=Homo sapiens OX=9606 PE=2 SV=1\n",
      "MSIAGVAAQEIRVPLKTGFLHNGRAMGNMRKTYWSSRSEFKNNFLNIDPITMAYSLNSSA\n",
      "QERLIPLGHASKSAPMNGHCFAENGPSQKSSLPPLLIPPSENLGPHEEDQVVCGFKKLTV\n",
      "NGVCASTPPLTPIKNSPSLFPCAPLCERGSRPLPPLPISEALSLDDTDCEVEFLTSSDTD\n",
      "FLLEDSTLSDFKYDVPGRRSFRGCGQINYAYFDTPAVSAADLSYVSDQNGGVPDPNPPPP\n",
      "QTHRRLRRSHSGPAGSFNKPAIRISNCCIHRASPNSDEDKPEVPPRVPIPPRPVKPDYRR\n",
      "WSAEVTSSAYSDEDRPPKVPPREPLSPSNSRTPSPKSLPSYLNGVMPPTQSFAPDPKYVS\n",
      "SKALQRQNSEGSASKVPCILPIIENGKKVSSTHYYLLPERPPYLDKYEKFFREAEETNGG\n",
      "AQIQPLPADCGISSATEKPDSKTKMDLGGHVKRKHLSYVVSP\n",
      ">sp|Q86T13|CLC14_HUMAN C-type lectin domain family 14 member A OS=Homo sapiens OX=9606 GN=CLEC14A PE=1 SV=1\n",
      "MRPAFALCLLWQALWPGPGGGEHPTADRAGCSASGACYSLHHATMKRQAAEEACILRGGA\n",
      "LSTVRAGAELRAVLALLRAGPGPGGGSKDLLFWVALERRRSHCTLENEPLRGFSWLSSDP\n",
      "GGLESDTLQWVEEPQRSCTARRCAVLQATGGVEPAGWKEMRCHLRANGYLCKYQFEVLCP\n",
      "APRPGAASNLSYRAPFQLHSAALDFSPPGTEVSALCRGQLPISVTCIADEIGARWDKLSG\n",
      "DVLCPCPGRYLRAGKCAELPNCLDDLGGFACECATGFELGKDGRSCVTSGEGQPTLGGTG\n",
      "VPTRRPPATATSPVPQRTWPIRVDEKLGETPLVPEQDNSVTSIPEIPRWGSQSTMSTLQM\n",
      "SLQAESKATITPSGSVISKFNSTTSSATPQAFDSSSAVVFIFVSTAVVVLVILTMTVLGL\n",
      "VKLCFHESPSSQPRKESMGPPGLESDPEPAALGSSSAHCTNNGVKVGDCDLRDRAEGALL\n",
      "AESPLGSSDA\n",
      ">sp|Q96AW1|VOPP1_HUMAN Vesicular, overexpressed in cancer, prosurvival protein 1 OS=Homo sapiens OX=9606 GN=VOPP1 PE=2 SV=1\n",
      "MRRQPAKVAALLLGLLLECTEAKKHCWYFEGLYPTYYICRSYEDCCGSRCCVRALSIQRL\n",
      "WYFWFLLMMGVLFCCGAGFFIRRRMYPPPLIEEPAFNVSYTRQPPNPGPGAQQPGPPYYT\n",
      "DPGGPGMNPVGNSMAMAFQVPPNSPQGSVACPPPPAYCNTPPPPYEQVVKAK\n",
      ">sp|Q8IYD2|KLD8A_HUMAN Kelch domain-containing protein 8A OS=Homo sapiens OX=9606 GN=KLHDC8A PE=1 SV=2\n",
      "MEVPNVKDFQWKRLAPLPSRRVYCSLLETGGQVYAIGGCDDNGVPMDCFEVYSPEADQWT\n",
      "ALPRLPTARAGVAVTALGKRIMVIGGVGTNQLPLKVVEMYNIDEGKWKKRSMLREAAMGI\n",
      "SVTAKDYRVYAAGGMGLDLRPHNHLQHYDMLKDMWVSLAPMPTPRYAATSFLRGSKIYVL\n",
      "GGRQSKYAVNAFEVFDIETRSWTKFPNIPYKRAFSSFVTLDNHLYSLGGLRQGRLYRQPK\n",
      "FLRTMDVFDMEQGGWLKMERSFFLKKRRADFVAGSLSGRVIVAGGLGNQPTVLETAEAFH\n",
      "PGKNKWEILPAMPTPRCACSSIVVKNCLLAVGGVNQGLSDAVEALCVSDS\n",
      ">tr|A0A2D3C337|A0A2D3C337_HUMAN SEC61G-EGFR fusion protein OS=Homo sapiens OX=9606 GN=SEC61G-EGFR fusion PE=2 SV=1\n",
      "MGENNTLVWKYADAGHVCHLCHPNCTYGPKIPSIATGMVGALLLLLVVALGIGLFMRRRH\n",
      "IVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWI\n",
      "PEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQL\n",
      "MPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVK\n",
      "ITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGS\n",
      "KPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMA\n",
      "RDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRT\n",
      "PLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEY\n",
      "INQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFD\n",
      "SPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA\n",
      ">tr|A0A2D3C335|A0A2D3C335_HUMAN SEC61G-EGFR fusion protein OS=Homo sapiens OX=9606 GN=SEC61G-EGFR fusion PE=2 SV=1\n",
      "MNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTY\n",
      "GPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAP\n",
      "NQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEI\n",
      "LDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCV\n",
      "QIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIK\n",
      "WMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPIC\n",
      "TIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYR\n",
      "ALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCP\n",
      "IKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAP\n",
      "SRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPK\n",
      "EAKPNGIFKGSTAENAEYLRVAPQSSEFIGA\n",
      ">tr|C9JVH1|C9JVH1_HUMAN Vesicular, overexpressed in cancer, prosurvival protein 1 OS=Homo sapiens OX=9606 GN=VOPP1 PE=1 SV=1\n",
      "MRIRSLHPVQQTEPTTCTEAKKHCWYFEGLYPTYYICRSYEDCCGSRCCVRALSIQRLWY\n",
      "FWFLLMMGVLFCCGAGFFIRRRMYPPPLIEEPAFNVSYTRQPPNPGPGAQQPGPPYYTDP\n",
      "GGPGMNPVGNSMAMAFQVPPNSPQGSVACPPPPAYCNTPPPPYEQVVKAK\n",
      ">tr|C9JTY8|C9JTY8_HUMAN Vesicular, overexpressed in cancer, prosurvival protein 1 (Fragment) OS=Homo sapiens OX=9606 GN=VOPP1 PE=1 SV=1\n",
      "MMGVLFCCGAGFFIRRRMYPPPLIEEPAFNVSYTRQPPNPGPGAQQPGPPYYTDPGGPGM\n",
      "NPVGNSMAMAFQVPPNSPQGSVACPPPPAYCNTPPP\n",
      ">tr|C9J548|C9J548_HUMAN Vesicular, overexpressed in cancer, prosurvival protein 1 (Fragment) OS=Homo sapiens OX=9606 GN=VOPP1 PE=1 SV=8\n",
      "MMGVLFCCGAGFFIRRRMYPPPLIEEPAFNVSYTRQPPNPGPGAQQPGPPYY\n",
      ">tr|C9J827|C9J827_HUMAN Vesicular, overexpressed in cancer, prosurvival protein 1 OS=Homo sapiens OX=9606 GN=VOPP1 PE=1 SV=1\n",
      "MFLLMMGVLFCCGAGFFIRRRMYPPPLIEEPAFNVSYTRQPPNPGPGAQQPGPPYYTDPG\n",
      "GPGMNPVGNSMAMAFQVPPNSPQGSVACPPPPAYCNTPPPPYEQVVKAK\n",
      ">tr|C9JF99|C9JF99_HUMAN Vesicular, overexpressed in cancer, prosurvival protein 1 (Fragment) OS=Homo sapiens OX=9606 GN=VOPP1 PE=1 SV=1\n",
      "MMGVLFCCGAGFFIRRRMYPPPLIEEPAFNVSYTRQPPNPGPGAQQPGPPYYTDPGGPGM\n",
      "NPVGNSMAMAFQVPPNSPQGSVACP\n",
      ">tr|C9JIM1|C9JIM1_HUMAN Vesicular, overexpressed in cancer, prosurvival protein 1 OS=Homo sapiens OX=9606 GN=VOPP1 PE=1 SV=1\n",
      "MMGVLFCCGAGFFIRRRMYPPPLIEEPAFNVSYTRQPPNPGPGAQQPGPPYYTDPGGPGM\n",
      "NPVGNSMAMAFQVPPNSPQGSVACPPPPAYCNTPPPPYEQVVKAK\n",
      ">tr|L0R6G1|L0R6G1_HUMAN Alternative protein EGFR OS=Homo sapiens OX=9606 GN=EGFR PE=4 SV=1\n",
      "MCATCAIQTAPTGPNKSSLSDFSLPLKLHFLSTISISPFASNKVLTLFI\n",
      ">tr|Q75MF2|Q75MF2_HUMAN Uncharacterized protein EGFR (Fragment) OS=Homo sapiens OX=9606 GN=EGFR PE=4 SV=1\n",
      "GMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMAL\n",
      "ESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDV\n",
      "YMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMD\n",
      "EEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKED\n",
      "SFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDP\n",
      "HYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKP\n",
      "NGIFKGSTAENAEYLRVAPQSSEFIGA\n",
      ">tr|A0A024QYZ2|A0A024QYZ2_HUMAN EGFR-coamplified and overexpressed protein, isoform CRA_a OS=Homo sapiens OX=9606 GN=ECOP PE=4 SV=1\n",
      "MPLLRGLLWLQVLCAGPLHTEAVVLLVPSDDGRAFLLRSRLLHPEAHVPPAADRGASLQC\n",
      "VLHQAAPKSRPRSPAAGAALLHRPRRTGDEPCREFHGNGFPGPTQLTPGECGLPAPSSLL\n",
      "QHASAPVRTGSEGQVVGCPRARGETGEGLSLAFLSSLMFTSRNGLVGC\n",
      ">sp|O95684|CEP43_HUMAN Centrosomal protein 43 OS=Homo sapiens OX=9606 GN=CEP43 PE=1 SV=1\n",
      "MAATAAAVVAEEDTELRDLLVQTLENSGVLNRIKAELRAAVFLALEEQEKVENKTPLVNE\n",
      "SLKKFLNTKDGRLVASLVAEFLQFFNLDFTLAVFQPETSTLQGLEGRENLARDLGIIEAE\n",
      "GTVGGPLLLEVIRRCQQKEKGPTTGEGALDLSDVHSPPKSPEGKTSAQTTPSKIPRYKGQ\n",
      "GKKKTSGQKAGDKKANDEANQSDTSVSLSEPKSKSSLHLLSHETKIGSFLSNRTLDGKDK\n",
      "AGLCPDEDDMEGDSFFDDPIPKPEKTYGLRKEPRKQAGSLASLSDAPPLKSGLSSLAGAP\n",
      "SLKDSESKRGNTVLKDLKLISDKIGSLGLGTGEDDDYVDDFNSTSHRSEKSEISIGEEIE\n",
      "EDLSVEIDDINTSDKLDDLTQDLTVSQLSDVADYLEDVA\n",
      ">sp|Q9NVK5|FGOP2_HUMAN FGFR1 oncogene partner 2 OS=Homo sapiens OX=9606 GN=FGFR1OP2 PE=1 SV=1\n",
      "MSCTIEKALADAKALVERLRDHDDAAESLIEQTTALNKRVEAMKQYQEEIQELNEVARHR\n",
      "PRSTLVMGIQQENRQIRELQQENKELRTSLEEHQSALELIMSKYREQMFRLLMASKKDDP\n",
      "GIIMKLKEQHSKIDMVHRNKSEGFFLDASRHILEAPQHGLERRHLEANQNELQAHVDQIT\n",
      "EMAAVMRKAIEIDEQQGCKEQERIFQLEQENKGLREILQITRESFLNLRKDDASESTSLS\n",
      "ALVTNSDLSLRKS\n",
      ">tr|B5A959|B5A959_HUMAN Soluble FGFR1 variant 2 OS=Homo sapiens OX=9606 GN=FGFR1 PE=2 SV=1\n",
      "MWSWKCLLFWAVLVTATLCTARPSPTLPEQDALPSSEDDDDDDDSSSEEKETDNTKPNRM\n",
      "PVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLRWLENGKEFKPGHRIGGYKVR\n",
      "YATWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVAL\n",
      "GSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLR\n",
      "NVSFEDAGEYTCLAGNSIGLSHHSAWLTVLEGTHCNFSSRCPALATGTGGACISRLGETQ\n",
      "RQESWKNGLLPAWCHILPQL\n",
      ">tr|J7M832|J7M832_HUMAN BCR/FGFR1 chimera protein (Fragment) OS=Homo sapiens OX=9606 PE=2 SV=1\n",
      "DADGSFGTPPGYGCAADRAEEQRRHQDGLPYIDDSPSSSPHLSSKGRGSRDALVSGALES\n",
      "TKASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTSQQIE\n",
      "TIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLVSADSSASMNSGVLLVRPSR\n",
      "LSSSGTPMLAGVSEYEL\n",
      ">tr|F5GX47|F5GX47_HUMAN FGFR1 oncogene partner 2 (Fragment) OS=Homo sapiens OX=9606 GN=FGFR1OP2 PE=1 SV=1\n",
      "MSCTIEKALADAKALVERLRDHDDAAESLIEQTTALNKRVEAMKQYQEEIQELNEVARHR\n",
      ">tr|J7M5B9|J7M5B9_HUMAN FGFR1/BCR chimera protein (Fragment) OS=Homo sapiens OX=9606 PE=2 SV=1\n",
      "SDFHSQMAVHKLAKSIPLRRQASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLR\n",
      "ARSNKDAKDPTTKNSLETLLYKPVDRVTRSTL\n",
      ">tr|A9XLN4|A9XLN4_HUMAN FGFR1/PLAG1 fusion variant 3 OS=Homo sapiens OX=9606 GN=FGFR1/PLAG1 fusion PE=2 SV=1\n",
      "MWSWKCLLFWAVLVTATLCTARPSPTLPEQGCLLVLPWPYLAPRMLHSVTVY\n",
      ">tr|B4DH64|B4DH64_HUMAN cDNA FLJ52986, highly similar to FGFR1 oncogene partner OS=Homo sapiens OX=9606 PE=2 SV=1\n",
      "MAATAAAVVAEEDTELRDLLVQTLENSGVLNRIKAELRAAVFLPLEEQEKVENKTPLVNE\n",
      "SLKKFLNTKDGRLVASLVAEFLQFFNLDFTLAVFQPETSTLQGLEGRENLARDLGIIEAE\n",
      "GTVGGPLLLEVIRRCQQKEKGPTTGEKANDEANQSDTSVSLSEPKSKSSLHLLSHETKIG\n",
      "SFLSNRTLDGKDKAGLCPDEDDMEGDSFFDDPIPKPEKTYGLRKEPRKQAGSLASLSDAP\n",
      "PLKSGLSSLAGAPSLKDSESKRGNTVLKDLKLISDKIGSLGLGTGEDDDYVDDFNSTSHR\n",
      "SEKSEISIGEEIEEDLSVEIDDINTSDKTITQLECLLSIGALHFKNTADIFLKVIFILLN\n",
      "KILPI\n",
      ">tr|B5A958|B5A958_HUMAN Fibroblast growth factor receptor 1 OS=Homo sapiens OX=9606 GN=FGFR1 PE=1 SV=1\n",
      "MWSWKCLLFWAVLVTATLCTARPSPTLPEQDALPSSEDDDDDDDSSSEEKETDNTKPNPV\n",
      "APYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYA\n",
      "TWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGS\n",
      "NVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKPWKRGRQ\n",
      "\n"
     ]
    }
   ],
   "source": [
    "result1 = u.search(\"Protein_name: ErbB-1  AND organism_name:human\", frmt=\"fasta\") #search for ErbB-1\n",
    "result2 = u.search(\"Protein_name: EGFR  AND organism_name:human\", frmt=\"fasta\") #search for EGFR\n",
    "result3 = u.search(\"Protein_name: FGFR1  AND organism_name:human\", frmt=\"fasta\") #search for FGFR1\n",
    "result = result1+result2+result3 #concatinate 3 searches to visualize in one dataframe\n",
    "print(result) #print for visualization.\n",
    " \n",
    "fastaout = open(\"/Users/Kaitlyn/Desktop/Searchresults.fasta\",'w')\n",
    "fastaout.write(result) #Write sequences to output file.\n",
    "fastaout.close()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d2a05f61",
   "metadata": {},
   "source": [
    "### 4.\tUse the fasta sequence data to create a histogram based on length of sequences and bins=100. 1 point"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "4a887630",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[<AxesSubplot:title={'center':'Length'}>]], dtype=object)"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#df.hist()\n",
    "df.hist('Length', bins=100)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1a530b9d",
   "metadata": {},
   "source": [
    "# Part III: COSMIC ACTIONABILITY ANALYSIS 8pts.\n",
    "### 1.\tParse the ACTIONABILITY file based on the following criteria:2 points\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;$ 1.\tEach line has 'ErbB-1 OR EGFR OR FGFR1' AND 'lung/carcinoma/non small cell carcinoma'\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;$ 2.\tReturn only columns with the following headers:\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;$ 1.\tGENE\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;$ 2.\tMUTATION_REMARK\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;$ 3.\tDISEASE\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;$ 4.\tACTIONABILITY_RANK\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;$ 5.\tDRUG_COMBINATION\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;$ 6.\tSOURCE\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;$ 7.\tPRIMARY_OUTCOME\n",
    "### 2.\tCreate a dataframe with parsed file in jupyter notebook. The dataframe must provide access to the full file. 2 points"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "52d135f8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>GENE</th>\n",
       "      <th>MUTATION_REMARK</th>\n",
       "      <th>DISEASE</th>\n",
       "      <th>ACTIONABILITY_RANK</th>\n",
       "      <th>DRUG_COMBINATION</th>\n",
       "      <th>SOURCE</th>\n",
       "      <th>PRIMARY_OUTCOME_MEASURE</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>(EGFR_Exon19del or EGFR_L858R or EGFR_T790M) a...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib + Savolitinib</td>\n",
       "      <td>NCT05261399</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>(EGFR_Exon19del or EGFR_L858R) and CD274_unspe...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT05255406</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>(EGFR_Exon19del or EGFR_L858R) and CD274_unspe...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Bevacizumab + Cisplatin + Pemetrexed + Tisleli...</td>\n",
       "      <td>NCT05394233</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>(EGFR_Exon19del or EGFR_L858R) and MET_unspeci...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Erlotinib + Telisotuzumab vedotin</td>\n",
       "      <td>10.1200/JCO.2019.37.15_suppl.3011</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>(EGFR_Exon19del or EGFR_L858R) and MET_unspeci...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Capmatinib + Erlotinib</td>\n",
       "      <td>NCT02468661</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>(EGFR_Exon19del or EGFR_L858R) and MET_unspeci...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Capmatinib + Nazartinib</td>\n",
       "      <td>10.1016/j.annonc.2020.08.1598</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>(EGFR_Exon19del or EGFR_L858R) and TP53_unspec...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Carboplatin + Osimertinib + Pemetrexed</td>\n",
       "      <td>NCT04695925</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>(FGFR1_unspecified or FGFR2_unspecified or FGF...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Pemigatinib + Sintilimab</td>\n",
       "      <td>NCT05004974</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3457</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_C797</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>BLU-701</td>\n",
       "      <td>NCT05153408</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3458</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_C797</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>WJ13404</td>\n",
       "      <td>NCT05662670</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3459</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_C797 or EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>JIN-A02</td>\n",
       "      <td>NCT05394831</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3460</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_C797S</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Dacomitinib</td>\n",
       "      <td>NCT03755102</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3461</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_C797S</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>QLH11811</td>\n",
       "      <td>NCT05555212</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3462</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_C797S</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Dacomitinib + Osimertinib</td>\n",
       "      <td>NCT03755102</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3463</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_C797S</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>HS-10375</td>\n",
       "      <td>NCT05435248</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3464</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_C797S and EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>BLU-945</td>\n",
       "      <td>NCT04862780</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3465</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_C797S and EGFR_no_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>BLU-945</td>\n",
       "      <td>NCT04862780</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3468</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_E709K/A</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>4</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>26354527</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3469</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_E709_T710delinsD</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>4</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>28625646</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3470</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_E709_T710delinsD</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>7</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>27785061</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3471</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_E709_T710delinsD</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>7</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>27785061</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3472</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon18</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Neratinib</td>\n",
       "      <td>10.1200/JCO.2021.39.15_suppl.9068</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3473</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>TAS-116</td>\n",
       "      <td>30679388</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3474</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib + Pemetrexed</td>\n",
       "      <td>27507876</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3475</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del and EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Crizotinib + Dacomitinib</td>\n",
       "      <td>26899759</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3476</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>29239002</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3477</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Fruquintinib + Genolimzumab</td>\n",
       "      <td>NCT03976856</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3478</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib + Rifampicin</td>\n",
       "      <td>NCT02197247</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3479</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Itraconazole + Osimertinib</td>\n",
       "      <td>29381826</td>\n",
       "      <td>Absorption rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3480</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>NCT02025218</td>\n",
       "      <td>Disease control rate, Clinical benefit rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3481</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib + Vinorelbine</td>\n",
       "      <td>https://www.jto.org/article/S1556-0864(19)3247...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3482</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib + Tepotinib</td>\n",
       "      <td>NCT01982955</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3483</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Atezolizumab + Bevacizumab + Carboplatin + Pem...</td>\n",
       "      <td>NCT04147351</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3484</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Erlotinib + Luminespib</td>\n",
       "      <td>25870087</td>\n",
       "      <td>MTD, ORR, Toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3485</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Erlotinib + Radiotherapy</td>\n",
       "      <td>NCT03074864</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3486</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib + Stereotactic Body Radiation Therapy</td>\n",
       "      <td>NCT02893332</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3487</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon20ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Afatinib + Cetuximab</td>\n",
       "      <td>29110849</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3488</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_Exon20ins or EGFR_G719 ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Necitumumab + Osimertinib</td>\n",
       "      <td>NCT02496663</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3489</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Afatinib + Pembrolizumab</td>\n",
       "      <td>NCT02364609</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3490</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Patritumab deruxtecan</td>\n",
       "      <td>10.1200/JCO.2021.39.15_suppl.9007</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3491</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib + Tremelimumab</td>\n",
       "      <td>34953624</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3492</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Navitoclax + Osimertinib</td>\n",
       "      <td>NCT02520778</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3493</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Icotinib</td>\n",
       "      <td>NCT05536505</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3494</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Carboplatin + Lazertinib + Pemetrexed</td>\n",
       "      <td>NCT05477615</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3495</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Atezolizumab + Rociletinib</td>\n",
       "      <td>NCT02630186</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3496</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Lazertinib</td>\n",
       "      <td>NCT05326425</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3497</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib + Stereotactic radiotherapy</td>\n",
       "      <td>NCT05033691</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3498</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>NCT03382795</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3499</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT04233021</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3500</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>NCT03382795</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3501</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Dasatinib + Osimertinib</td>\n",
       "      <td>10.1016/j.jtho.2018.08.603</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3502</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Afatinib + Cyclophosphamide + EGF-PTI</td>\n",
       "      <td>10.1016/j.jtho.2021.08.117</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3503</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>33077354</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3504</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>10.1016/j.jtho.2021.08.383</td>\n",
       "      <td>Complete response, Pathological complete response</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3505</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3506</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib + Ramucirumab</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3507</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>10.1200/JCO.2020.38.18_suppl.LBA5</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3508</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>29151359</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3509</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Dacomitinib</td>\n",
       "      <td>29864379</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3510</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3511</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3512</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Not defined</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3513</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3514</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3515</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>15329413</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3516</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>15329413</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3517</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>15118073</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3518</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Pemetrexed</td>\n",
       "      <td>21642865</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3519</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>31809241</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3520</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>YL202</td>\n",
       "      <td>NCT05653752</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3521</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>QLH11811</td>\n",
       "      <td>NCT05555212</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3522</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib + Gentuximab</td>\n",
       "      <td>NCT05223595</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3523</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Triptolide</td>\n",
       "      <td>NCT05166616</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3524</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Camrelizumab + Carboplatin + Pemetrexed</td>\n",
       "      <td>NCT04970043</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3525</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Tegavivint</td>\n",
       "      <td>NCT04780568</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3526</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Temozolomide</td>\n",
       "      <td>NCT04541407</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3527</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Erlotinib</td>\n",
       "      <td>10.1200/JCO.2021.39.15_suppl.e21073</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3528</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Nazartinib + Ribociclib</td>\n",
       "      <td>NCT03333343</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3529</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Naporafenib + Nazartinib</td>\n",
       "      <td>NCT03333343</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3530</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Nazartinib + Trametinib</td>\n",
       "      <td>NCT03516214</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3531</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Nazartinib + Trametinib</td>\n",
       "      <td>NCT03333343</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3532</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Savolitinib</td>\n",
       "      <td>32139298</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3533</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>AV-412</td>\n",
       "      <td>NCT00381654</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3534</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Selumetinib</td>\n",
       "      <td>32139298</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3535</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Durvalumab + Osimertinib</td>\n",
       "      <td>32139298</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3536</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Nazartinib</td>\n",
       "      <td>NCT03333343</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3537</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Capmatinib + Nazartinib</td>\n",
       "      <td>NCT03333343</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3538</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Savolitinib</td>\n",
       "      <td>10.1200/JCO.2016.34.15_suppl.e20559</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3539</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Zorifertinib</td>\n",
       "      <td>29056570</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3540</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>DS-1205c + Gefitinib</td>\n",
       "      <td>10.1016/j.annonc.2020.08.684</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3541</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib + Xentuzumab</td>\n",
       "      <td>34590052</td>\n",
       "      <td>MTD, ORR, Toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3542</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Sapanisertib</td>\n",
       "      <td>NCT02503722</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3543</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>27083334</td>\n",
       "      <td>PFS, TTP, OS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3544</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Bevacizumab + Lazertinib</td>\n",
       "      <td>NCT05601973</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3545</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib + R-(-)-gossypol acetic acid</td>\n",
       "      <td>NCT00988169</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3546</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>EMB-01 + Osimertinib</td>\n",
       "      <td>NCT05498389</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3547</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib + Bevacizumab + Carboplatin + Pemet...</td>\n",
       "      <td>NCT05334277</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3548</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib + Carboplatin + Pemetrexed</td>\n",
       "      <td>NCT05334277</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3549</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Lazertinib + Stereotactic Body Radiation Therapy</td>\n",
       "      <td>NCT05167851</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3550</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>BLU-701 + Carboplatin + Pemetrexed</td>\n",
       "      <td>NCT05153408</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3551</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>BLU-701 + Osimertinib</td>\n",
       "      <td>NCT05153408</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3552</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>BLU-701</td>\n",
       "      <td>NCT05153408</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3553</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Carboplatin + Cisplatin + Icotinib + Pemetrexed</td>\n",
       "      <td>NCT05132985</td>\n",
       "      <td>Major pathologic response</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3554</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Carboplatin + Cisplatin + Icotinib + Pemetrexed</td>\n",
       "      <td>NCT05104788</td>\n",
       "      <td>Major pathologic response</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3555</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Carboplatin + Lenvatinib + Pembrolizumab + Pem...</td>\n",
       "      <td>NCT05258279</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3556</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>LY3295668 + Osimertinib</td>\n",
       "      <td>NCT05017025</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3557</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Carboplatin + Lazertinib + Pemet...</td>\n",
       "      <td>NCT05498428</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3558</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Carboplatin + Lazertinib + Pemet...</td>\n",
       "      <td>NCT05299125</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3559</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Cisplatin + Osimertinib + Pemetrexed</td>\n",
       "      <td>NCT05011487</td>\n",
       "      <td>Lymph node clearance rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3560</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Befotertinib + Icotinib</td>\n",
       "      <td>NCT05007938</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3561</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04922138</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3562</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib + Anlotinib</td>\n",
       "      <td>NCT04895930</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3563</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Keynatinib</td>\n",
       "      <td>NCT04824079</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3564</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib + Cisplatin + Pemetrexed + Radiotherapy</td>\n",
       "      <td>10.1200/JCO.2018.36.15_suppl.8544</td>\n",
       "      <td>Response rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3565</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib + Microwave ablation</td>\n",
       "      <td>NCT04755738</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3566</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Lenvatinib + Pembrolizumab</td>\n",
       "      <td>NCT05078931</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3567</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Pemetrexed + Platinum-based chem...</td>\n",
       "      <td>NCT05281406</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3568</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Lazertinib</td>\n",
       "      <td>NCT05498428</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3569</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Atezolizumab + Bevacizumab</td>\n",
       "      <td>NCT04099836</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3570</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Ascorbic acid + Tyrosine Kinase Inhibitor</td>\n",
       "      <td>NCT03799094</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3571</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Gefitinib</td>\n",
       "      <td>NCT04358562</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3572</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Durvalumab + Tremelimumab</td>\n",
       "      <td>NCT03994393</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3573</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>ZN-e4</td>\n",
       "      <td>NCT03446417</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3574</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Chemotherapy + Icotinib</td>\n",
       "      <td>NCT03396185</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3575</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Cisplatin + Icotinib + Pemetrexed</td>\n",
       "      <td>NCT03544814</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3576</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Pemetrexed + Toripalimab</td>\n",
       "      <td>10.1200/JCO.2020.38.15_suppl.e21618</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3577</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Stereotactic radiotherapy</td>\n",
       "      <td>NCT03769103</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3578</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Icotinib</td>\n",
       "      <td>10.1016/j.annonc.2020.08.1656</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3579</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Tyrosine Kinase Inhibitor</td>\n",
       "      <td>10.1200/JCO.2021.39.15_suppl.9030</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3580</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Carboplatin + Icotinib + Pemetrexed</td>\n",
       "      <td>NCT02737774</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3581</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Carboplatin + Icotinib + Pemetrexed</td>\n",
       "      <td>NCT03151161</td>\n",
       "      <td>Clinical activity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3582</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Carboplatin + Pemetrexed</td>\n",
       "      <td>10.1016/j.jtho.2021.01.1093</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3583</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Gefitinib</td>\n",
       "      <td>25695221</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3584</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Gefitinib</td>\n",
       "      <td>NCT02930954</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3585</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Local Consolidation Therapy + Osimertinib</td>\n",
       "      <td>NCT03410043</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3586</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Selumetinib</td>\n",
       "      <td>NCT03392246</td>\n",
       "      <td>Best overall response</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3587</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Thalidomide</td>\n",
       "      <td>NCT03341494</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3588</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Cyclophosphamide + Fludarabine + Interleukin-2...</td>\n",
       "      <td>26898607</td>\n",
       "      <td>Response rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3589</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Atezolizumab + Bevacizumab + Carboplatin + Pem...</td>\n",
       "      <td>NCT04512430</td>\n",
       "      <td>Major pathologic response</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3590</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Cisplatin + Pemetrexed</td>\n",
       "      <td>NCT03050437</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3591</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Ramucirumab</td>\n",
       "      <td>NCT03909334</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3592</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Fruquintinib + Gefitinib</td>\n",
       "      <td>10.1093/annonc/mdz437.004</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3593</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT05334277</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3594</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT05165355</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3595</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT05079022</td>\n",
       "      <td>Clearance of ctDNA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3596</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT04965831</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3597</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT04982900</td>\n",
       "      <td>Response rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3598</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT05379803</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3599</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Trastuzumab-emtansine</td>\n",
       "      <td>https://www.onclive.com/view/tdm-1-osimertinib...</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3600</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Nazartinib</td>\n",
       "      <td>NCT03292133</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3601</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Capmatinib + Nazartinib</td>\n",
       "      <td>10.1016/j.annonc.2020.08.1598</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3602</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Capmatinib + Nazartinib</td>\n",
       "      <td>10.1016/j.annonc.2020.08.1598</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3603</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib + Linsitinib</td>\n",
       "      <td>27686971</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3604</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Osimertinib</td>\n",
       "      <td>10.1200/JCO.2020.38.15_suppl.9507</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3605</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Olaparib</td>\n",
       "      <td>10.1200/JCO.2018.36.15_suppl.9012</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3606</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Berberine + Gefitinib</td>\n",
       "      <td>NCT03486496</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3607</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Erlotinib</td>\n",
       "      <td>10.1200/JCO.2022.40.16_suppl.9107</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3608</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Erlotinib</td>\n",
       "      <td>NCT01532089</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3609</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Tegafur-gimeracil-oteracil potassium</td>\n",
       "      <td>NCT03457337</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3610</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Telaglenastat</td>\n",
       "      <td>NCT03831932</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3611</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Ficlatuzumab + Gefitinib</td>\n",
       "      <td>27448761</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3612</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Poziotinib</td>\n",
       "      <td>NCT01819428</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3613</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Neratinib</td>\n",
       "      <td>20479403</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3614</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Lapatinib</td>\n",
       "      <td>20215545</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3615</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Lazertinib</td>\n",
       "      <td>NCT05463224</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3616</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Lazertinib</td>\n",
       "      <td>NCT03046992</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3617</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Olmutinib</td>\n",
       "      <td>NCT02444819</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3618</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Nazartinib</td>\n",
       "      <td>https://oncologypro.esmo.org/meeting-resources...</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3619</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Tesevatinib</td>\n",
       "      <td>NCT02616393</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3620</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Tesevatinib</td>\n",
       "      <td>NCT02616393</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3621</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Tesevatinib</td>\n",
       "      <td>NCT02616393</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3622</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Tesevatinib</td>\n",
       "      <td>22011666</td>\n",
       "      <td>Response rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3623</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Tesevatinib</td>\n",
       "      <td>22722787</td>\n",
       "      <td>Response rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3624</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT04591002</td>\n",
       "      <td>Clinical activity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3625</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT03769103</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3626</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT03586453</td>\n",
       "      <td>Biomarker discovery</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3627</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Dacomitinib</td>\n",
       "      <td>NCT04027647</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3628</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib</td>\n",
       "      <td>NCT05514314</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3629</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib</td>\n",
       "      <td>35862035</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3630</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib</td>\n",
       "      <td>NCT03349203</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3631</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib</td>\n",
       "      <td>NCT03749213</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3632</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>NCT03399669</td>\n",
       "      <td>Time to progression</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3633</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>NCT02347839</td>\n",
       "      <td>Resection rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3634</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>10.1200/JCO.2017.35.15_suppl.9035</td>\n",
       "      <td>Disease control rate, Clinical benefit rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3635</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>10.1186/s12885-021-07861-1</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3636</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>20493771</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3637</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Carboplatin + Pemetrexed</td>\n",
       "      <td>NCT04988295</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3638</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Carboplatin + Lazertinib + Pemet...</td>\n",
       "      <td>NCT04988295</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3639</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib + Chemotherapy</td>\n",
       "      <td>NCT04923906</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3640</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>EGFR-TKI + JY025</td>\n",
       "      <td>NCT04874844</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3641</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib or Erlotinib + Niacinamaide</td>\n",
       "      <td>10.1016/j.jtho.2022.07.769</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3642</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Lazertinib + Placebo</td>\n",
       "      <td>NCT04487080</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3643</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Placebo</td>\n",
       "      <td>NCT04487080</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3644</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Lazertinib</td>\n",
       "      <td>NCT05388669</td>\n",
       "      <td>PFS, ORR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3645</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Lazertinib</td>\n",
       "      <td>NCT04487080</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3646</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib + Carboplatin + Pemetrexed</td>\n",
       "      <td>NCT04500717</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3647</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib + Carboplatin + Pemetrexed</td>\n",
       "      <td>NCT04500704</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3648</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib + Stereotactic radiotherapy</td>\n",
       "      <td>NCT04058704</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3649</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Gefitinib</td>\n",
       "      <td>NCT04028778</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3650</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Chemotherapy + Osimertinib</td>\n",
       "      <td>NCT03521154</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3651</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Patritumab deruxtecan</td>\n",
       "      <td>NCT05338970</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3652</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Chemotherapy + Erlotinib</td>\n",
       "      <td>23782814</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3653</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Yiqi-yangyin-jiedu Decoction</td>\n",
       "      <td>NCT02929693</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3654</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Apatinib + Gefitinib</td>\n",
       "      <td>34033974</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3655</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Naquotinib</td>\n",
       "      <td>NCT02588261</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3656</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Naquotinib</td>\n",
       "      <td>NCT02588261</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3657</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04951635</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3658</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>10.1200/JCO.2021.39.15_suppl.9013</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3659</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT04143607</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3660</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>35662408</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3661</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Zorifertinib</td>\n",
       "      <td>NCT03653546</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3662</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Abivertinib</td>\n",
       "      <td>NCT03856697</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3663</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Erlotinib</td>\n",
       "      <td>https://oncologypro.esmo.org/meeting-resources...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3664</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Erlotinib</td>\n",
       "      <td>https://oncologypro.esmo.org/meeting-resources...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3665</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib + Cetuximab</td>\n",
       "      <td>NCT02442349</td>\n",
       "      <td>OS, PFS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3666</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Cisplatin + Gefitinib + Pemetrexed</td>\n",
       "      <td>NCT02518802</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3667</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Cisplatin + Gefitinib + Pemetrexed</td>\n",
       "      <td>NCT03381066</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3668</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Olmutinib</td>\n",
       "      <td>https://www.boehringer-ingelheim.us/press-rele...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3669</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Nazartinib</td>\n",
       "      <td>NCT03529084</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3670</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Tesevatinib</td>\n",
       "      <td>NCT01487174</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3671</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT05120349</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3672</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT04351555</td>\n",
       "      <td>Major pathologic response</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3673</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT04035486</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3674</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib</td>\n",
       "      <td>34280355</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3675</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib</td>\n",
       "      <td>23948351</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3676</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>10.1200/JCO.21.01729</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3677</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>28103612</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3678</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Dacomitinib</td>\n",
       "      <td>NCT04511533</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3679</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Apatinib + Erlotinib</td>\n",
       "      <td>NCT03634059</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3680</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Apatinib + Icotinib</td>\n",
       "      <td>NCT03634059</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3681</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Gefitinib + Icotinib</td>\n",
       "      <td>NCT03766490</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3682</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Radiotherapy</td>\n",
       "      <td>NCT03381430</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3684</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R or EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>10.1016/j.jtho.2021.10.024</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3685</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R or EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Almonertinib + Chemotherapy</td>\n",
       "      <td>NCT04952168</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3686</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R or EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Almonertinib + Chemotherapy</td>\n",
       "      <td>NCT04905550</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3687</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R or EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Afatinib + Cetuximab</td>\n",
       "      <td>NCT02442349</td>\n",
       "      <td>OS, PFS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3688</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or EGFR_L858R or EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04687241</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3689</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon19del or Exon20ins or EGFR_G719 or EG...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Bintrafusp alfa + Carboplatin + Cisplatin + Pe...</td>\n",
       "      <td>NCT04971187</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3692</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon20ins or ERBB2_Exon20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Mobocertinib</td>\n",
       "      <td>NCT02716116</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3693</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_19ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>4</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>29483495</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3694</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Mobocertinib</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3695</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3696</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>24353160</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3697</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib</td>\n",
       "      <td>https://www.jto.org/article/S1556-0864(17)3288...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3698</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>10.1016/j.annonc.2021.08.1815</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3699</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>BLU-451</td>\n",
       "      <td>NCT05241873</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3700</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>JMT101</td>\n",
       "      <td>NCT04448379</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3701</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT04858958</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3702</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT04958967</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3703</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>NCT02369484</td>\n",
       "      <td>Disease control rate, Clinical benefit rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3704</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>HS-10376</td>\n",
       "      <td>NCT05435274</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3705</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>JMT101 + Osimertinib</td>\n",
       "      <td>NCT05132777</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3706</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Carboplatin + Mobocertinib + Pemetrexed</td>\n",
       "      <td>NCT02716116</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3707</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Poziotinib + Ramucirumab</td>\n",
       "      <td>NCT05045404</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3708</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Carboplatin + Pemetrexed</td>\n",
       "      <td>NCT05498428</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3709</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Pyrotinib</td>\n",
       "      <td>35101045</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3710</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Pyrotinib</td>\n",
       "      <td>NCT04063462</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3711</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Tarloxotinib</td>\n",
       "      <td>10.1016/annonc/annonc325</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3712</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>CLN-081</td>\n",
       "      <td>10.1200/JCO.2021.39.15_suppl.9077</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3713</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>DZD9008</td>\n",
       "      <td>10.1200/JCO.2021.39.15_suppl.9008</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3714</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Mobocertinib</td>\n",
       "      <td>NCT02716116</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3715</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Mobocertinib</td>\n",
       "      <td>NCT04576208</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3716</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Sintilimab</td>\n",
       "      <td>10.1016/j.annonc.2022.02.030</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3717</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Pirotinib</td>\n",
       "      <td>NCT03574402</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3718</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Luminespib</td>\n",
       "      <td>NCT01922583</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3719</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT05466149</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3720</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib + Cetuximab</td>\n",
       "      <td>10.1200/JCO.2021.39.15_suppl.9112</td>\n",
       "      <td>Disease control rate, Clinical benefit rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3721</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib + Onalespib lactate</td>\n",
       "      <td>34140248</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3722</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Poziotinib</td>\n",
       "      <td>https://oncologypro.esmo.org/meeting-resources...</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3723</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Poziotinib</td>\n",
       "      <td>NCT04402008</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3724</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Poziotinib</td>\n",
       "      <td>NCT04044170</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3725</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Poziotinib</td>\n",
       "      <td>NCT03318939</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3726</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Poziotinib</td>\n",
       "      <td>10.1016/j.jtho.2018.08.243</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3727</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT03191149</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3728</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>10.1093/annonc/mdz260.051</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3729</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Poziotinib</td>\n",
       "      <td>NCT05378763</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3730</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Carboplatin + Pemetrexed</td>\n",
       "      <td>NCT04538664</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3731</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Pyrotinib</td>\n",
       "      <td>NCT04447118</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3732</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>DZD9008</td>\n",
       "      <td>NCT05668988</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3733</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Mobocertinib</td>\n",
       "      <td>NCT04129502</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3734</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Entrectinib</td>\n",
       "      <td>NCT03178552</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3735</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT05607550</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3736</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT05513664</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3737</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_Exon_20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>DZD9008</td>\n",
       "      <td>NCT05559645</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3738</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Not defined</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3739</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>28184913</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3740</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>15118073</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3741</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Neratinib</td>\n",
       "      <td>20479403</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3742</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>26051236</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3743</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>34540680</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3744</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719 or EGFR_L861Q or EGFR_S768I</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT03434418</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3745</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719 or EGFR_L861Q or EGFR_S768I</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Afatinib + Bevacizumab</td>\n",
       "      <td>NCT05267288</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3746</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719 or EGFR_L861Q or EGFR_S768I</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Sutetinib</td>\n",
       "      <td>NCT05168566</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3747</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719 or EGFR_L861Q or EGFR_S768I</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib + Pemetrexed + Platinum-based chem...</td>\n",
       "      <td>NCT05215951</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3748</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719 or EGFR_L861Q or EGFR_S768I</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT05548348</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3749</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719 or EGFR_L861Q or EGFR_S768I</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT05546866</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3750</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719 or EGFR_L861Q or EGFR_S768I</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>10.1200/JCO.2018.36.15_suppl.9050</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3751</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_G719 or EGFR_L861Q or EGFR_S768I</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04951648</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3752</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Bevacizumab + Osimertinib</td>\n",
       "      <td>NCT04988607</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3753</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Anlotinib + Dacomitinib</td>\n",
       "      <td>NCT05271916</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3754</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib + Pemetrexed</td>\n",
       "      <td>27507876</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3755</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Bevacizumab + Icotinib</td>\n",
       "      <td>NCT05263947</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3756</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_L858R_Exon19del and (TP53_Exon4 or TP53_E...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib or Erlotinib</td>\n",
       "      <td>33317922</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3757</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_L858R_Exon19del and EGFR_no_T790M and MET...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Capmatinib + Osimertinib</td>\n",
       "      <td>NCT04816214</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3758</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_L858R_Exon19del and TP53_not_Exon4 and TP...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib or Erlotinib</td>\n",
       "      <td>33317922</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3759</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_L861Q</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Not defined</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3760</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_L861Q</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>10.1200/JCO.2018.36.15_suppl.9050</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3761</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_L861Q</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>26051236</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3762</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_S768I</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Not defined</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3763</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_S768I</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>10.1200/JCO.2018.36.15_suppl.9050</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3764</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_S768I</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>26051236</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3765</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_S768I or EGFR_V769L</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>4</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>17045698</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3767</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>25923549</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3768</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>22071596</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3769</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>24035188</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3770</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Sapanisertib</td>\n",
       "      <td>NCT04479306</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3771</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>QLH11811</td>\n",
       "      <td>NCT05555212</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3772</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + VIC-1911</td>\n",
       "      <td>NCT05489731</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3773</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alisertib + Osimertinib</td>\n",
       "      <td>NCT04479306</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3774</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>SH-1028</td>\n",
       "      <td>NCT03618043</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3775</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>SH-1028</td>\n",
       "      <td>NCT03603262</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3776</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>D0316</td>\n",
       "      <td>35274722</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3777</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Avitinib</td>\n",
       "      <td>NCT03053219</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3778</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Savolitinib</td>\n",
       "      <td>32139298</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3779</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Selumetinib</td>\n",
       "      <td>32139298</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3780</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib + Ruxolitinib</td>\n",
       "      <td>31319994</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3781</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Durvalumab + Osimertinib</td>\n",
       "      <td>32139298</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3782</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Nazartinib + Nivolumab</td>\n",
       "      <td>NCT02323126</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3783</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Ramucirumab</td>\n",
       "      <td>33046516</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3784</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Necitumumab + Osimertinib</td>\n",
       "      <td>NCT02789345</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3785</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>BPI-7711</td>\n",
       "      <td>10.1093/annonc/mdz437.002</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3786</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Naquotinib</td>\n",
       "      <td>28954786</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3787</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Abivertinib</td>\n",
       "      <td>30032814</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3788</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib + Cetuximab</td>\n",
       "      <td>29110849</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3789</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Olmutinib</td>\n",
       "      <td>NCT04510415</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3790</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>25923549</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3791</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>EMB-01 + Osimertinib</td>\n",
       "      <td>NCT05498389</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3792</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Carboplatin + Pemetrexed + Sulfatinib + Toripa...</td>\n",
       "      <td>NCT05003037</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3793</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib + Radiotherapy</td>\n",
       "      <td>NCT04970693</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3794</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib + Carboplatin + Pemetrexed</td>\n",
       "      <td>NCT04592666</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3795</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Osimertinib</td>\n",
       "      <td>NCT04438902</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3796</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>ZN-e4</td>\n",
       "      <td>NCT03446417</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3797</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>D0316</td>\n",
       "      <td>10.1158/1538-7445.AM2021-CT170</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3798</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Avitinib</td>\n",
       "      <td>NCT03574402</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3799</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Interleukin-2 + WT1-sensitized allogenic T cells</td>\n",
       "      <td>NCT04764214</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3800</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Local Consolidation Therapy + Osimertinib</td>\n",
       "      <td>NCT03410043</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3801</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Luminespib</td>\n",
       "      <td>NCT01922583</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3802</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Brigatinib</td>\n",
       "      <td>NCT01449461</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3803</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Emibetuzumab + Erlotinib</td>\n",
       "      <td>https://ascopubs.org/doi/abs/10.1200/JCO.2017....</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3804</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Emibetuzumab + Erlotinib</td>\n",
       "      <td>https://meetinglibrary.asco.org/record/123487/...</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3805</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Itacitinib + Osimertinib</td>\n",
       "      <td>NCT02917993</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3806</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Cabozantinib + Erlotinib</td>\n",
       "      <td>30915273</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3807</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Lerociclib + Osimertinib</td>\n",
       "      <td>NCT03455829</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3808</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Aspirin + Osimertinib</td>\n",
       "      <td>NCT03532698</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3809</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Aspirin + Osimertinib</td>\n",
       "      <td>NCT03543683</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3810</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Osimertinib</td>\n",
       "      <td>NCT02971501</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3811</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Osimertinib</td>\n",
       "      <td>10.1016/j.annonc.2021.11.010</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3812</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>BPI-7711</td>\n",
       "      <td>36049654</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3813</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Malvertinib</td>\n",
       "      <td>https://www.jto.org/article/S1556-0864(16)3290...</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3814</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Rociletinib</td>\n",
       "      <td>25923550</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3815</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>BMS-690514</td>\n",
       "      <td>23490650</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3816</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>10.1016/j.jtho.2022.05.011</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3817</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>10.1200/JCO.2020.38.15_suppl.9602</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3818</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib + Ruxolitinib</td>\n",
       "      <td>27613527</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3819</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Abivertinib</td>\n",
       "      <td>NCT03300115</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3820</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Poziotinib</td>\n",
       "      <td>NCT01819428</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3821</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Canertinib</td>\n",
       "      <td>17761977</td>\n",
       "      <td>Clinical activity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3822</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Lazertinib</td>\n",
       "      <td>10.1200/JCO.2019.37.15_suppl.9037</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3823</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Olmutinib</td>\n",
       "      <td>NCT03228277</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3824</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Olmutinib</td>\n",
       "      <td>10.1093/annonc/mdx671.001</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3825</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Olmutinib</td>\n",
       "      <td>NCT02444819</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3826</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Olmutinib</td>\n",
       "      <td>https://www.boehringer-ingelheim.com/press-rel...</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3827</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT05536505</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3828</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT04563871</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3829</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>35156036</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3830</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT02824952</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>10.1016/j.jtocrr.2020.100099</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>32669708</td>\n",
       "      <td>ORR, PFS, DOR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT03394118</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT02094261</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT02442349</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3836</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>https://www.clinicaltrialsregister.eu/ctr-sear...</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3837</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT02856893</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3838</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>32200138</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3839</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>32634610</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3840</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Durvalumab + Osimertinib</td>\n",
       "      <td>30763730</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3841</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Rociletinib</td>\n",
       "      <td>10.1093/annonc/mdw140</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3842</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04870190</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3843</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Olmutinib</td>\n",
       "      <td>https://www.hopkinsmedicine.org/singapore/_dow...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3844</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Olmutinib</td>\n",
       "      <td>https://www.boehringer-ingelheim.us/press-rele...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3845</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>32634610</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3846</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT02474355</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3847</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>32817079</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3848</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>29858027</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3849</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT03853551</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3850</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>1</td>\n",
       "      <td>Lazertinib</td>\n",
       "      <td>NCT05377788</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3851</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib + Savolitinib</td>\n",
       "      <td>33052556</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3852</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_T790M and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Gefitinib + Tepotinib</td>\n",
       "      <td>NCT01982955</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3853</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_C797S and EGFR_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>BLU-945</td>\n",
       "      <td>NCT04862780</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3854</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_Exon19del and EGFR_no_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04785742</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3855</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_Exon19del and EGFR_no_L858R</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Anlotinib + Sintilimab</td>\n",
       "      <td>10.1016/j.annonc.2022.02.030</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3856</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_Exon20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04841811</td>\n",
       "      <td>ORR, EFS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3857</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_Exon20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>EMB-01 + Osimertinib</td>\n",
       "      <td>NCT05498389</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3858</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_Exon20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Alflutinib + Cisplatin + Pemetrexed</td>\n",
       "      <td>NCT05430802</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3859</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_Exon20ins</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>FWD1509</td>\n",
       "      <td>NCT05068024</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3860</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Neoantigen vaccine + Tyrosine Kinase Inhibitor</td>\n",
       "      <td>NCT04487093</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3861</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Glumetinib</td>\n",
       "      <td>NCT04338243</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3862</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Afatinib + Osimertinib</td>\n",
       "      <td>NCT04413201</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3863</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_T790M</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>DZD9008</td>\n",
       "      <td>NCT05559645</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3864</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_no_T790M and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib + Savolitinib</td>\n",
       "      <td>32027846</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3994</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Docetaxel + Ramucirumab</td>\n",
       "      <td>https://www.accessdata.fda.gov/drugsatfda_docs...</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3995</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Pemetrexed</td>\n",
       "      <td>21111508</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3996</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>NCT03711422</td>\n",
       "      <td>OS, PFS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3997</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib + SHR1701</td>\n",
       "      <td>NCT05503888</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3998</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Dalpiciclib + EGFR-TKI</td>\n",
       "      <td>NCT05497076</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3999</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carotuximab + Osimertinib</td>\n",
       "      <td>NCT05401110</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4000</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Ipilimumab</td>\n",
       "      <td>10.1016/j.jtho.2017.09.010</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4001</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BDTX-1535</td>\n",
       "      <td>NCT05256290</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4002</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Autologous personalized DC vaccine</td>\n",
       "      <td>NCT05195619</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4003</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Autologous EGFR-IL13RA2 CAR-T cells + Cyclopho...</td>\n",
       "      <td>NCT05168423</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4004</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BAY2927088_formulation A</td>\n",
       "      <td>NCT05099172</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4005</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BAY2927088_formulation B_1</td>\n",
       "      <td>NCT05099172</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4006</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BAY2927088_formulation B_2</td>\n",
       "      <td>NCT05099172</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4007</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>CXCR5 modified EGFR CAR-T cells</td>\n",
       "      <td>NCT05060796</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4008</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>TAS2940</td>\n",
       "      <td>NCT04982926</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4009</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib + Bevacizumab</td>\n",
       "      <td>NCT04944069</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4010</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Repotrectinib</td>\n",
       "      <td>NCT04772235</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4011</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>MRX-2843 + Osimertinib</td>\n",
       "      <td>NCT04762199</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4012</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BBP-398</td>\n",
       "      <td>NCT05621525</td>\n",
       "      <td>ORR, DOR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4013</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BBP-398</td>\n",
       "      <td>NCT04528836</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4014</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Amivantamab + Lazertinib</td>\n",
       "      <td>NCT02609776</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4015</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BCA101</td>\n",
       "      <td>NCT04429542</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4016</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BCA101 + Pembrolizumab</td>\n",
       "      <td>NCT04429542</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4017</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Individualized neoantigen peptides vaccine</td>\n",
       "      <td>NCT04397926</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4018</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Alisertib + Osimertinib</td>\n",
       "      <td>NCT04085315</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4019</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>TY-9591</td>\n",
       "      <td>NCT04204473</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4020</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Afatinib + Talcum powder</td>\n",
       "      <td>NCT03827070</td>\n",
       "      <td>Clinical activity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4021</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Pemetrexed + Zimberelimab</td>\n",
       "      <td>NCT03846310</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4022</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Etrumadenant + Pemetrexed + Zimb...</td>\n",
       "      <td>NCT03846310</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4023</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Palcitoclax</td>\n",
       "      <td>NCT04001777</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4024</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Niraparib + Osimertinib</td>\n",
       "      <td>NCT03891615</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4025</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Ipilimumab + Osimertinib</td>\n",
       "      <td>NCT04141644</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4026</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>JNJ-61186372 + Lazertinib</td>\n",
       "      <td>NCT04077463</td>\n",
       "      <td>ORR, PFS, DOR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4027</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Pembrolizumab + Stereotactic Body Radiation Th...</td>\n",
       "      <td>NCT03436056</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4028</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Stereotactic radiotherapy</td>\n",
       "      <td>NCT03535363</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4029</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gatipotuzumab + Tomuzotuximab</td>\n",
       "      <td>10.1016/S0959-8049(20)31083-2</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4030</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>DV281</td>\n",
       "      <td>NCT03326752</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4031</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cisplatin + Etoposide + Osimertinib</td>\n",
       "      <td>NCT03567642</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4032</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Abemaciclib + Necitumumab</td>\n",
       "      <td>NCT02411591</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4033</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib + Savolitinib</td>\n",
       "      <td>NCT02374645</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4034</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cucurmin + EGFR-TKI</td>\n",
       "      <td>10.1200/JCO.2019.37.15_suppl.e20611</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4035</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Buparlisib + Gefitinib</td>\n",
       "      <td>10.1200/jco.2013.31.15_suppl.8107</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4036</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Dasatinib + Erlotinib</td>\n",
       "      <td>NCT00903734</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4037</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Bortezomib + Erlotinib</td>\n",
       "      <td>NCT00903734</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4038</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cetuximab + Erlotinib</td>\n",
       "      <td>NCT00903734</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4039</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Durvalumab + Gefitinib</td>\n",
       "      <td>33012782</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4040</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Durvalumab + Gefitinib</td>\n",
       "      <td>33012782</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4041</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Momelotinib</td>\n",
       "      <td>10.1016/j.jtho.2017.09.1294</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4042</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Pacritinib</td>\n",
       "      <td>NCT02342353</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4043</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Crizotinib + Ipilimumab</td>\n",
       "      <td>NCT01998126</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4044</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Nivolumab + Sym004</td>\n",
       "      <td>NCT02924233</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4045</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Matuzumab + Pemetrexed</td>\n",
       "      <td>16533873</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4046</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Binimetinib + Erlotinib</td>\n",
       "      <td>NCT01859026</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4047</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Afatinib + Necitumumab</td>\n",
       "      <td>NCT03054038</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4048</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Dacomitinib + Osimertinib</td>\n",
       "      <td>NCT03755102</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4049</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Dacomitinib + Osimertinib</td>\n",
       "      <td>NCT03810807</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4050</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Afatinib + Dasatinib</td>\n",
       "      <td>30880334</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4051</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Naquotinib</td>\n",
       "      <td>NCT03082300</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4052</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04455594</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4053</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>DS-1205c + Osimertinib</td>\n",
       "      <td>NCT03255083</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4054</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Pelitinib</td>\n",
       "      <td>16364494</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4055</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Dacomitinib</td>\n",
       "      <td>NCT03755102</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4056</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Ipilimumab + Nivolumab</td>\n",
       "      <td>36426287</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4057</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>AK112 + AK119 + Carboplatin + Pemetrexed</td>\n",
       "      <td>NCT05636267</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4058</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>AK112 + AK119</td>\n",
       "      <td>NCT05636267</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4059</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>H002</td>\n",
       "      <td>NCT05552781</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4060</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>H002</td>\n",
       "      <td>NCT05519293</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4061</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + OBI-821 + OBI-833</td>\n",
       "      <td>NCT05442060</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4062</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BPI-361175</td>\n",
       "      <td>NCT05393466</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4063</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Platinum-based chemotherapy + SKB264 + Tagitan...</td>\n",
       "      <td>NCT05351788</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4064</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Afatinib + Carboplatin + Osimertinib + Pemetrexed</td>\n",
       "      <td>NCT05298176</td>\n",
       "      <td>Disease control rate, Clinical benefit rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4065</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + TQB3525</td>\n",
       "      <td>NCT05284994</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4066</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>NRC-2694-A + Paclitaxel</td>\n",
       "      <td>NCT05283226</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4067</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Nab-paclitaxel + Sintilimab</td>\n",
       "      <td>NCT05244213</td>\n",
       "      <td>Complete response, Pathological complete response</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4068</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Afatinib + Thoracic surgery</td>\n",
       "      <td>NCT05215548</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4069</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Pemetrexed + Pimurutamab</td>\n",
       "      <td>NCT05215925</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4070</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Docetaxel + Pimurutamab</td>\n",
       "      <td>NCT05215925</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4071</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Pimurutamab</td>\n",
       "      <td>NCT05215925</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4072</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Alflutinib + Chemotherapy</td>\n",
       "      <td>NCT05209256</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4073</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>AFM24 + SNK01</td>\n",
       "      <td>NCT05099549</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4074</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Radiotherapy</td>\n",
       "      <td>NCT05089916</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4075</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>SI-B001</td>\n",
       "      <td>NCT05044897</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4076</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Lenvatinib + Pembrolizumab + Pem...</td>\n",
       "      <td>NCT04989322</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4077</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Lenvatinib + Pembrolizumab + Pem...</td>\n",
       "      <td>NCT04989322</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4078</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>ERAS-007 + Osimertinib</td>\n",
       "      <td>NCT04959981</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4079</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib + Anlotinib</td>\n",
       "      <td>NCT04978753</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4080</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Buparlisib + Erlotinib</td>\n",
       "      <td>NCT01487265</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4081</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Tivantinib</td>\n",
       "      <td>27843623</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4082</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Gemcitabine + Platinum-based chemo...</td>\n",
       "      <td>NCT02098954</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4083</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Sapitinib</td>\n",
       "      <td>10.1200/JCO.2021.39.15_suppl.9095</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4084</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Cetuximab + Gemcitabine + SIM180...</td>\n",
       "      <td>NCT04872634</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4085</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Gemcitabine + SNK01</td>\n",
       "      <td>NCT04872634</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4086</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>AK112</td>\n",
       "      <td>NCT05636267</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4087</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BBT-176 + Cetuximab</td>\n",
       "      <td>NCT04820023</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4088</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BBT-176</td>\n",
       "      <td>NCT04820023</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4089</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>MRG003</td>\n",
       "      <td>NCT04838548</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4090</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>APL-101 + Osimertinib</td>\n",
       "      <td>NCT04743505</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4091</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Nivolumab + Pemetrexed</td>\n",
       "      <td>NCT03256136</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4092</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Abemaciclib + Osimertinib</td>\n",
       "      <td>NCT04545710</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4093</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Osimertinib + Pemetrexed</td>\n",
       "      <td>NCT04335292</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4094</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Bevacizumab + Cisplatin + Durvalumab + Stereot...</td>\n",
       "      <td>NCT04517526</td>\n",
       "      <td>OS, PFS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4095</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Necitumumab + Osimertinib + Trastuzumab</td>\n",
       "      <td>NCT04285671</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4096</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Afatinib + Cisplatin + Pemetrexed</td>\n",
       "      <td>NCT04470076</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4097</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Quaratusugene ozeplasmid</td>\n",
       "      <td>NCT04486833</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4098</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Amivantamab + Lazertinib</td>\n",
       "      <td>NCT04965090</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4099</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Osimertinib + Paclitaxel</td>\n",
       "      <td>NCT04410796</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4100</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Pemetrexed + Tislelizumab</td>\n",
       "      <td>https://oncologypro.esmo.org/meeting-resources...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4101</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Famitinb + HS-10296</td>\n",
       "      <td>NCT03904823</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4102</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>TY-9591</td>\n",
       "      <td>NCT05146219</td>\n",
       "      <td>Intracranial Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4103</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Apatinib + Tyrosine Kinase Inhibitor</td>\n",
       "      <td>NCT03811054</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4104</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>EMB-01</td>\n",
       "      <td>NCT03797391</td>\n",
       "      <td>OS, PFS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4105</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Anlotinib + Osimertinib</td>\n",
       "      <td>10.1200/JCO.2022.40.16_suppl.e21140</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4106</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Anlotinib + Osimertinib</td>\n",
       "      <td>NCT04029350</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4107</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + RMC-4630</td>\n",
       "      <td>NCT03989115</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4108</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + RMC-4630</td>\n",
       "      <td>NCT03989115</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4109</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Mobocertinib</td>\n",
       "      <td>NCT03574402</td>\n",
       "      <td>Response rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4110</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Pembrolizumab + Ramucirumab</td>\n",
       "      <td>NCT04120454</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4111</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>GC1118 + Paclitaxel</td>\n",
       "      <td>NCT04077255</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4112</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Stereotactic Body Radiation Therapy</td>\n",
       "      <td>NCT04908956</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4113</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Stereotactic Body Radiation Therapy</td>\n",
       "      <td>NCT03667820</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4114</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Anlotinib + Sintilimab</td>\n",
       "      <td>NCT03765775</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4115</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>FCN-411</td>\n",
       "      <td>35248866</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4116</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Dihydroartemisinin + Icotinib</td>\n",
       "      <td>NCT03402464</td>\n",
       "      <td>OS, PFS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4117</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Afatinib + Tucidinostat</td>\n",
       "      <td>NCT03574402</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4118</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>SH-1028</td>\n",
       "      <td>10.1016/j.annonc.2022.02.016</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4119</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>AZD4205 + Osimertinib</td>\n",
       "      <td>NCT03450330</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4120</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Stereotactic radiotherapy</td>\n",
       "      <td>NCT04519983</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4121</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Stereotactic radiotherapy</td>\n",
       "      <td>NCT03497767</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4122</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Stereotactic Body Radiation Therapy + Tyrosine...</td>\n",
       "      <td>10.1016/j.jtho.2019.08.499</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4123</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib + Ningetinib</td>\n",
       "      <td>10.1200/JCO.2020.38.15_suppl.9583</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4124</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Apatinib + Chemotherapy</td>\n",
       "      <td>NCT03758677</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4125</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Autologous T-Cells with enhanced TCRs specific...</td>\n",
       "      <td>NCT03709706</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4126</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Autologous T-Cells with enhanced TCRs specific...</td>\n",
       "      <td>NCT03709706</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4127</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Avitinib</td>\n",
       "      <td>NCT03574402</td>\n",
       "      <td>Response rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4128</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>AVID100</td>\n",
       "      <td>NCT03094169</td>\n",
       "      <td>Clinical activity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4129</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Icotinib + Stereotactic Body Radiation Therapy</td>\n",
       "      <td>NCT03153358</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4130</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Icotinib + Stereotactic Body Radiation Therapy</td>\n",
       "      <td>NCT03754530</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4131</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Atezolizumab + Cabozantinib</td>\n",
       "      <td>NCT03170960</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4132</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Sunitinib</td>\n",
       "      <td>NCT00265317</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4133</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Anlotinib + Docetaxel</td>\n",
       "      <td>NCT04619563</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4134</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Durvalumab + Pemetrexed</td>\n",
       "      <td>NCT03944772</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4135</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Tepotinib</td>\n",
       "      <td>NCT03940703</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4136</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Tepotinib</td>\n",
       "      <td>NCT03940703</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4137</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Savolitinib</td>\n",
       "      <td>NCT03944772</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4138</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cetuximab + Cilengitide + Cisplatin + Vinorelbine</td>\n",
       "      <td>NCT00842712</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4139</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Cetuximab + Pemetrexed + Radioth...</td>\n",
       "      <td>NCT00117962</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4140</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Foretinib</td>\n",
       "      <td>29050231</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4141</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cetuximab + Natural killer cell immunotherapy</td>\n",
       "      <td>29888109</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4142</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Bevacizumab + Carboplatin + Pemetrexed</td>\n",
       "      <td>26774201</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4143</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Rociletinib + Trametinib</td>\n",
       "      <td>NCT02580708</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4144</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>MP0250 + Osimertinib</td>\n",
       "      <td>NCT03418532</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4145</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cetuximab + Chemotherapy + Radiotherapy</td>\n",
       "      <td>NCT00492206</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4146</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + MK2206</td>\n",
       "      <td>NCT01294306</td>\n",
       "      <td>DCR, ORR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4147</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Apatinib + Erlotinib</td>\n",
       "      <td>NCT02704767</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4148</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Capecitabine + Cetuximab + Oxaliplatin</td>\n",
       "      <td>NCT00444678</td>\n",
       "      <td>Response rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4149</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Atezolizumab + Bevacizumab + Carboplatin + Pem...</td>\n",
       "      <td>10.1016/annonc/annonc367</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4150</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Atezolizumab + Bevacizumab + Carboplatin + Pac...</td>\n",
       "      <td>NCT04245085</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4151</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Durvalumab + Olaparib</td>\n",
       "      <td>NCT04538378</td>\n",
       "      <td>Best overall response</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4152</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gemcitabine + Vandetanib</td>\n",
       "      <td>10.1200/jco.2012.30.15_suppl.7550</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4153</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Fruquintinib</td>\n",
       "      <td>https://www.chi-med.com/wp-content/uploads/201...</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4154</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Fruquintinib</td>\n",
       "      <td>29528793</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4155</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cisplatin + Panitumumab + Pemetrexed</td>\n",
       "      <td>NCT00979212</td>\n",
       "      <td>Clinical activity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4156</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cisplatin + Panitumumab + Pemetrexed</td>\n",
       "      <td>10.1200/jco.2013.31.15_suppl.8062</td>\n",
       "      <td>Time to progression</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4157</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cisplatin + Panitumumab + Pemetrexed</td>\n",
       "      <td>26094080</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4158</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cisplatin + Panitumumab + Pemetrexed</td>\n",
       "      <td>NCT01038037</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4159</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Fruquintinib + Gefitinib</td>\n",
       "      <td>https://www.healio.com/hematology-oncology/lun...</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4160</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Matuzumab + Pemetrexed</td>\n",
       "      <td>20978446</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4161</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cisplatin + Gemcitabine + Imgatuzumab + Pemetr...</td>\n",
       "      <td>10.1200/jco.2012.30.15_suppl.7544</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4162</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Erlotinib + Paclitaxel</td>\n",
       "      <td>NCT00126581</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4163</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Nimotuzumab + Nivolumab</td>\n",
       "      <td>NCT02947386</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4164</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib + Metformin</td>\n",
       "      <td>10.1200/JCO.2019.37.15_suppl.9035</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4165</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Celecoxib + Erlotinib</td>\n",
       "      <td>26033830</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4166</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Trametinib</td>\n",
       "      <td>10.1200/PO.20.00315</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4167</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Fulvestrant + Gefitinib</td>\n",
       "      <td>10.1200/JCO.2018.36.15_suppl.9097</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4168</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Dacomitinib + Osimertinib</td>\n",
       "      <td>NCT04811001</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4169</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Necitumumab + Osimertinib</td>\n",
       "      <td>NCT03944772</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4170</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Bevacizumab + Osimertinib</td>\n",
       "      <td>32463456</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4171</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BMS-690514</td>\n",
       "      <td>NCT01167244</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4172</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT05662813</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4173</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04882345</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4174</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04423185</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4175</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04685070</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4176</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04808752</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4177</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04553887</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4178</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04354961</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4179</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT05469022</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4180</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT05465343</td>\n",
       "      <td>PFS, ORR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4181</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>AZD4635 + Oleclumab</td>\n",
       "      <td>10.1158/1538-7445.AM2021-CT163</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4182</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Oleclumab + Osimertinib</td>\n",
       "      <td>10.1158/1538-7445.AM2021-CT163</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4183</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib + Osimertinib</td>\n",
       "      <td>NCT03944772</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4184</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Zorifertinib</td>\n",
       "      <td>NCT03574402</td>\n",
       "      <td>Response rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4185</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Afatinib + Cetuximab</td>\n",
       "      <td>10.1200/JCO.2019.37.15_suppl.9079</td>\n",
       "      <td>Time to progression</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4186</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Hydroxychloroquine</td>\n",
       "      <td>10.1200/jco.2014.32.15_suppl.8088</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4187</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Ficlatuzumab + Gefitinib</td>\n",
       "      <td>27448761</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4188</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Canertinib</td>\n",
       "      <td>17761977</td>\n",
       "      <td>Clinical activity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4189</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Lazertinib</td>\n",
       "      <td>NCT05338619</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4190</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Lazertinib</td>\n",
       "      <td>NCT05277701</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4191</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Lazertinib</td>\n",
       "      <td>NCT04075396</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4192</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Pelitinib</td>\n",
       "      <td>NCT00067548</td>\n",
       "      <td>Not defined</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4193</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Vandetanib</td>\n",
       "      <td>10.1200/JCO.2021.39.15_suppl.9095</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4194</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Vandetanib</td>\n",
       "      <td>24075125</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4195</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Docetaxel + Vandetanib</td>\n",
       "      <td>23689430</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4196</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT05526755</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4197</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT03804580</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4198</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT03865511</td>\n",
       "      <td>Biomarker discovery</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4199</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT03460275</td>\n",
       "      <td>Clinical activity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4200</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>35156036</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4201</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT03239340</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4202</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Dacomitinib</td>\n",
       "      <td>NCT00818441</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4203</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Dacomitinib</td>\n",
       "      <td>NCT04423185</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4204</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Dacomitinib</td>\n",
       "      <td>NCT04339829</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4205</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Dacomitinib</td>\n",
       "      <td>NCT04504071</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4206</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>NCT00344773</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4207</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>NCT00411047</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4208</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>NCT02804776</td>\n",
       "      <td>Tumour volume</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4209</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>25667274</td>\n",
       "      <td>Response rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4210</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>NCT00087412</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4211</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>NCT02183883</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4212</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>NCT04201756</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4213</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Ipilimumab + Nivolumab</td>\n",
       "      <td>NCT03256136</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4214</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>NCT02193282</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4215</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>EGFR-TKI + Metformin</td>\n",
       "      <td>NCT05445791</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4216</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + TY-9591</td>\n",
       "      <td>NCT05382728</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4217</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Atezolizumab + Bevacizumab + Carboplatin + Pac...</td>\n",
       "      <td>NCT04194203</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4218</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Pemetrexed + Placebo + Platinum-based chemothe...</td>\n",
       "      <td>NCT05132413</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4219</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Bevacizumab + Pemetrexed + Platinum-based chem...</td>\n",
       "      <td>NCT05132413</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4220</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib + Chemotherapy</td>\n",
       "      <td>NCT05493501</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4221</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>AK112</td>\n",
       "      <td>NCT05184712</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4222</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib + Cisplatin + Pemetrexed</td>\n",
       "      <td>NCT04762459</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4223</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Pemetrexed + Platinum-based chem...</td>\n",
       "      <td>NCT04765059</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4224</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib + Pemetrexed + Platinum-based chem...</td>\n",
       "      <td>NCT04351555</td>\n",
       "      <td>Major pathologic response</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4225</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Pemetrexed + Toripalimab</td>\n",
       "      <td>10.1038/s41392-021-00751-9</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4226</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cisplatin + Pemetrexed + Placebo + Sintilimab</td>\n",
       "      <td>10.1016/j.annonc.2021.10.007</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4227</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Cisplatin + IBI305  + Pemetrexed + Sintilimab</td>\n",
       "      <td>10.1016/j.annonc.2021.10.007</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4228</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>SH-1028</td>\n",
       "      <td>NCT04239833</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4229</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>D0316</td>\n",
       "      <td>NCT04206072</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4230</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Pembrolizumab + Pemetrexed</td>\n",
       "      <td>NCT03515837</td>\n",
       "      <td>OS, PFS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4231</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Stereotactic Body Radiation Therapy + Tyrosine...</td>\n",
       "      <td>NCT03727867</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4232</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Anlotinib + Icotinib</td>\n",
       "      <td>NCT04797806</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4233</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Endostatin + Tyrosine Kinase Inhibitor</td>\n",
       "      <td>NCT03008109</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4234</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Vinorelbine</td>\n",
       "      <td>NCT03203590</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4235</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Sunitinib</td>\n",
       "      <td>NCT00558103</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4236</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Sunitinib</td>\n",
       "      <td>NCT00558103</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4237</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Stereotactic Body Radiation Therapy</td>\n",
       "      <td>NCT02882984</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4238</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib + Stereotactic Body Radiation Therapy</td>\n",
       "      <td>NCT02882984</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4239</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib + Thalidomide</td>\n",
       "      <td>NCT02387086</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4240</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Chemotherapy + Gefitinib</td>\n",
       "      <td>26159065</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4241</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Fruquintinib</td>\n",
       "      <td>10.1016/j.lungcan.2020.06.016</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4242</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Erlotinib + Onartuzumab</td>\n",
       "      <td>NCT02031744</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4243</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Erlotinib + Paclitaxel</td>\n",
       "      <td>16043829</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4244</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Bevacizumab + Osimertinib</td>\n",
       "      <td>NCT05104281</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4245</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>BPI-7711</td>\n",
       "      <td>NCT03866499</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4246</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Rociletinib</td>\n",
       "      <td>NCT02186301</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4247</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT05493501</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4248</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04762459</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4249</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT04853342</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4250</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Bevacizumab + Erlotinib</td>\n",
       "      <td>10.1200/JCO.2018.36.15_suppl.9006</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4251</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Lazertinib</td>\n",
       "      <td>NCT04248829</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4252</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Docetaxel + Vandetanib</td>\n",
       "      <td>25057173</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4253</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>NCT03656393</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4254</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>22674612</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4255</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>18779611</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4256</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>33332190</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4257</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Beta-elemene + Tyrosine Kinase Inhibitor</td>\n",
       "      <td>NCT04401059</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4258</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT03969823</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4259</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Carboplatin + Pemetrexed + Tyrosine Kinase Inh...</td>\n",
       "      <td>NCT04552613</td>\n",
       "      <td>OS, PFS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4260</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Chemotherapy + Icotinib</td>\n",
       "      <td>NCT03983811</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4261</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>DZD9008</td>\n",
       "      <td>NCT05559645</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4262</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Anlotinib + Tyrosine Kinase Inhibitor</td>\n",
       "      <td>NCT04007835</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4263</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Radiotherapy + Tyrosine Kinase Inhibitor</td>\n",
       "      <td>NCT03916913</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4264</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Metformin + Tyrosine Kinase Inhibitor</td>\n",
       "      <td>31486833</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4265</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>NCT04778800</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4266</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>2</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>NCT04737382</td>\n",
       "      <td>Biomarker discovery</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4323</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and ERBB2_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Erlotinib + Gemcitabine + Platinum-based chemo...</td>\n",
       "      <td>NCT02098954</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4327</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and KRAS_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Erlotinib + Gemcitabine + Platinum-based chemo...</td>\n",
       "      <td>NCT02098954</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4328</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Capmatinib + Erlotinib</td>\n",
       "      <td>10.1200/jco.2015.33.15_suppl.2587</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4329</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib + Tepotinib</td>\n",
       "      <td>NCT05120960</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4330</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib + Savolitinib</td>\n",
       "      <td>NCT03778229</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4331</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Capmatinib + Osimertinib + Ramucirumab</td>\n",
       "      <td>NCT05642572</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4332</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Tepotinib</td>\n",
       "      <td>NCT03940703</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4333</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Capmatinib + Gefitinib</td>\n",
       "      <td>30156984</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4334</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Capmatinib + Osimertinib</td>\n",
       "      <td>NCT05642572</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4335</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib + Tepotinib</td>\n",
       "      <td>NCT03940703</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4336</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib + Savolitinib</td>\n",
       "      <td>NCT05163249</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4337</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib + Savolitinib</td>\n",
       "      <td>NCT04606771</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4338</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Erlotinib + Onartuzumab</td>\n",
       "      <td>27937096</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4339</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Osimertinib + Savolitinib</td>\n",
       "      <td>NCT05015608</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4340</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MET_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Erlotinib + Onartuzumab</td>\n",
       "      <td>https://www.clinicaltrialsregister.eu/ctr-sear...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4342</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and MUC1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>M1231</td>\n",
       "      <td>NCT04695847</td>\n",
       "      <td>ORR, DOR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4343</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and PIK3CA_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Erlotinib + Gemcitabine + Platinum-based chemo...</td>\n",
       "      <td>NCT02098954</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4344</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified and TP53_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Bevacizumab + Carboplatin + Osimertinib + Peme...</td>\n",
       "      <td>NCT05507606</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4346</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified or ERBB2_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Neratinib</td>\n",
       "      <td>19318484</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4347</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified or ERBB2_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>PLB1004</td>\n",
       "      <td>NCT05347628</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4348</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified or ERBB2_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Mobocertinib</td>\n",
       "      <td>NCT03807778</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4349</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified or ERBB2_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>NCT05364073</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4350</th>\n",
       "      <td>EGFR</td>\n",
       "      <td>EGFR_unspecified or ERBB2_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>DZD9008</td>\n",
       "      <td>NCT03974022</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6176</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Regorafenib</td>\n",
       "      <td>26003007</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6177</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Nintedanib + Pembrolizumab</td>\n",
       "      <td>NCT02856425</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6178</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Pazopanib</td>\n",
       "      <td>NCT02193152</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6179</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Nintedanib</td>\n",
       "      <td>10.1200/JCO.2020.38.15_suppl.e21694</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6180</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>AZD4547</td>\n",
       "      <td>10.1200/JCO.2021.39.15_suppl.9095</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6181</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Ponatinib</td>\n",
       "      <td>30297175</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6182</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>AZD4547 + Docetaxel</td>\n",
       "      <td>NCT01824901</td>\n",
       "      <td>Maximum tolerated dose/toxicity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6183</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Methotrexate + Regorafenib</td>\n",
       "      <td>NCT03520842</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6184</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Pazopanib</td>\n",
       "      <td>NCT00367679</td>\n",
       "      <td>Tumour volume</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6185</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Nintedanib</td>\n",
       "      <td>NCT01948141</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6186</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Dovitinib</td>\n",
       "      <td>27315356</td>\n",
       "      <td>Response rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6187</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Dovitinib</td>\n",
       "      <td>10.1200/jco.2016.34.4_suppl.616</td>\n",
       "      <td>Unknown</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6188</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Docetaxel + Nintedanib</td>\n",
       "      <td>NCT02231164</td>\n",
       "      <td>Disease control rate, Clinical benefit rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6189</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Pazopanib</td>\n",
       "      <td>26074395</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6229</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified or FGFR2_unspecified or FGFR...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Erdafitinib</td>\n",
       "      <td>NCT02699606</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6230</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified or FGFR2_unspecified or FGFR...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Pemigatinib</td>\n",
       "      <td>NCT05287386</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6231</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified or FGFR2_unspecified or FGFR...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Pemigatinib</td>\n",
       "      <td>NCT05253807</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6232</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified or FGFR2_unspecified or FGFR...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Rogaratinib</td>\n",
       "      <td>10.1200/JCO.2019.37.15_suppl.e20661</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6233</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FGFR1_unspecified or FGFR2_unspecified or FGFR...</td>\n",
       "      <td>lung / carcinoma / non small cell carcinoma</td>\n",
       "      <td>3</td>\n",
       "      <td>Pemigatinib</td>\n",
       "      <td>NCT05210946</td>\n",
       "      <td>Overall Response Rate</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       GENE                                    MUTATION_REMARK  \\\n",
       "28     EGFR  (EGFR_Exon19del or EGFR_L858R or EGFR_T790M) a...   \n",
       "29     EGFR  (EGFR_Exon19del or EGFR_L858R) and CD274_unspe...   \n",
       "30     EGFR  (EGFR_Exon19del or EGFR_L858R) and CD274_unspe...   \n",
       "31     EGFR  (EGFR_Exon19del or EGFR_L858R) and MET_unspeci...   \n",
       "32     EGFR  (EGFR_Exon19del or EGFR_L858R) and MET_unspeci...   \n",
       "33     EGFR  (EGFR_Exon19del or EGFR_L858R) and MET_unspeci...   \n",
       "34     EGFR  (EGFR_Exon19del or EGFR_L858R) and TP53_unspec...   \n",
       "35    FGFR1  (FGFR1_unspecified or FGFR2_unspecified or FGF...   \n",
       "3457   EGFR                                          EGFR_C797   \n",
       "3458   EGFR                                          EGFR_C797   \n",
       "3459   EGFR                            EGFR_C797 or EGFR_T790M   \n",
       "3460   EGFR                                         EGFR_C797S   \n",
       "3461   EGFR                                         EGFR_C797S   \n",
       "3462   EGFR                                         EGFR_C797S   \n",
       "3463   EGFR                                         EGFR_C797S   \n",
       "3464   EGFR                         EGFR_C797S and EGFR_T790M    \n",
       "3465   EGFR                       EGFR_C797S and EGFR_no_T790M   \n",
       "3468   EGFR                                       EGFR_E709K/A   \n",
       "3469   EGFR                              EGFR_E709_T710delinsD   \n",
       "3470   EGFR                              EGFR_E709_T710delinsD   \n",
       "3471   EGFR                              EGFR_E709_T710delinsD   \n",
       "3472   EGFR                                        EGFR_Exon18   \n",
       "3473   EGFR                                     EGFR_Exon19del   \n",
       "3474   EGFR                                     EGFR_Exon19del   \n",
       "3475   EGFR                      EGFR_Exon19del and EGFR_T790M   \n",
       "3476   EGFR  EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...   \n",
       "3477   EGFR  EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...   \n",
       "3478   EGFR  EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...   \n",
       "3479   EGFR  EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...   \n",
       "3480   EGFR  EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...   \n",
       "3481   EGFR  EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...   \n",
       "3482   EGFR  EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...   \n",
       "3483   EGFR  EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...   \n",
       "3484   EGFR  EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...   \n",
       "3485   EGFR  EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...   \n",
       "3486   EGFR  EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 ...   \n",
       "3487   EGFR  EGFR_Exon19del or EGFR_Exon20ins or EGFR_G719 ...   \n",
       "3488   EGFR  EGFR_Exon19del or EGFR_Exon20ins or EGFR_G719 ...   \n",
       "3489   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...   \n",
       "3490   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...   \n",
       "3491   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...   \n",
       "3492   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...   \n",
       "3493   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...   \n",
       "3494   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...   \n",
       "3495   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...   \n",
       "3496   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R  or ...   \n",
       "3497   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...   \n",
       "3498   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...   \n",
       "3499   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...   \n",
       "3500   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...   \n",
       "3501   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...   \n",
       "3502   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...   \n",
       "3503   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...   \n",
       "3504   EGFR  EGFR_Exon19del or EGFR_G719 or EGFR_L858R or E...   \n",
       "3505   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3506   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3507   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3508   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3509   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3510   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3511   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3512   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3513   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3514   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3515   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3516   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3517   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3518   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3519   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3520   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3521   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3522   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3523   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3524   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3525   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3526   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3527   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3528   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3529   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3530   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3531   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3532   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3533   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3534   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3535   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3536   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3537   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3538   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3539   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3540   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3541   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3542   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3543   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3544   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3545   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3546   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3547   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3548   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3549   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3550   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3551   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3552   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3553   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3554   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3555   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3556   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3557   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3558   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3559   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3560   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3561   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3562   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3563   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3564   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3565   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3566   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3567   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3568   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3569   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3570   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3571   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3572   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3573   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3574   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3575   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3576   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3577   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3578   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3579   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3580   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3581   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3582   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3583   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3584   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3585   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3586   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3587   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3588   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3589   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3590   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3591   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3592   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3593   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3594   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3595   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3596   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3597   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3598   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3599   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3600   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3601   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3602   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3603   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3604   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3605   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3606   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3607   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3608   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3609   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3610   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3611   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3612   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3613   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3614   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3615   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3616   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3617   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3618   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3619   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3620   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3621   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3622   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3623   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3624   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3625   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3626   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3627   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3628   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3629   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3630   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3631   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3632   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3633   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3634   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3635   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3636   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3637   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3638   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3639   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3640   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3641   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3642   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3643   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3644   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3645   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3646   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3647   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3648   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3649   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3650   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3651   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3652   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3653   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3654   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3655   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3656   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3657   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3658   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3659   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3660   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3661   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3662   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3663   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3664   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3665   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3666   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3667   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3668   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3669   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3670   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3671   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3672   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3673   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3674   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3675   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3676   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3677   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3678   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3679   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3680   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3681   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3682   EGFR                       EGFR_Exon19del or EGFR_L858R   \n",
       "3684   EGFR         EGFR_Exon19del or EGFR_L858R or EGFR_T790M   \n",
       "3685   EGFR         EGFR_Exon19del or EGFR_L858R or EGFR_T790M   \n",
       "3686   EGFR         EGFR_Exon19del or EGFR_L858R or EGFR_T790M   \n",
       "3687   EGFR         EGFR_Exon19del or EGFR_L858R or EGFR_T790M   \n",
       "3688   EGFR         EGFR_Exon19del or EGFR_L858R or EGFR_T790M   \n",
       "3689   EGFR  EGFR_Exon19del or Exon20ins or EGFR_G719 or EG...   \n",
       "3692   EGFR                  EGFR_Exon20ins or ERBB2_Exon20ins   \n",
       "3693   EGFR                                    EGFR_Exon_19ins   \n",
       "3694   EGFR                                    EGFR_Exon_20ins   \n",
       "3695   EGFR                                    EGFR_Exon_20ins   \n",
       "3696   EGFR                                    EGFR_Exon_20ins   \n",
       "3697   EGFR                                    EGFR_Exon_20ins   \n",
       "3698   EGFR                                    EGFR_Exon_20ins   \n",
       "3699   EGFR                                    EGFR_Exon_20ins   \n",
       "3700   EGFR                                    EGFR_Exon_20ins   \n",
       "3701   EGFR                                    EGFR_Exon_20ins   \n",
       "3702   EGFR                                    EGFR_Exon_20ins   \n",
       "3703   EGFR                                    EGFR_Exon_20ins   \n",
       "3704   EGFR                                    EGFR_Exon_20ins   \n",
       "3705   EGFR                                    EGFR_Exon_20ins   \n",
       "3706   EGFR                                    EGFR_Exon_20ins   \n",
       "3707   EGFR                                    EGFR_Exon_20ins   \n",
       "3708   EGFR                                    EGFR_Exon_20ins   \n",
       "3709   EGFR                                    EGFR_Exon_20ins   \n",
       "3710   EGFR                                    EGFR_Exon_20ins   \n",
       "3711   EGFR                                    EGFR_Exon_20ins   \n",
       "3712   EGFR                                    EGFR_Exon_20ins   \n",
       "3713   EGFR                                    EGFR_Exon_20ins   \n",
       "3714   EGFR                                    EGFR_Exon_20ins   \n",
       "3715   EGFR                                    EGFR_Exon_20ins   \n",
       "3716   EGFR                                    EGFR_Exon_20ins   \n",
       "3717   EGFR                                    EGFR_Exon_20ins   \n",
       "3718   EGFR                                    EGFR_Exon_20ins   \n",
       "3719   EGFR                                    EGFR_Exon_20ins   \n",
       "3720   EGFR                                    EGFR_Exon_20ins   \n",
       "3721   EGFR                                    EGFR_Exon_20ins   \n",
       "3722   EGFR                                    EGFR_Exon_20ins   \n",
       "3723   EGFR                                    EGFR_Exon_20ins   \n",
       "3724   EGFR                                    EGFR_Exon_20ins   \n",
       "3725   EGFR                                    EGFR_Exon_20ins   \n",
       "3726   EGFR                                    EGFR_Exon_20ins   \n",
       "3727   EGFR                                    EGFR_Exon_20ins   \n",
       "3728   EGFR                                    EGFR_Exon_20ins   \n",
       "3729   EGFR                                    EGFR_Exon_20ins   \n",
       "3730   EGFR                                    EGFR_Exon_20ins   \n",
       "3731   EGFR                                    EGFR_Exon_20ins   \n",
       "3732   EGFR                                    EGFR_Exon_20ins   \n",
       "3733   EGFR                                    EGFR_Exon_20ins   \n",
       "3734   EGFR                                    EGFR_Exon_20ins   \n",
       "3735   EGFR                                    EGFR_Exon_20ins   \n",
       "3736   EGFR                                    EGFR_Exon_20ins   \n",
       "3737   EGFR                                    EGFR_Exon_20ins   \n",
       "3738   EGFR                                          EGFR_G719   \n",
       "3739   EGFR                                          EGFR_G719   \n",
       "3740   EGFR                                          EGFR_G719   \n",
       "3741   EGFR                                          EGFR_G719   \n",
       "3742   EGFR                                          EGFR_G719   \n",
       "3743   EGFR                                          EGFR_G719   \n",
       "3744   EGFR              EGFR_G719 or EGFR_L861Q or EGFR_S768I   \n",
       "3745   EGFR              EGFR_G719 or EGFR_L861Q or EGFR_S768I   \n",
       "3746   EGFR              EGFR_G719 or EGFR_L861Q or EGFR_S768I   \n",
       "3747   EGFR              EGFR_G719 or EGFR_L861Q or EGFR_S768I   \n",
       "3748   EGFR              EGFR_G719 or EGFR_L861Q or EGFR_S768I   \n",
       "3749   EGFR              EGFR_G719 or EGFR_L861Q or EGFR_S768I   \n",
       "3750   EGFR              EGFR_G719 or EGFR_L861Q or EGFR_S768I   \n",
       "3751   EGFR              EGFR_G719 or EGFR_L861Q or EGFR_S768I   \n",
       "3752   EGFR                                         EGFR_L858R   \n",
       "3753   EGFR                                         EGFR_L858R   \n",
       "3754   EGFR                                         EGFR_L858R   \n",
       "3755   EGFR                                         EGFR_L858R   \n",
       "3756   EGFR  EGFR_L858R_Exon19del and (TP53_Exon4 or TP53_E...   \n",
       "3757   EGFR  EGFR_L858R_Exon19del and EGFR_no_T790M and MET...   \n",
       "3758   EGFR  EGFR_L858R_Exon19del and TP53_not_Exon4 and TP...   \n",
       "3759   EGFR                                         EGFR_L861Q   \n",
       "3760   EGFR                                         EGFR_L861Q   \n",
       "3761   EGFR                                         EGFR_L861Q   \n",
       "3762   EGFR                                         EGFR_S768I   \n",
       "3763   EGFR                                         EGFR_S768I   \n",
       "3764   EGFR                                         EGFR_S768I   \n",
       "3765   EGFR                           EGFR_S768I or EGFR_V769L   \n",
       "3767   EGFR                                         EGFR_T790M   \n",
       "3768   EGFR                                         EGFR_T790M   \n",
       "3769   EGFR                                         EGFR_T790M   \n",
       "3770   EGFR                                         EGFR_T790M   \n",
       "3771   EGFR                                         EGFR_T790M   \n",
       "3772   EGFR                                         EGFR_T790M   \n",
       "3773   EGFR                                         EGFR_T790M   \n",
       "3774   EGFR                                         EGFR_T790M   \n",
       "3775   EGFR                                         EGFR_T790M   \n",
       "3776   EGFR                                         EGFR_T790M   \n",
       "3777   EGFR                                         EGFR_T790M   \n",
       "3778   EGFR                                         EGFR_T790M   \n",
       "3779   EGFR                                         EGFR_T790M   \n",
       "3780   EGFR                                         EGFR_T790M   \n",
       "3781   EGFR                                         EGFR_T790M   \n",
       "3782   EGFR                                         EGFR_T790M   \n",
       "3783   EGFR                                         EGFR_T790M   \n",
       "3784   EGFR                                         EGFR_T790M   \n",
       "3785   EGFR                                         EGFR_T790M   \n",
       "3786   EGFR                                         EGFR_T790M   \n",
       "3787   EGFR                                         EGFR_T790M   \n",
       "3788   EGFR                                         EGFR_T790M   \n",
       "3789   EGFR                                         EGFR_T790M   \n",
       "3790   EGFR                                         EGFR_T790M   \n",
       "3791   EGFR                                         EGFR_T790M   \n",
       "3792   EGFR                                         EGFR_T790M   \n",
       "3793   EGFR                                         EGFR_T790M   \n",
       "3794   EGFR                                         EGFR_T790M   \n",
       "3795   EGFR                                         EGFR_T790M   \n",
       "3796   EGFR                                         EGFR_T790M   \n",
       "3797   EGFR                                         EGFR_T790M   \n",
       "3798   EGFR                                         EGFR_T790M   \n",
       "3799   EGFR                                         EGFR_T790M   \n",
       "3800   EGFR                                         EGFR_T790M   \n",
       "3801   EGFR                                         EGFR_T790M   \n",
       "3802   EGFR                                         EGFR_T790M   \n",
       "3803   EGFR                                         EGFR_T790M   \n",
       "3804   EGFR                                         EGFR_T790M   \n",
       "3805   EGFR                                         EGFR_T790M   \n",
       "3806   EGFR                                         EGFR_T790M   \n",
       "3807   EGFR                                         EGFR_T790M   \n",
       "3808   EGFR                                         EGFR_T790M   \n",
       "3809   EGFR                                         EGFR_T790M   \n",
       "3810   EGFR                                         EGFR_T790M   \n",
       "3811   EGFR                                         EGFR_T790M   \n",
       "3812   EGFR                                         EGFR_T790M   \n",
       "3813   EGFR                                         EGFR_T790M   \n",
       "3814   EGFR                                         EGFR_T790M   \n",
       "3815   EGFR                                         EGFR_T790M   \n",
       "3816   EGFR                                         EGFR_T790M   \n",
       "3817   EGFR                                         EGFR_T790M   \n",
       "3818   EGFR                                         EGFR_T790M   \n",
       "3819   EGFR                                         EGFR_T790M   \n",
       "3820   EGFR                                         EGFR_T790M   \n",
       "3821   EGFR                                         EGFR_T790M   \n",
       "3822   EGFR                                         EGFR_T790M   \n",
       "3823   EGFR                                         EGFR_T790M   \n",
       "3824   EGFR                                         EGFR_T790M   \n",
       "3825   EGFR                                         EGFR_T790M   \n",
       "3826   EGFR                                         EGFR_T790M   \n",
       "3827   EGFR                                         EGFR_T790M   \n",
       "3828   EGFR                                         EGFR_T790M   \n",
       "3829   EGFR                                         EGFR_T790M   \n",
       "3830   EGFR                                         EGFR_T790M   \n",
       "3831   EGFR                                         EGFR_T790M   \n",
       "3832   EGFR                                         EGFR_T790M   \n",
       "3833   EGFR                                         EGFR_T790M   \n",
       "3834   EGFR                                         EGFR_T790M   \n",
       "3835   EGFR                                         EGFR_T790M   \n",
       "3836   EGFR                                         EGFR_T790M   \n",
       "3837   EGFR                                         EGFR_T790M   \n",
       "3838   EGFR                                         EGFR_T790M   \n",
       "3839   EGFR                                         EGFR_T790M   \n",
       "3840   EGFR                                         EGFR_T790M   \n",
       "3841   EGFR                                         EGFR_T790M   \n",
       "3842   EGFR                                         EGFR_T790M   \n",
       "3843   EGFR                                         EGFR_T790M   \n",
       "3844   EGFR                                         EGFR_T790M   \n",
       "3845   EGFR                                         EGFR_T790M   \n",
       "3846   EGFR                                         EGFR_T790M   \n",
       "3847   EGFR                                         EGFR_T790M   \n",
       "3848   EGFR                                         EGFR_T790M   \n",
       "3849   EGFR                                         EGFR_T790M   \n",
       "3850   EGFR                                         EGFR_T790M   \n",
       "3851   EGFR                     EGFR_T790M and MET_unspecified   \n",
       "3852   EGFR                     EGFR_T790M and MET_unspecified   \n",
       "3853   EGFR                       EGFR_no_C797S and EGFR_T790M   \n",
       "3854   EGFR                EGFR_no_Exon19del and EGFR_no_L858R   \n",
       "3855   EGFR                EGFR_no_Exon19del and EGFR_no_L858R   \n",
       "3856   EGFR                                  EGFR_no_Exon20ins   \n",
       "3857   EGFR                                  EGFR_no_Exon20ins   \n",
       "3858   EGFR                                  EGFR_no_Exon20ins   \n",
       "3859   EGFR                                  EGFR_no_Exon20ins   \n",
       "3860   EGFR                                      EGFR_no_T790M   \n",
       "3861   EGFR                                      EGFR_no_T790M   \n",
       "3862   EGFR                                      EGFR_no_T790M   \n",
       "3863   EGFR                                      EGFR_no_T790M   \n",
       "3864   EGFR                  EGFR_no_T790M and MET_unspecified   \n",
       "3994   EGFR                                   EGFR_unspecified   \n",
       "3995   EGFR                                   EGFR_unspecified   \n",
       "3996   EGFR                                   EGFR_unspecified   \n",
       "3997   EGFR                                   EGFR_unspecified   \n",
       "3998   EGFR                                   EGFR_unspecified   \n",
       "3999   EGFR                                   EGFR_unspecified   \n",
       "4000   EGFR                                   EGFR_unspecified   \n",
       "4001   EGFR                                   EGFR_unspecified   \n",
       "4002   EGFR                                   EGFR_unspecified   \n",
       "4003   EGFR                                   EGFR_unspecified   \n",
       "4004   EGFR                                   EGFR_unspecified   \n",
       "4005   EGFR                                   EGFR_unspecified   \n",
       "4006   EGFR                                   EGFR_unspecified   \n",
       "4007   EGFR                                   EGFR_unspecified   \n",
       "4008   EGFR                                   EGFR_unspecified   \n",
       "4009   EGFR                                   EGFR_unspecified   \n",
       "4010   EGFR                                   EGFR_unspecified   \n",
       "4011   EGFR                                   EGFR_unspecified   \n",
       "4012   EGFR                                   EGFR_unspecified   \n",
       "4013   EGFR                                   EGFR_unspecified   \n",
       "4014   EGFR                                   EGFR_unspecified   \n",
       "4015   EGFR                                   EGFR_unspecified   \n",
       "4016   EGFR                                   EGFR_unspecified   \n",
       "4017   EGFR                                   EGFR_unspecified   \n",
       "4018   EGFR                                   EGFR_unspecified   \n",
       "4019   EGFR                                   EGFR_unspecified   \n",
       "4020   EGFR                                   EGFR_unspecified   \n",
       "4021   EGFR                                   EGFR_unspecified   \n",
       "4022   EGFR                                   EGFR_unspecified   \n",
       "4023   EGFR                                   EGFR_unspecified   \n",
       "4024   EGFR                                   EGFR_unspecified   \n",
       "4025   EGFR                                   EGFR_unspecified   \n",
       "4026   EGFR                                   EGFR_unspecified   \n",
       "4027   EGFR                                   EGFR_unspecified   \n",
       "4028   EGFR                                   EGFR_unspecified   \n",
       "4029   EGFR                                   EGFR_unspecified   \n",
       "4030   EGFR                                   EGFR_unspecified   \n",
       "4031   EGFR                                   EGFR_unspecified   \n",
       "4032   EGFR                                   EGFR_unspecified   \n",
       "4033   EGFR                                   EGFR_unspecified   \n",
       "4034   EGFR                                   EGFR_unspecified   \n",
       "4035   EGFR                                   EGFR_unspecified   \n",
       "4036   EGFR                                   EGFR_unspecified   \n",
       "4037   EGFR                                   EGFR_unspecified   \n",
       "4038   EGFR                                   EGFR_unspecified   \n",
       "4039   EGFR                                   EGFR_unspecified   \n",
       "4040   EGFR                                   EGFR_unspecified   \n",
       "4041   EGFR                                   EGFR_unspecified   \n",
       "4042   EGFR                                   EGFR_unspecified   \n",
       "4043   EGFR                                   EGFR_unspecified   \n",
       "4044   EGFR                                   EGFR_unspecified   \n",
       "4045   EGFR                                   EGFR_unspecified   \n",
       "4046   EGFR                                   EGFR_unspecified   \n",
       "4047   EGFR                                   EGFR_unspecified   \n",
       "4048   EGFR                                   EGFR_unspecified   \n",
       "4049   EGFR                                   EGFR_unspecified   \n",
       "4050   EGFR                                   EGFR_unspecified   \n",
       "4051   EGFR                                   EGFR_unspecified   \n",
       "4052   EGFR                                   EGFR_unspecified   \n",
       "4053   EGFR                                   EGFR_unspecified   \n",
       "4054   EGFR                                   EGFR_unspecified   \n",
       "4055   EGFR                                   EGFR_unspecified   \n",
       "4056   EGFR                                   EGFR_unspecified   \n",
       "4057   EGFR                                   EGFR_unspecified   \n",
       "4058   EGFR                                   EGFR_unspecified   \n",
       "4059   EGFR                                   EGFR_unspecified   \n",
       "4060   EGFR                                   EGFR_unspecified   \n",
       "4061   EGFR                                   EGFR_unspecified   \n",
       "4062   EGFR                                   EGFR_unspecified   \n",
       "4063   EGFR                                   EGFR_unspecified   \n",
       "4064   EGFR                                   EGFR_unspecified   \n",
       "4065   EGFR                                   EGFR_unspecified   \n",
       "4066   EGFR                                   EGFR_unspecified   \n",
       "4067   EGFR                                   EGFR_unspecified   \n",
       "4068   EGFR                                   EGFR_unspecified   \n",
       "4069   EGFR                                   EGFR_unspecified   \n",
       "4070   EGFR                                   EGFR_unspecified   \n",
       "4071   EGFR                                   EGFR_unspecified   \n",
       "4072   EGFR                                   EGFR_unspecified   \n",
       "4073   EGFR                                   EGFR_unspecified   \n",
       "4074   EGFR                                   EGFR_unspecified   \n",
       "4075   EGFR                                   EGFR_unspecified   \n",
       "4076   EGFR                                   EGFR_unspecified   \n",
       "4077   EGFR                                   EGFR_unspecified   \n",
       "4078   EGFR                                   EGFR_unspecified   \n",
       "4079   EGFR                                   EGFR_unspecified   \n",
       "4080   EGFR                                   EGFR_unspecified   \n",
       "4081   EGFR                                   EGFR_unspecified   \n",
       "4082   EGFR                                   EGFR_unspecified   \n",
       "4083   EGFR                                   EGFR_unspecified   \n",
       "4084   EGFR                                   EGFR_unspecified   \n",
       "4085   EGFR                                   EGFR_unspecified   \n",
       "4086   EGFR                                   EGFR_unspecified   \n",
       "4087   EGFR                                   EGFR_unspecified   \n",
       "4088   EGFR                                   EGFR_unspecified   \n",
       "4089   EGFR                                   EGFR_unspecified   \n",
       "4090   EGFR                                   EGFR_unspecified   \n",
       "4091   EGFR                                   EGFR_unspecified   \n",
       "4092   EGFR                                   EGFR_unspecified   \n",
       "4093   EGFR                                   EGFR_unspecified   \n",
       "4094   EGFR                                   EGFR_unspecified   \n",
       "4095   EGFR                                   EGFR_unspecified   \n",
       "4096   EGFR                                   EGFR_unspecified   \n",
       "4097   EGFR                                   EGFR_unspecified   \n",
       "4098   EGFR                                   EGFR_unspecified   \n",
       "4099   EGFR                                   EGFR_unspecified   \n",
       "4100   EGFR                                   EGFR_unspecified   \n",
       "4101   EGFR                                   EGFR_unspecified   \n",
       "4102   EGFR                                   EGFR_unspecified   \n",
       "4103   EGFR                                   EGFR_unspecified   \n",
       "4104   EGFR                                   EGFR_unspecified   \n",
       "4105   EGFR                                   EGFR_unspecified   \n",
       "4106   EGFR                                   EGFR_unspecified   \n",
       "4107   EGFR                                   EGFR_unspecified   \n",
       "4108   EGFR                                   EGFR_unspecified   \n",
       "4109   EGFR                                   EGFR_unspecified   \n",
       "4110   EGFR                                   EGFR_unspecified   \n",
       "4111   EGFR                                   EGFR_unspecified   \n",
       "4112   EGFR                                   EGFR_unspecified   \n",
       "4113   EGFR                                   EGFR_unspecified   \n",
       "4114   EGFR                                   EGFR_unspecified   \n",
       "4115   EGFR                                   EGFR_unspecified   \n",
       "4116   EGFR                                   EGFR_unspecified   \n",
       "4117   EGFR                                   EGFR_unspecified   \n",
       "4118   EGFR                                   EGFR_unspecified   \n",
       "4119   EGFR                                   EGFR_unspecified   \n",
       "4120   EGFR                                   EGFR_unspecified   \n",
       "4121   EGFR                                   EGFR_unspecified   \n",
       "4122   EGFR                                   EGFR_unspecified   \n",
       "4123   EGFR                                   EGFR_unspecified   \n",
       "4124   EGFR                                   EGFR_unspecified   \n",
       "4125   EGFR                                   EGFR_unspecified   \n",
       "4126   EGFR                                   EGFR_unspecified   \n",
       "4127   EGFR                                   EGFR_unspecified   \n",
       "4128   EGFR                                   EGFR_unspecified   \n",
       "4129   EGFR                                   EGFR_unspecified   \n",
       "4130   EGFR                                   EGFR_unspecified   \n",
       "4131   EGFR                                   EGFR_unspecified   \n",
       "4132   EGFR                                   EGFR_unspecified   \n",
       "4133   EGFR                                   EGFR_unspecified   \n",
       "4134   EGFR                                   EGFR_unspecified   \n",
       "4135   EGFR                                   EGFR_unspecified   \n",
       "4136   EGFR                                   EGFR_unspecified   \n",
       "4137   EGFR                                   EGFR_unspecified   \n",
       "4138   EGFR                                   EGFR_unspecified   \n",
       "4139   EGFR                                   EGFR_unspecified   \n",
       "4140   EGFR                                   EGFR_unspecified   \n",
       "4141   EGFR                                   EGFR_unspecified   \n",
       "4142   EGFR                                   EGFR_unspecified   \n",
       "4143   EGFR                                   EGFR_unspecified   \n",
       "4144   EGFR                                   EGFR_unspecified   \n",
       "4145   EGFR                                   EGFR_unspecified   \n",
       "4146   EGFR                                   EGFR_unspecified   \n",
       "4147   EGFR                                   EGFR_unspecified   \n",
       "4148   EGFR                                   EGFR_unspecified   \n",
       "4149   EGFR                                   EGFR_unspecified   \n",
       "4150   EGFR                                   EGFR_unspecified   \n",
       "4151   EGFR                                   EGFR_unspecified   \n",
       "4152   EGFR                                   EGFR_unspecified   \n",
       "4153   EGFR                                   EGFR_unspecified   \n",
       "4154   EGFR                                   EGFR_unspecified   \n",
       "4155   EGFR                                   EGFR_unspecified   \n",
       "4156   EGFR                                   EGFR_unspecified   \n",
       "4157   EGFR                                   EGFR_unspecified   \n",
       "4158   EGFR                                   EGFR_unspecified   \n",
       "4159   EGFR                                   EGFR_unspecified   \n",
       "4160   EGFR                                   EGFR_unspecified   \n",
       "4161   EGFR                                   EGFR_unspecified   \n",
       "4162   EGFR                                   EGFR_unspecified   \n",
       "4163   EGFR                                   EGFR_unspecified   \n",
       "4164   EGFR                                   EGFR_unspecified   \n",
       "4165   EGFR                                   EGFR_unspecified   \n",
       "4166   EGFR                                   EGFR_unspecified   \n",
       "4167   EGFR                                   EGFR_unspecified   \n",
       "4168   EGFR                                   EGFR_unspecified   \n",
       "4169   EGFR                                   EGFR_unspecified   \n",
       "4170   EGFR                                   EGFR_unspecified   \n",
       "4171   EGFR                                   EGFR_unspecified   \n",
       "4172   EGFR                                   EGFR_unspecified   \n",
       "4173   EGFR                                   EGFR_unspecified   \n",
       "4174   EGFR                                   EGFR_unspecified   \n",
       "4175   EGFR                                   EGFR_unspecified   \n",
       "4176   EGFR                                   EGFR_unspecified   \n",
       "4177   EGFR                                   EGFR_unspecified   \n",
       "4178   EGFR                                   EGFR_unspecified   \n",
       "4179   EGFR                                   EGFR_unspecified   \n",
       "4180   EGFR                                   EGFR_unspecified   \n",
       "4181   EGFR                                   EGFR_unspecified   \n",
       "4182   EGFR                                   EGFR_unspecified   \n",
       "4183   EGFR                                   EGFR_unspecified   \n",
       "4184   EGFR                                   EGFR_unspecified   \n",
       "4185   EGFR                                   EGFR_unspecified   \n",
       "4186   EGFR                                   EGFR_unspecified   \n",
       "4187   EGFR                                   EGFR_unspecified   \n",
       "4188   EGFR                                   EGFR_unspecified   \n",
       "4189   EGFR                                   EGFR_unspecified   \n",
       "4190   EGFR                                   EGFR_unspecified   \n",
       "4191   EGFR                                   EGFR_unspecified   \n",
       "4192   EGFR                                   EGFR_unspecified   \n",
       "4193   EGFR                                   EGFR_unspecified   \n",
       "4194   EGFR                                   EGFR_unspecified   \n",
       "4195   EGFR                                   EGFR_unspecified   \n",
       "4196   EGFR                                   EGFR_unspecified   \n",
       "4197   EGFR                                   EGFR_unspecified   \n",
       "4198   EGFR                                   EGFR_unspecified   \n",
       "4199   EGFR                                   EGFR_unspecified   \n",
       "4200   EGFR                                   EGFR_unspecified   \n",
       "4201   EGFR                                   EGFR_unspecified   \n",
       "4202   EGFR                                   EGFR_unspecified   \n",
       "4203   EGFR                                   EGFR_unspecified   \n",
       "4204   EGFR                                   EGFR_unspecified   \n",
       "4205   EGFR                                   EGFR_unspecified   \n",
       "4206   EGFR                                   EGFR_unspecified   \n",
       "4207   EGFR                                   EGFR_unspecified   \n",
       "4208   EGFR                                   EGFR_unspecified   \n",
       "4209   EGFR                                   EGFR_unspecified   \n",
       "4210   EGFR                                   EGFR_unspecified   \n",
       "4211   EGFR                                   EGFR_unspecified   \n",
       "4212   EGFR                                   EGFR_unspecified   \n",
       "4213   EGFR                                   EGFR_unspecified   \n",
       "4214   EGFR                                   EGFR_unspecified   \n",
       "4215   EGFR                                   EGFR_unspecified   \n",
       "4216   EGFR                                   EGFR_unspecified   \n",
       "4217   EGFR                                   EGFR_unspecified   \n",
       "4218   EGFR                                   EGFR_unspecified   \n",
       "4219   EGFR                                   EGFR_unspecified   \n",
       "4220   EGFR                                   EGFR_unspecified   \n",
       "4221   EGFR                                   EGFR_unspecified   \n",
       "4222   EGFR                                   EGFR_unspecified   \n",
       "4223   EGFR                                   EGFR_unspecified   \n",
       "4224   EGFR                                   EGFR_unspecified   \n",
       "4225   EGFR                                   EGFR_unspecified   \n",
       "4226   EGFR                                   EGFR_unspecified   \n",
       "4227   EGFR                                   EGFR_unspecified   \n",
       "4228   EGFR                                   EGFR_unspecified   \n",
       "4229   EGFR                                   EGFR_unspecified   \n",
       "4230   EGFR                                   EGFR_unspecified   \n",
       "4231   EGFR                                   EGFR_unspecified   \n",
       "4232   EGFR                                   EGFR_unspecified   \n",
       "4233   EGFR                                   EGFR_unspecified   \n",
       "4234   EGFR                                   EGFR_unspecified   \n",
       "4235   EGFR                                   EGFR_unspecified   \n",
       "4236   EGFR                                   EGFR_unspecified   \n",
       "4237   EGFR                                   EGFR_unspecified   \n",
       "4238   EGFR                                   EGFR_unspecified   \n",
       "4239   EGFR                                   EGFR_unspecified   \n",
       "4240   EGFR                                   EGFR_unspecified   \n",
       "4241   EGFR                                   EGFR_unspecified   \n",
       "4242   EGFR                                   EGFR_unspecified   \n",
       "4243   EGFR                                   EGFR_unspecified   \n",
       "4244   EGFR                                   EGFR_unspecified   \n",
       "4245   EGFR                                   EGFR_unspecified   \n",
       "4246   EGFR                                   EGFR_unspecified   \n",
       "4247   EGFR                                   EGFR_unspecified   \n",
       "4248   EGFR                                   EGFR_unspecified   \n",
       "4249   EGFR                                   EGFR_unspecified   \n",
       "4250   EGFR                                   EGFR_unspecified   \n",
       "4251   EGFR                                   EGFR_unspecified   \n",
       "4252   EGFR                                   EGFR_unspecified   \n",
       "4253   EGFR                                   EGFR_unspecified   \n",
       "4254   EGFR                                   EGFR_unspecified   \n",
       "4255   EGFR                                   EGFR_unspecified   \n",
       "4256   EGFR                                   EGFR_unspecified   \n",
       "4257   EGFR                                   EGFR_unspecified   \n",
       "4258   EGFR                                   EGFR_unspecified   \n",
       "4259   EGFR                                   EGFR_unspecified   \n",
       "4260   EGFR                                   EGFR_unspecified   \n",
       "4261   EGFR                                   EGFR_unspecified   \n",
       "4262   EGFR                                   EGFR_unspecified   \n",
       "4263   EGFR                                   EGFR_unspecified   \n",
       "4264   EGFR                                   EGFR_unspecified   \n",
       "4265   EGFR                                   EGFR_unspecified   \n",
       "4266   EGFR                                   EGFR_unspecified   \n",
       "4323   EGFR             EGFR_unspecified and ERBB2_unspecified   \n",
       "4327   EGFR              EGFR_unspecified and KRAS_unspecified   \n",
       "4328   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4329   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4330   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4331   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4332   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4333   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4334   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4335   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4336   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4337   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4338   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4339   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4340   EGFR               EGFR_unspecified and MET_unspecified   \n",
       "4342   EGFR              EGFR_unspecified and MUC1_unspecified   \n",
       "4343   EGFR            EGFR_unspecified and PIK3CA_unspecified   \n",
       "4344   EGFR              EGFR_unspecified and TP53_unspecified   \n",
       "4346   EGFR              EGFR_unspecified or ERBB2_unspecified   \n",
       "4347   EGFR              EGFR_unspecified or ERBB2_unspecified   \n",
       "4348   EGFR              EGFR_unspecified or ERBB2_unspecified   \n",
       "4349   EGFR              EGFR_unspecified or ERBB2_unspecified   \n",
       "4350   EGFR              EGFR_unspecified or ERBB2_unspecified   \n",
       "6176  FGFR1                                  FGFR1_unspecified   \n",
       "6177  FGFR1                                  FGFR1_unspecified   \n",
       "6178  FGFR1                                  FGFR1_unspecified   \n",
       "6179  FGFR1                                  FGFR1_unspecified   \n",
       "6180  FGFR1                                  FGFR1_unspecified   \n",
       "6181  FGFR1                                  FGFR1_unspecified   \n",
       "6182  FGFR1                                  FGFR1_unspecified   \n",
       "6183  FGFR1                                  FGFR1_unspecified   \n",
       "6184  FGFR1                                  FGFR1_unspecified   \n",
       "6185  FGFR1                                  FGFR1_unspecified   \n",
       "6186  FGFR1                                  FGFR1_unspecified   \n",
       "6187  FGFR1                                  FGFR1_unspecified   \n",
       "6188  FGFR1                                  FGFR1_unspecified   \n",
       "6189  FGFR1                                  FGFR1_unspecified   \n",
       "6229  FGFR1  FGFR1_unspecified or FGFR2_unspecified or FGFR...   \n",
       "6230  FGFR1  FGFR1_unspecified or FGFR2_unspecified or FGFR...   \n",
       "6231  FGFR1  FGFR1_unspecified or FGFR2_unspecified or FGFR...   \n",
       "6232  FGFR1  FGFR1_unspecified or FGFR2_unspecified or FGFR...   \n",
       "6233  FGFR1  FGFR1_unspecified or FGFR2_unspecified or FGFR...   \n",
       "\n",
       "                                          DISEASE ACTIONABILITY_RANK  \\\n",
       "28    lung / carcinoma / non small cell carcinoma                  3   \n",
       "29    lung / carcinoma / non small cell carcinoma                  3   \n",
       "30    lung / carcinoma / non small cell carcinoma                  3   \n",
       "31    lung / carcinoma / non small cell carcinoma                  3   \n",
       "32    lung / carcinoma / non small cell carcinoma                  3   \n",
       "33    lung / carcinoma / non small cell carcinoma                  3   \n",
       "34    lung / carcinoma / non small cell carcinoma                  3   \n",
       "35    lung / carcinoma / non small cell carcinoma                  3   \n",
       "3457  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3458  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3459  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3460  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3461  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3462  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3463  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3464  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3465  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3468  lung / carcinoma / non small cell carcinoma                  4   \n",
       "3469  lung / carcinoma / non small cell carcinoma                  4   \n",
       "3470  lung / carcinoma / non small cell carcinoma                  7   \n",
       "3471  lung / carcinoma / non small cell carcinoma                  7   \n",
       "3472  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3473  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3474  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3475  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3476  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3477  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3478  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3479  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3480  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3481  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3482  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3483  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3484  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3485  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3486  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3487  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3488  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3489  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3490  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3491  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3492  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3493  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3494  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3495  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3496  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3497  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3498  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3499  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3500  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3501  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3502  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3503  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3504  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3505  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3506  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3507  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3508  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3509  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3510  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3511  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3512  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3513  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3514  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3515  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3516  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3517  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3518  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3519  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3520  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3521  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3522  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3523  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3524  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3525  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3526  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3527  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3528  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3529  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3530  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3531  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3532  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3533  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3534  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3535  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3536  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3537  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3538  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3539  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3540  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3541  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3542  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3543  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3544  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3545  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3546  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3547  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3548  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3549  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3550  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3551  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3552  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3553  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3554  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3555  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3556  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3557  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3558  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3559  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3560  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3561  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3562  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3563  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3564  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3565  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3566  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3567  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3568  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3569  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3570  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3571  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3572  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3573  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3574  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3575  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3576  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3577  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3578  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3579  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3580  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3581  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3582  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3583  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3584  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3585  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3586  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3587  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3588  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3589  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3590  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3591  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3592  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3593  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3594  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3595  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3596  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3597  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3598  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3599  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3600  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3601  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3602  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3603  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3604  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3605  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3606  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3607  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3608  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3609  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3610  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3611  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3612  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3613  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3614  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3615  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3616  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3617  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3618  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3619  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3620  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3621  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3622  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3623  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3624  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3625  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3626  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3627  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3628  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3629  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3630  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3631  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3632  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3633  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3634  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3635  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3636  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3637  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3638  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3639  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3640  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3641  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3642  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3643  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3644  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3645  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3646  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3647  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3648  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3649  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3650  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3651  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3652  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3653  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3654  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3655  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3656  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3657  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3658  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3659  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3660  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3661  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3662  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3663  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3664  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3665  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3666  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3667  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3668  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3669  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3670  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3671  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3672  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3673  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3674  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3675  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3676  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3677  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3678  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3679  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3680  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3681  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3682  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3684  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3685  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3686  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3687  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3688  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3689  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3692  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3693  lung / carcinoma / non small cell carcinoma                  4   \n",
       "3694  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3695  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3696  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3697  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3698  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3699  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3700  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3701  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3702  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3703  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3704  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3705  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3706  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3707  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3708  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3709  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3710  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3711  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3712  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3713  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3714  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3715  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3716  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3717  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3718  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3719  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3720  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3721  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3722  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3723  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3724  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3725  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3726  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3727  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3728  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3729  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3730  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3731  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3732  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3733  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3734  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3735  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3736  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3737  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3738  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3739  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3740  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3741  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3742  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3743  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3744  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3745  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3746  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3747  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3748  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3749  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3750  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3751  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3752  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3753  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3754  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3755  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3756  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3757  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3758  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3759  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3760  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3761  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3762  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3763  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3764  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3765  lung / carcinoma / non small cell carcinoma                  4   \n",
       "3767  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3768  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3769  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3770  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3771  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3772  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3773  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3774  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3775  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3776  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3777  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3778  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3779  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3780  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3781  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3782  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3783  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3784  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3785  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3786  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3787  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3788  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3789  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3790  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3791  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3792  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3793  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3794  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3795  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3796  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3797  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3798  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3799  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3800  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3801  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3802  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3803  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3804  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3805  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3806  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3807  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3808  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3809  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3810  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3811  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3812  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3813  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3814  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3815  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3816  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3817  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3818  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3819  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3820  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3821  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3822  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3823  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3824  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3825  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3826  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3827  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3828  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3829  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3830  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3831  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3832  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3833  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3834  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3835  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3836  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3837  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3838  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3839  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3840  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3841  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3842  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3843  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3844  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3845  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3846  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3847  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3848  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3849  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3850  lung / carcinoma / non small cell carcinoma                  1   \n",
       "3851  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3852  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3853  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3854  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3855  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3856  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3857  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3858  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3859  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3860  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3861  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3862  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3863  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3864  lung / carcinoma / non small cell carcinoma                  3   \n",
       "3994  lung / carcinoma / non small cell carcinoma                  2   \n",
       "3995  lung / carcinoma / non small cell carcinoma                  2   \n",
       "3996  lung / carcinoma / non small cell carcinoma                  2   \n",
       "3997  lung / carcinoma / non small cell carcinoma                  2   \n",
       "3998  lung / carcinoma / non small cell carcinoma                  2   \n",
       "3999  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4000  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4001  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4002  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4003  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4004  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4005  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4006  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4007  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4008  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4009  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4010  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4011  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4012  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4013  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4014  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4015  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4016  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4017  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4018  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4019  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4020  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4021  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4022  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4023  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4024  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4025  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4026  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4027  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4028  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4029  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4030  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4031  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4032  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4033  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4034  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4035  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4036  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4037  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4038  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4039  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4040  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4041  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4042  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4043  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4044  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4045  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4046  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4047  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4048  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4049  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4050  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4051  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4052  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4053  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4054  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4055  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4056  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4057  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4058  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4059  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4060  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4061  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4062  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4063  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4064  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4065  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4066  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4067  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4068  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4069  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4070  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4071  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4072  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4073  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4074  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4075  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4076  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4077  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4078  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4079  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4080  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4081  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4082  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4083  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4084  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4085  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4086  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4087  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4088  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4089  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4090  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4091  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4092  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4093  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4094  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4095  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4096  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4097  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4098  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4099  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4100  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4101  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4102  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4103  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4104  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4105  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4106  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4107  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4108  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4109  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4110  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4111  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4112  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4113  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4114  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4115  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4116  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4117  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4118  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4119  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4120  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4121  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4122  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4123  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4124  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4125  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4126  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4127  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4128  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4129  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4130  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4131  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4132  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4133  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4134  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4135  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4136  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4137  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4138  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4139  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4140  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4141  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4142  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4143  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4144  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4145  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4146  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4147  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4148  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4149  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4150  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4151  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4152  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4153  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4154  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4155  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4156  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4157  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4158  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4159  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4160  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4161  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4162  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4163  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4164  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4165  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4166  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4167  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4168  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4169  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4170  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4171  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4172  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4173  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4174  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4175  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4176  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4177  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4178  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4179  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4180  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4181  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4182  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4183  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4184  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4185  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4186  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4187  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4188  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4189  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4190  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4191  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4192  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4193  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4194  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4195  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4196  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4197  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4198  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4199  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4200  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4201  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4202  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4203  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4204  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4205  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4206  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4207  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4208  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4209  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4210  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4211  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4212  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4213  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4214  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4215  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4216  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4217  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4218  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4219  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4220  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4221  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4222  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4223  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4224  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4225  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4226  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4227  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4228  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4229  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4230  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4231  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4232  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4233  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4234  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4235  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4236  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4237  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4238  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4239  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4240  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4241  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4242  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4243  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4244  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4245  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4246  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4247  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4248  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4249  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4250  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4251  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4252  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4253  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4254  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4255  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4256  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4257  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4258  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4259  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4260  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4261  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4262  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4263  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4264  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4265  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4266  lung / carcinoma / non small cell carcinoma                  2   \n",
       "4323  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4327  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4328  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4329  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4330  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4331  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4332  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4333  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4334  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4335  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4336  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4337  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4338  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4339  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4340  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4342  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4343  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4344  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4346  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4347  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4348  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4349  lung / carcinoma / non small cell carcinoma                  3   \n",
       "4350  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6176  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6177  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6178  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6179  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6180  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6181  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6182  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6183  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6184  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6185  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6186  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6187  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6188  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6189  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6229  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6230  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6231  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6232  lung / carcinoma / non small cell carcinoma                  3   \n",
       "6233  lung / carcinoma / non small cell carcinoma                  3   \n",
       "\n",
       "                                       DRUG_COMBINATION  \\\n",
       "28                            Osimertinib + Savolitinib   \n",
       "29                                           Alflutinib   \n",
       "30    Bevacizumab + Cisplatin + Pemetrexed + Tisleli...   \n",
       "31                    Erlotinib + Telisotuzumab vedotin   \n",
       "32                               Capmatinib + Erlotinib   \n",
       "33                              Capmatinib + Nazartinib   \n",
       "34               Carboplatin + Osimertinib + Pemetrexed   \n",
       "35                             Pemigatinib + Sintilimab   \n",
       "3457                                            BLU-701   \n",
       "3458                                            WJ13404   \n",
       "3459                                            JIN-A02   \n",
       "3460                                        Dacomitinib   \n",
       "3461                                           QLH11811   \n",
       "3462                          Dacomitinib + Osimertinib   \n",
       "3463                                           HS-10375   \n",
       "3464                                            BLU-945   \n",
       "3465                                            BLU-945   \n",
       "3468                                           Afatinib   \n",
       "3469                                           Afatinib   \n",
       "3470                                          Gefitinib   \n",
       "3471                                          Erlotinib   \n",
       "3472                                          Neratinib   \n",
       "3473                                            TAS-116   \n",
       "3474                             Gefitinib + Pemetrexed   \n",
       "3475                           Crizotinib + Dacomitinib   \n",
       "3476                                        Osimertinib   \n",
       "3477                        Fruquintinib + Genolimzumab   \n",
       "3478                           Osimertinib + Rifampicin   \n",
       "3479                         Itraconazole + Osimertinib   \n",
       "3480                                          Gefitinib   \n",
       "3481                            Gefitinib + Vinorelbine   \n",
       "3482                             Gefitinib + Tepotinib    \n",
       "3483  Atezolizumab + Bevacizumab + Carboplatin + Pem...   \n",
       "3484                             Erlotinib + Luminespib   \n",
       "3485                           Erlotinib + Radiotherapy   \n",
       "3486    Gefitinib + Stereotactic Body Radiation Therapy   \n",
       "3487                               Afatinib + Cetuximab   \n",
       "3488                          Necitumumab + Osimertinib   \n",
       "3489                           Afatinib + Pembrolizumab   \n",
       "3490                              Patritumab deruxtecan   \n",
       "3491                           Gefitinib + Tremelimumab   \n",
       "3492                           Navitoclax + Osimertinib   \n",
       "3493                                           Icotinib   \n",
       "3494              Carboplatin + Lazertinib + Pemetrexed   \n",
       "3495                         Atezolizumab + Rociletinib   \n",
       "3496                                         Lazertinib   \n",
       "3497            Osimertinib + Stereotactic radiotherapy   \n",
       "3498                                          Erlotinib   \n",
       "3499                                        Osimertinib   \n",
       "3500                                          Gefitinib   \n",
       "3501                            Dasatinib + Osimertinib   \n",
       "3502              Afatinib + Cyclophosphamide + EGF-PTI   \n",
       "3503                                         Alflutinib   \n",
       "3504                                        Osimertinib   \n",
       "3505                                           Afatinib   \n",
       "3506                            Erlotinib + Ramucirumab   \n",
       "3507                                        Osimertinib   \n",
       "3508                                        Osimertinib   \n",
       "3509                                        Dacomitinib   \n",
       "3510                                          Gefitinib   \n",
       "3511                                          Gefitinib   \n",
       "3512                                          Erlotinib   \n",
       "3513                                          Erlotinib   \n",
       "3514                                          Erlotinib   \n",
       "3515                                          Erlotinib   \n",
       "3516                                          Gefitinib   \n",
       "3517                                          Gefitinib   \n",
       "3518                                         Pemetrexed   \n",
       "3519                                        Osimertinib   \n",
       "3520                                              YL202   \n",
       "3521                                           QLH11811   \n",
       "3522                          Almonertinib + Gentuximab   \n",
       "3523                           Osimertinib + Triptolide   \n",
       "3524            Camrelizumab + Carboplatin + Pemetrexed   \n",
       "3525                           Osimertinib + Tegavivint   \n",
       "3526                         Osimertinib + Temozolomide   \n",
       "3527                              Anlotinib + Erlotinib   \n",
       "3528                            Nazartinib + Ribociclib   \n",
       "3529                           Naporafenib + Nazartinib   \n",
       "3530                            Nazartinib + Trametinib   \n",
       "3531                            Nazartinib + Trametinib   \n",
       "3532                          Osimertinib + Savolitinib   \n",
       "3533                                             AV-412   \n",
       "3534                          Osimertinib + Selumetinib   \n",
       "3535                           Durvalumab + Osimertinib   \n",
       "3536                             Gefitinib + Nazartinib   \n",
       "3537                            Capmatinib + Nazartinib   \n",
       "3538                            Gefitinib + Savolitinib   \n",
       "3539                                       Zorifertinib   \n",
       "3540                               DS-1205c + Gefitinib   \n",
       "3541                              Afatinib + Xentuzumab   \n",
       "3542                         Osimertinib + Sapanisertib   \n",
       "3543                                           Afatinib   \n",
       "3544             Amivantamab + Bevacizumab + Lazertinib   \n",
       "3545             Erlotinib + R-(-)-gossypol acetic acid   \n",
       "3546                               EMB-01 + Osimertinib   \n",
       "3547  Alflutinib + Bevacizumab + Carboplatin + Pemet...   \n",
       "3548              Alflutinib + Carboplatin + Pemetrexed   \n",
       "3549   Lazertinib + Stereotactic Body Radiation Therapy   \n",
       "3550                 BLU-701 + Carboplatin + Pemetrexed   \n",
       "3551                              BLU-701 + Osimertinib   \n",
       "3552                                            BLU-701   \n",
       "3553    Carboplatin + Cisplatin + Icotinib + Pemetrexed   \n",
       "3554    Carboplatin + Cisplatin + Icotinib + Pemetrexed   \n",
       "3555  Carboplatin + Lenvatinib + Pembrolizumab + Pem...   \n",
       "3556                            LY3295668 + Osimertinib   \n",
       "3557  Amivantamab + Carboplatin + Lazertinib + Pemet...   \n",
       "3558  Amivantamab + Carboplatin + Lazertinib + Pemet...   \n",
       "3559               Cisplatin + Osimertinib + Pemetrexed   \n",
       "3560                            Befotertinib + Icotinib   \n",
       "3561                                       Almonertinib   \n",
       "3562                             Alflutinib + Anlotinib   \n",
       "3563                                         Keynatinib   \n",
       "3564   Afatinib + Cisplatin + Pemetrexed + Radiotherapy   \n",
       "3565                  Almonertinib + Microwave ablation   \n",
       "3566                         Lenvatinib + Pembrolizumab   \n",
       "3567  Osimertinib + Pemetrexed + Platinum-based chem...   \n",
       "3568                           Amivantamab + Lazertinib   \n",
       "3569                         Atezolizumab + Bevacizumab   \n",
       "3570          Ascorbic acid + Tyrosine Kinase Inhibitor   \n",
       "3571                              Anlotinib + Gefitinib   \n",
       "3572                          Durvalumab + Tremelimumab   \n",
       "3573                                              ZN-e4   \n",
       "3574                            Chemotherapy + Icotinib   \n",
       "3575                  Cisplatin + Icotinib + Pemetrexed   \n",
       "3576                           Pemetrexed + Toripalimab   \n",
       "3577            Osimertinib + Stereotactic radiotherapy   \n",
       "3578                               Anlotinib + Icotinib   \n",
       "3579              Anlotinib + Tyrosine Kinase Inhibitor   \n",
       "3580                Carboplatin + Icotinib + Pemetrexed   \n",
       "3581                Carboplatin + Icotinib + Pemetrexed   \n",
       "3582               Anlotinib + Carboplatin + Pemetrexed   \n",
       "3583                            Bevacizumab + Gefitinib   \n",
       "3584                            Bevacizumab + Gefitinib   \n",
       "3585          Local Consolidation Therapy + Osimertinib   \n",
       "3586                          Osimertinib + Selumetinib   \n",
       "3587                            Gefitinib + Thalidomide   \n",
       "3588  Cyclophosphamide + Fludarabine + Interleukin-2...   \n",
       "3589  Atezolizumab + Bevacizumab + Carboplatin + Pem...   \n",
       "3590                             Cisplatin + Pemetrexed   \n",
       "3591                          Osimertinib + Ramucirumab   \n",
       "3592                           Fruquintinib + Gefitinib   \n",
       "3593                                         Alflutinib   \n",
       "3594                                         Alflutinib   \n",
       "3595                                         Alflutinib   \n",
       "3596                                         Alflutinib   \n",
       "3597                                         Alflutinib   \n",
       "3598                                         Alflutinib   \n",
       "3599                Osimertinib + Trastuzumab-emtansine   \n",
       "3600                             Gefitinib + Nazartinib   \n",
       "3601                            Capmatinib + Nazartinib   \n",
       "3602                            Capmatinib + Nazartinib   \n",
       "3603                             Erlotinib + Linsitinib   \n",
       "3604                            Gefitinib + Osimertinib   \n",
       "3605                               Gefitinib + Olaparib   \n",
       "3606                              Berberine + Gefitinib   \n",
       "3607                            Bevacizumab + Erlotinib   \n",
       "3608                            Bevacizumab + Erlotinib   \n",
       "3609   Gefitinib + Tegafur-gimeracil-oteracil potassium   \n",
       "3610                        Osimertinib + Telaglenastat   \n",
       "3611                           Ficlatuzumab + Gefitinib   \n",
       "3612                                         Poziotinib   \n",
       "3613                                          Neratinib   \n",
       "3614                                          Lapatinib   \n",
       "3615                                         Lazertinib   \n",
       "3616                                         Lazertinib   \n",
       "3617                                          Olmutinib   \n",
       "3618                                         Nazartinib   \n",
       "3619                                        Tesevatinib   \n",
       "3620                                        Tesevatinib   \n",
       "3621                                        Tesevatinib   \n",
       "3622                                        Tesevatinib   \n",
       "3623                                        Tesevatinib   \n",
       "3624                                        Osimertinib   \n",
       "3625                                        Osimertinib   \n",
       "3626                                        Osimertinib   \n",
       "3627                                        Dacomitinib   \n",
       "3628                                           Icotinib   \n",
       "3629                                           Icotinib   \n",
       "3630                                           Icotinib   \n",
       "3631                                           Icotinib   \n",
       "3632                                          Gefitinib   \n",
       "3633                                          Gefitinib   \n",
       "3634                                          Gefitinib   \n",
       "3635                                           Afatinib   \n",
       "3636                                          Erlotinib   \n",
       "3637             Amivantamab + Carboplatin + Pemetrexed   \n",
       "3638  Amivantamab + Carboplatin + Lazertinib + Pemet...   \n",
       "3639                        Almonertinib + Chemotherapy   \n",
       "3640                                   EGFR-TKI + JY025   \n",
       "3641              Gefitinib or Erlotinib + Niacinamaide   \n",
       "3642                               Lazertinib + Placebo   \n",
       "3643                              Osimertinib + Placebo   \n",
       "3644                           Amivantamab + Lazertinib   \n",
       "3645                           Amivantamab + Lazertinib   \n",
       "3646            Almonertinib + Carboplatin + Pemetrexed   \n",
       "3647            Almonertinib + Carboplatin + Pemetrexed   \n",
       "3648               Icotinib + Stereotactic radiotherapy   \n",
       "3649                              Anlotinib + Gefitinib   \n",
       "3650                         Chemotherapy + Osimertinib   \n",
       "3651                              Patritumab deruxtecan   \n",
       "3652                           Chemotherapy + Erlotinib   \n",
       "3653           Gefitinib + Yiqi-yangyin-jiedu Decoction   \n",
       "3654                               Apatinib + Gefitinib   \n",
       "3655                                         Naquotinib   \n",
       "3656                                         Naquotinib   \n",
       "3657                                       Almonertinib   \n",
       "3658                                       Almonertinib   \n",
       "3659                                         Alflutinib   \n",
       "3660                                         Alflutinib   \n",
       "3661                                       Zorifertinib   \n",
       "3662                                        Abivertinib   \n",
       "3663                            Bevacizumab + Erlotinib   \n",
       "3664                            Bevacizumab + Erlotinib   \n",
       "3665                               Afatinib + Cetuximab   \n",
       "3666                 Cisplatin + Gefitinib + Pemetrexed   \n",
       "3667                 Cisplatin + Gefitinib + Pemetrexed   \n",
       "3668                                          Olmutinib   \n",
       "3669                                         Nazartinib   \n",
       "3670                                        Tesevatinib   \n",
       "3671                                        Osimertinib   \n",
       "3672                                        Osimertinib   \n",
       "3673                                        Osimertinib   \n",
       "3674                                           Icotinib   \n",
       "3675                                           Icotinib   \n",
       "3676                                          Gefitinib   \n",
       "3677                                          Erlotinib   \n",
       "3678                                        Dacomitinib   \n",
       "3679                               Apatinib + Erlotinib   \n",
       "3680                                Apatinib + Icotinib   \n",
       "3681                   Anlotinib + Gefitinib + Icotinib   \n",
       "3682                           Gefitinib + Radiotherapy   \n",
       "3684                                       Almonertinib   \n",
       "3685                        Almonertinib + Chemotherapy   \n",
       "3686                        Almonertinib + Chemotherapy   \n",
       "3687                               Afatinib + Cetuximab   \n",
       "3688                                       Almonertinib   \n",
       "3689  Bintrafusp alfa + Carboplatin + Cisplatin + Pe...   \n",
       "3692                                       Mobocertinib   \n",
       "3693                                          Gefitinib   \n",
       "3694                                       Mobocertinib   \n",
       "3695                                        Amivantamab   \n",
       "3696                                          Erlotinib   \n",
       "3697                                           Icotinib   \n",
       "3698                                         Alflutinib   \n",
       "3699                                            BLU-451   \n",
       "3700                                             JMT101   \n",
       "3701                                         Alflutinib   \n",
       "3702                                         Alflutinib   \n",
       "3703                                           Afatinib   \n",
       "3704                                           HS-10376   \n",
       "3705                               JMT101 + Osimertinib   \n",
       "3706            Carboplatin + Mobocertinib + Pemetrexed   \n",
       "3707                           Poziotinib + Ramucirumab   \n",
       "3708             Amivantamab + Carboplatin + Pemetrexed   \n",
       "3709                                          Pyrotinib   \n",
       "3710                                          Pyrotinib   \n",
       "3711                                       Tarloxotinib   \n",
       "3712                                            CLN-081   \n",
       "3713                                            DZD9008   \n",
       "3714                                       Mobocertinib   \n",
       "3715                                       Mobocertinib   \n",
       "3716                             Anlotinib + Sintilimab   \n",
       "3717                                          Pirotinib   \n",
       "3718                                         Luminespib   \n",
       "3719                                         Alflutinib   \n",
       "3720                               Afatinib + Cetuximab   \n",
       "3721                      Erlotinib + Onalespib lactate   \n",
       "3722                                         Poziotinib   \n",
       "3723                                         Poziotinib   \n",
       "3724                                         Poziotinib   \n",
       "3725                                         Poziotinib   \n",
       "3726                                         Poziotinib   \n",
       "3727                                        Osimertinib   \n",
       "3728                                        Osimertinib   \n",
       "3729                                         Poziotinib   \n",
       "3730             Amivantamab + Carboplatin + Pemetrexed   \n",
       "3731                                          Pyrotinib   \n",
       "3732                                            DZD9008   \n",
       "3733                                       Mobocertinib   \n",
       "3734                                        Entrectinib   \n",
       "3735                                         Alflutinib   \n",
       "3736                                        Osimertinib   \n",
       "3737                                            DZD9008   \n",
       "3738                                           Afatinib   \n",
       "3739                                          Gefitinib   \n",
       "3740                                          Gefitinib   \n",
       "3741                                          Neratinib   \n",
       "3742                                           Afatinib   \n",
       "3743                                           Afatinib   \n",
       "3744                                        Osimertinib   \n",
       "3745                             Afatinib + Bevacizumab   \n",
       "3746                                          Sutetinib   \n",
       "3747  Osimertinib + Pemetrexed + Platinum-based chem...   \n",
       "3748                                         Alflutinib   \n",
       "3749                                        Osimertinib   \n",
       "3750                                        Osimertinib   \n",
       "3751                                       Almonertinib   \n",
       "3752                          Bevacizumab + Osimertinib   \n",
       "3753                            Anlotinib + Dacomitinib   \n",
       "3754                             Gefitinib + Pemetrexed   \n",
       "3755                             Bevacizumab + Icotinib   \n",
       "3756                             Gefitinib or Erlotinib   \n",
       "3757                           Capmatinib + Osimertinib   \n",
       "3758                             Gefitinib or Erlotinib   \n",
       "3759                                           Afatinib   \n",
       "3760                                        Osimertinib   \n",
       "3761                                           Afatinib   \n",
       "3762                                           Afatinib   \n",
       "3763                                        Osimertinib   \n",
       "3764                                           Afatinib   \n",
       "3765                                          Gefitinib   \n",
       "3767                                        Osimertinib   \n",
       "3768                                           Afatinib   \n",
       "3769                                           Afatinib   \n",
       "3770                         Osimertinib + Sapanisertib   \n",
       "3771                                           QLH11811   \n",
       "3772                             Osimertinib + VIC-1911   \n",
       "3773                            Alisertib + Osimertinib   \n",
       "3774                                            SH-1028   \n",
       "3775                                            SH-1028   \n",
       "3776                                              D0316   \n",
       "3777                                           Avitinib   \n",
       "3778                          Osimertinib + Savolitinib   \n",
       "3779                          Osimertinib + Selumetinib   \n",
       "3780                             Afatinib + Ruxolitinib   \n",
       "3781                           Durvalumab + Osimertinib   \n",
       "3782                             Nazartinib + Nivolumab   \n",
       "3783                          Osimertinib + Ramucirumab   \n",
       "3784                          Necitumumab + Osimertinib   \n",
       "3785                                           BPI-7711   \n",
       "3786                                         Naquotinib   \n",
       "3787                                        Abivertinib   \n",
       "3788                               Afatinib + Cetuximab   \n",
       "3789                                          Olmutinib   \n",
       "3790                                        Osimertinib   \n",
       "3791                               EMB-01 + Osimertinib   \n",
       "3792  Carboplatin + Pemetrexed + Sulfatinib + Toripa...   \n",
       "3793                          Alflutinib + Radiotherapy   \n",
       "3794            Almonertinib + Carboplatin + Pemetrexed   \n",
       "3795                            Anlotinib + Osimertinib   \n",
       "3796                                              ZN-e4   \n",
       "3797                                              D0316   \n",
       "3798                                           Avitinib   \n",
       "3799   Interleukin-2 + WT1-sensitized allogenic T cells   \n",
       "3800          Local Consolidation Therapy + Osimertinib   \n",
       "3801                                         Luminespib   \n",
       "3802                                         Brigatinib   \n",
       "3803                           Emibetuzumab + Erlotinib   \n",
       "3804                           Emibetuzumab + Erlotinib   \n",
       "3805                           Itacitinib + Osimertinib   \n",
       "3806                           Cabozantinib + Erlotinib   \n",
       "3807                           Lerociclib + Osimertinib   \n",
       "3808                              Aspirin + Osimertinib   \n",
       "3809                              Aspirin + Osimertinib   \n",
       "3810                          Bevacizumab + Osimertinib   \n",
       "3811                          Bevacizumab + Osimertinib   \n",
       "3812                                           BPI-7711   \n",
       "3813                                        Malvertinib   \n",
       "3814                                        Rociletinib   \n",
       "3815                                         BMS-690514   \n",
       "3816                                         Alflutinib   \n",
       "3817                                         Alflutinib   \n",
       "3818                            Erlotinib + Ruxolitinib   \n",
       "3819                                        Abivertinib   \n",
       "3820                                         Poziotinib   \n",
       "3821                                         Canertinib   \n",
       "3822                                         Lazertinib   \n",
       "3823                                          Olmutinib   \n",
       "3824                                          Olmutinib   \n",
       "3825                                          Olmutinib   \n",
       "3826                                          Olmutinib   \n",
       "3827                                        Osimertinib   \n",
       "3828                                        Osimertinib   \n",
       "3829                                        Osimertinib   \n",
       "3830                                        Osimertinib   \n",
       "3831                                        Osimertinib   \n",
       "3832                                        Osimertinib   \n",
       "3833                                        Osimertinib   \n",
       "3834                                        Osimertinib   \n",
       "3835                                        Osimertinib   \n",
       "3836                                        Osimertinib   \n",
       "3837                                        Osimertinib   \n",
       "3838                                        Osimertinib   \n",
       "3839                                        Osimertinib   \n",
       "3840                           Durvalumab + Osimertinib   \n",
       "3841                                        Rociletinib   \n",
       "3842                                       Almonertinib   \n",
       "3843                                          Olmutinib   \n",
       "3844                                          Olmutinib   \n",
       "3845                                        Osimertinib   \n",
       "3846                                        Osimertinib   \n",
       "3847                                        Osimertinib   \n",
       "3848                                        Osimertinib   \n",
       "3849                                        Osimertinib   \n",
       "3850                                         Lazertinib   \n",
       "3851                            Gefitinib + Savolitinib   \n",
       "3852                             Gefitinib + Tepotinib    \n",
       "3853                                            BLU-945   \n",
       "3854                                       Almonertinib   \n",
       "3855                             Anlotinib + Sintilimab   \n",
       "3856                                       Almonertinib   \n",
       "3857                               EMB-01 + Osimertinib   \n",
       "3858                Alflutinib + Cisplatin + Pemetrexed   \n",
       "3859                                            FWD1509   \n",
       "3860     Neoantigen vaccine + Tyrosine Kinase Inhibitor   \n",
       "3861                                         Glumetinib   \n",
       "3862                             Afatinib + Osimertinib   \n",
       "3863                                            DZD9008   \n",
       "3864                          Osimertinib + Savolitinib   \n",
       "3994                            Docetaxel + Ramucirumab   \n",
       "3995                                         Pemetrexed   \n",
       "3996                                           Afatinib   \n",
       "3997                             Almonertinib + SHR1701   \n",
       "3998                             Dalpiciclib + EGFR-TKI   \n",
       "3999                          Carotuximab + Osimertinib   \n",
       "4000                             Erlotinib + Ipilimumab   \n",
       "4001                                          BDTX-1535   \n",
       "4002                 Autologous personalized DC vaccine   \n",
       "4003  Autologous EGFR-IL13RA2 CAR-T cells + Cyclopho...   \n",
       "4004                           BAY2927088_formulation A   \n",
       "4005                         BAY2927088_formulation B_1   \n",
       "4006                         BAY2927088_formulation B_2   \n",
       "4007                    CXCR5 modified EGFR CAR-T cells   \n",
       "4008                                            TAS2940   \n",
       "4009                         Almonertinib + Bevacizumab   \n",
       "4010                        Osimertinib + Repotrectinib   \n",
       "4011                             MRX-2843 + Osimertinib   \n",
       "4012                                            BBP-398   \n",
       "4013                                            BBP-398   \n",
       "4014                           Amivantamab + Lazertinib   \n",
       "4015                                             BCA101   \n",
       "4016                             BCA101 + Pembrolizumab   \n",
       "4017         Individualized neoantigen peptides vaccine   \n",
       "4018                            Alisertib + Osimertinib   \n",
       "4019                                            TY-9591   \n",
       "4020                           Afatinib + Talcum powder   \n",
       "4021            Carboplatin + Pemetrexed + Zimberelimab   \n",
       "4022  Carboplatin + Etrumadenant + Pemetrexed + Zimb...   \n",
       "4023                          Osimertinib + Palcitoclax   \n",
       "4024                            Niraparib + Osimertinib   \n",
       "4025                           Ipilimumab + Osimertinib   \n",
       "4026                          JNJ-61186372 + Lazertinib   \n",
       "4027  Pembrolizumab + Stereotactic Body Radiation Th...   \n",
       "4028            Osimertinib + Stereotactic radiotherapy   \n",
       "4029                      Gatipotuzumab + Tomuzotuximab   \n",
       "4030                                              DV281   \n",
       "4031                Cisplatin + Etoposide + Osimertinib   \n",
       "4032                          Abemaciclib + Necitumumab   \n",
       "4033                            Gefitinib + Savolitinib   \n",
       "4034                                Cucurmin + EGFR-TKI   \n",
       "4035                             Buparlisib + Gefitinib   \n",
       "4036                              Dasatinib + Erlotinib   \n",
       "4037                             Bortezomib + Erlotinib   \n",
       "4038                              Cetuximab + Erlotinib   \n",
       "4039                             Durvalumab + Gefitinib   \n",
       "4040                             Durvalumab + Gefitinib   \n",
       "4041                            Erlotinib + Momelotinib   \n",
       "4042                                         Pacritinib   \n",
       "4043                            Crizotinib + Ipilimumab   \n",
       "4044                                 Nivolumab + Sym004   \n",
       "4045                             Matuzumab + Pemetrexed   \n",
       "4046                            Binimetinib + Erlotinib   \n",
       "4047                             Afatinib + Necitumumab   \n",
       "4048                          Dacomitinib + Osimertinib   \n",
       "4049                          Dacomitinib + Osimertinib   \n",
       "4050                               Afatinib + Dasatinib   \n",
       "4051                                         Naquotinib   \n",
       "4052                                       Almonertinib   \n",
       "4053                             DS-1205c + Osimertinib   \n",
       "4054                                          Pelitinib   \n",
       "4055                                        Dacomitinib   \n",
       "4056                             Ipilimumab + Nivolumab   \n",
       "4057           AK112 + AK119 + Carboplatin + Pemetrexed   \n",
       "4058                                      AK112 + AK119   \n",
       "4059                                               H002   \n",
       "4060                                               H002   \n",
       "4061                      Erlotinib + OBI-821 + OBI-833   \n",
       "4062                                         BPI-361175   \n",
       "4063  Platinum-based chemotherapy + SKB264 + Tagitan...   \n",
       "4064  Afatinib + Carboplatin + Osimertinib + Pemetrexed   \n",
       "4065                              Osimertinib + TQB3525   \n",
       "4066                            NRC-2694-A + Paclitaxel   \n",
       "4067          Carboplatin + Nab-paclitaxel + Sintilimab   \n",
       "4068                        Afatinib + Thoracic surgery   \n",
       "4069             Carboplatin + Pemetrexed + Pimurutamab   \n",
       "4070                            Docetaxel + Pimurutamab   \n",
       "4071                                        Pimurutamab   \n",
       "4072                          Alflutinib + Chemotherapy   \n",
       "4073                                      AFM24 + SNK01   \n",
       "4074                         Osimertinib + Radiotherapy   \n",
       "4075                                            SI-B001   \n",
       "4076  Carboplatin + Lenvatinib + Pembrolizumab + Pem...   \n",
       "4077  Carboplatin + Lenvatinib + Pembrolizumab + Pem...   \n",
       "4078                             ERAS-007 + Osimertinib   \n",
       "4079                           Almonertinib + Anlotinib   \n",
       "4080                             Buparlisib + Erlotinib   \n",
       "4081                             Erlotinib + Tivantinib   \n",
       "4082  Erlotinib + Gemcitabine + Platinum-based chemo...   \n",
       "4083                                          Sapitinib   \n",
       "4084  Carboplatin + Cetuximab + Gemcitabine + SIM180...   \n",
       "4085                  Carboplatin + Gemcitabine + SNK01   \n",
       "4086                                              AK112   \n",
       "4087                                BBT-176 + Cetuximab   \n",
       "4088                                            BBT-176   \n",
       "4089                                             MRG003   \n",
       "4090                              APL-101 + Osimertinib   \n",
       "4091               Carboplatin + Nivolumab + Pemetrexed   \n",
       "4092                          Abemaciclib + Osimertinib   \n",
       "4093             Carboplatin + Osimertinib + Pemetrexed   \n",
       "4094  Bevacizumab + Cisplatin + Durvalumab + Stereot...   \n",
       "4095            Necitumumab + Osimertinib + Trastuzumab   \n",
       "4096                  Afatinib + Cisplatin + Pemetrexed   \n",
       "4097             Osimertinib + Quaratusugene ozeplasmid   \n",
       "4098                           Amivantamab + Lazertinib   \n",
       "4099             Carboplatin + Osimertinib + Paclitaxel   \n",
       "4100            Carboplatin + Pemetrexed + Tislelizumab   \n",
       "4101                                Famitinb + HS-10296   \n",
       "4102                                            TY-9591   \n",
       "4103               Apatinib + Tyrosine Kinase Inhibitor   \n",
       "4104                                             EMB-01   \n",
       "4105                            Anlotinib + Osimertinib   \n",
       "4106                            Anlotinib + Osimertinib   \n",
       "4107                             Osimertinib + RMC-4630   \n",
       "4108                             Osimertinib + RMC-4630   \n",
       "4109                                       Mobocertinib   \n",
       "4110                        Pembrolizumab + Ramucirumab   \n",
       "4111                                GC1118 + Paclitaxel   \n",
       "4112  Osimertinib + Stereotactic Body Radiation Therapy   \n",
       "4113  Osimertinib + Stereotactic Body Radiation Therapy   \n",
       "4114                             Anlotinib + Sintilimab   \n",
       "4115                                            FCN-411   \n",
       "4116                      Dihydroartemisinin + Icotinib   \n",
       "4117                            Afatinib + Tucidinostat   \n",
       "4118                                            SH-1028   \n",
       "4119                              AZD4205 + Osimertinib   \n",
       "4120            Osimertinib + Stereotactic radiotherapy   \n",
       "4121            Osimertinib + Stereotactic radiotherapy   \n",
       "4122  Stereotactic Body Radiation Therapy + Tyrosine...   \n",
       "4123                             Gefitinib + Ningetinib   \n",
       "4124                            Apatinib + Chemotherapy   \n",
       "4125  Autologous T-Cells with enhanced TCRs specific...   \n",
       "4126  Autologous T-Cells with enhanced TCRs specific...   \n",
       "4127                                           Avitinib   \n",
       "4128                                            AVID100   \n",
       "4129     Icotinib + Stereotactic Body Radiation Therapy   \n",
       "4130     Icotinib + Stereotactic Body Radiation Therapy   \n",
       "4131                        Atezolizumab + Cabozantinib   \n",
       "4132                              Erlotinib + Sunitinib   \n",
       "4133                              Anlotinib + Docetaxel   \n",
       "4134              Carboplatin + Durvalumab + Pemetrexed   \n",
       "4135                           Osimertinib + Tepotinib    \n",
       "4136                           Osimertinib + Tepotinib    \n",
       "4137                          Osimertinib + Savolitinib   \n",
       "4138  Cetuximab + Cilengitide + Cisplatin + Vinorelbine   \n",
       "4139  Carboplatin + Cetuximab + Pemetrexed + Radioth...   \n",
       "4140                              Erlotinib + Foretinib   \n",
       "4141      Cetuximab + Natural killer cell immunotherapy   \n",
       "4142             Bevacizumab + Carboplatin + Pemetrexed   \n",
       "4143                           Rociletinib + Trametinib   \n",
       "4144                               MP0250 + Osimertinib   \n",
       "4145            Cetuximab + Chemotherapy + Radiotherapy   \n",
       "4146                                 Erlotinib + MK2206   \n",
       "4147                               Apatinib + Erlotinib   \n",
       "4148             Capecitabine + Cetuximab + Oxaliplatin   \n",
       "4149  Atezolizumab + Bevacizumab + Carboplatin + Pem...   \n",
       "4150  Atezolizumab + Bevacizumab + Carboplatin + Pac...   \n",
       "4151                              Durvalumab + Olaparib   \n",
       "4152                           Gemcitabine + Vandetanib   \n",
       "4153                                       Fruquintinib   \n",
       "4154                                       Fruquintinib   \n",
       "4155               Cisplatin + Panitumumab + Pemetrexed   \n",
       "4156               Cisplatin + Panitumumab + Pemetrexed   \n",
       "4157               Cisplatin + Panitumumab + Pemetrexed   \n",
       "4158               Cisplatin + Panitumumab + Pemetrexed   \n",
       "4159                           Fruquintinib + Gefitinib   \n",
       "4160                             Matuzumab + Pemetrexed   \n",
       "4161  Cisplatin + Gemcitabine + Imgatuzumab + Pemetr...   \n",
       "4162               Carboplatin + Erlotinib + Paclitaxel   \n",
       "4163                            Nimotuzumab + Nivolumab   \n",
       "4164                              Gefitinib + Metformin   \n",
       "4165                              Celecoxib + Erlotinib   \n",
       "4166                             Erlotinib + Trametinib   \n",
       "4167                            Fulvestrant + Gefitinib   \n",
       "4168                          Dacomitinib + Osimertinib   \n",
       "4169                          Necitumumab + Osimertinib   \n",
       "4170                          Bevacizumab + Osimertinib   \n",
       "4171                                         BMS-690514   \n",
       "4172                                       Almonertinib   \n",
       "4173                                       Almonertinib   \n",
       "4174                                       Almonertinib   \n",
       "4175                                       Almonertinib   \n",
       "4176                                       Almonertinib   \n",
       "4177                                       Almonertinib   \n",
       "4178                                       Almonertinib   \n",
       "4179                                         Alflutinib   \n",
       "4180                                         Alflutinib   \n",
       "4181                                AZD4635 + Oleclumab   \n",
       "4182                            Oleclumab + Osimertinib   \n",
       "4183                            Gefitinib + Osimertinib   \n",
       "4184                                       Zorifertinib   \n",
       "4185                               Afatinib + Cetuximab   \n",
       "4186                     Erlotinib + Hydroxychloroquine   \n",
       "4187                           Ficlatuzumab + Gefitinib   \n",
       "4188                                         Canertinib   \n",
       "4189                                         Lazertinib   \n",
       "4190                                         Lazertinib   \n",
       "4191                                         Lazertinib   \n",
       "4192                                          Pelitinib   \n",
       "4193                                         Vandetanib   \n",
       "4194                                         Vandetanib   \n",
       "4195                             Docetaxel + Vandetanib   \n",
       "4196                                        Osimertinib   \n",
       "4197                                        Osimertinib   \n",
       "4198                                        Osimertinib   \n",
       "4199                                        Osimertinib   \n",
       "4200                                        Osimertinib   \n",
       "4201                                        Osimertinib   \n",
       "4202                                        Dacomitinib   \n",
       "4203                                        Dacomitinib   \n",
       "4204                                        Dacomitinib   \n",
       "4205                                        Dacomitinib   \n",
       "4206                                          Gefitinib   \n",
       "4207                                          Gefitinib   \n",
       "4208                                          Gefitinib   \n",
       "4209                                          Erlotinib   \n",
       "4210                                          Erlotinib   \n",
       "4211                                           Afatinib   \n",
       "4212                                           Afatinib   \n",
       "4213                             Ipilimumab + Nivolumab   \n",
       "4214                                          Erlotinib   \n",
       "4215                               EGFR-TKI + Metformin   \n",
       "4216                              Osimertinib + TY-9591   \n",
       "4217  Atezolizumab + Bevacizumab + Carboplatin + Pac...   \n",
       "4218  Pemetrexed + Placebo + Platinum-based chemothe...   \n",
       "4219  Bevacizumab + Pemetrexed + Platinum-based chem...   \n",
       "4220                        Almonertinib + Chemotherapy   \n",
       "4221                                              AK112   \n",
       "4222              Almonertinib + Cisplatin + Pemetrexed   \n",
       "4223  Osimertinib + Pemetrexed + Platinum-based chem...   \n",
       "4224  Osimertinib + Pemetrexed + Platinum-based chem...   \n",
       "4225             Carboplatin + Pemetrexed + Toripalimab   \n",
       "4226      Cisplatin + Pemetrexed + Placebo + Sintilimab   \n",
       "4227      Cisplatin + IBI305  + Pemetrexed + Sintilimab   \n",
       "4228                                            SH-1028   \n",
       "4229                                              D0316   \n",
       "4230           Carboplatin + Pembrolizumab + Pemetrexed   \n",
       "4231  Stereotactic Body Radiation Therapy + Tyrosine...   \n",
       "4232                               Anlotinib + Icotinib   \n",
       "4233             Endostatin + Tyrosine Kinase Inhibitor   \n",
       "4234                          Carboplatin + Vinorelbine   \n",
       "4235                              Erlotinib + Sunitinib   \n",
       "4236                              Erlotinib + Sunitinib   \n",
       "4237    Erlotinib + Stereotactic Body Radiation Therapy   \n",
       "4238    Gefitinib + Stereotactic Body Radiation Therapy   \n",
       "4239                            Gefitinib + Thalidomide   \n",
       "4240                           Chemotherapy + Gefitinib   \n",
       "4241                                       Fruquintinib   \n",
       "4242                            Erlotinib + Onartuzumab   \n",
       "4243               Carboplatin + Erlotinib + Paclitaxel   \n",
       "4244                          Bevacizumab + Osimertinib   \n",
       "4245                                           BPI-7711   \n",
       "4246                                        Rociletinib   \n",
       "4247                                       Almonertinib   \n",
       "4248                                       Almonertinib   \n",
       "4249                                         Alflutinib   \n",
       "4250                            Bevacizumab + Erlotinib   \n",
       "4251                                         Lazertinib   \n",
       "4252                             Docetaxel + Vandetanib   \n",
       "4253                                          Gefitinib   \n",
       "4254                                          Gefitinib   \n",
       "4255                                          Gefitinib   \n",
       "4256                                          Gefitinib   \n",
       "4257           Beta-elemene + Tyrosine Kinase Inhibitor   \n",
       "4258                                        Osimertinib   \n",
       "4259  Carboplatin + Pemetrexed + Tyrosine Kinase Inh...   \n",
       "4260                            Chemotherapy + Icotinib   \n",
       "4261                                            DZD9008   \n",
       "4262              Anlotinib + Tyrosine Kinase Inhibitor   \n",
       "4263           Radiotherapy + Tyrosine Kinase Inhibitor   \n",
       "4264              Metformin + Tyrosine Kinase Inhibitor   \n",
       "4265                                       Almonertinib   \n",
       "4266                                        Osimertinib   \n",
       "4323  Erlotinib + Gemcitabine + Platinum-based chemo...   \n",
       "4327  Erlotinib + Gemcitabine + Platinum-based chemo...   \n",
       "4328                             Capmatinib + Erlotinib   \n",
       "4329                            Osimertinib + Tepotinib   \n",
       "4330                          Osimertinib + Savolitinib   \n",
       "4331             Capmatinib + Osimertinib + Ramucirumab   \n",
       "4332                                          Tepotinib   \n",
       "4333                             Capmatinib + Gefitinib   \n",
       "4334                           Capmatinib + Osimertinib   \n",
       "4335                           Osimertinib + Tepotinib    \n",
       "4336                          Osimertinib + Savolitinib   \n",
       "4337                          Osimertinib + Savolitinib   \n",
       "4338                            Erlotinib + Onartuzumab   \n",
       "4339                          Osimertinib + Savolitinib   \n",
       "4340                            Erlotinib + Onartuzumab   \n",
       "4342                                              M1231   \n",
       "4343  Erlotinib + Gemcitabine + Platinum-based chemo...   \n",
       "4344  Bevacizumab + Carboplatin + Osimertinib + Peme...   \n",
       "4346                                          Neratinib   \n",
       "4347                                            PLB1004   \n",
       "4348                                       Mobocertinib   \n",
       "4349                                         Alflutinib   \n",
       "4350                                            DZD9008   \n",
       "6176                                        Regorafenib   \n",
       "6177                         Nintedanib + Pembrolizumab   \n",
       "6178                                          Pazopanib   \n",
       "6179                                         Nintedanib   \n",
       "6180                                            AZD4547   \n",
       "6181                                          Ponatinib   \n",
       "6182                                AZD4547 + Docetaxel   \n",
       "6183                         Methotrexate + Regorafenib   \n",
       "6184                                          Pazopanib   \n",
       "6185                                         Nintedanib   \n",
       "6186                                          Dovitinib   \n",
       "6187                                          Dovitinib   \n",
       "6188                             Docetaxel + Nintedanib   \n",
       "6189                                          Pazopanib   \n",
       "6229                                        Erdafitinib   \n",
       "6230                                        Pemigatinib   \n",
       "6231                                        Pemigatinib   \n",
       "6232                                        Rogaratinib   \n",
       "6233                                        Pemigatinib   \n",
       "\n",
       "                                                 SOURCE  \\\n",
       "28                                          NCT05261399   \n",
       "29                                          NCT05255406   \n",
       "30                                          NCT05394233   \n",
       "31                    10.1200/JCO.2019.37.15_suppl.3011   \n",
       "32                                          NCT02468661   \n",
       "33                        10.1016/j.annonc.2020.08.1598   \n",
       "34                                          NCT04695925   \n",
       "35                                          NCT05004974   \n",
       "3457                                        NCT05153408   \n",
       "3458                                        NCT05662670   \n",
       "3459                                        NCT05394831   \n",
       "3460                                        NCT03755102   \n",
       "3461                                        NCT05555212   \n",
       "3462                                        NCT03755102   \n",
       "3463                                        NCT05435248   \n",
       "3464                                        NCT04862780   \n",
       "3465                                        NCT04862780   \n",
       "3468                                           26354527   \n",
       "3469                                           28625646   \n",
       "3470                                           27785061   \n",
       "3471                                           27785061   \n",
       "3472                  10.1200/JCO.2021.39.15_suppl.9068   \n",
       "3473                                           30679388   \n",
       "3474                                           27507876   \n",
       "3475                                           26899759   \n",
       "3476                                           29239002   \n",
       "3477                                        NCT03976856   \n",
       "3478                                        NCT02197247   \n",
       "3479                                           29381826   \n",
       "3480                                        NCT02025218   \n",
       "3481  https://www.jto.org/article/S1556-0864(19)3247...   \n",
       "3482                                        NCT01982955   \n",
       "3483                                        NCT04147351   \n",
       "3484                                           25870087   \n",
       "3485                                        NCT03074864   \n",
       "3486                                        NCT02893332   \n",
       "3487                                           29110849   \n",
       "3488                                        NCT02496663   \n",
       "3489                                        NCT02364609   \n",
       "3490                  10.1200/JCO.2021.39.15_suppl.9007   \n",
       "3491                                           34953624   \n",
       "3492                                        NCT02520778   \n",
       "3493                                        NCT05536505   \n",
       "3494                                        NCT05477615   \n",
       "3495                                        NCT02630186   \n",
       "3496                                        NCT05326425   \n",
       "3497                                        NCT05033691   \n",
       "3498                                        NCT03382795   \n",
       "3499                                        NCT04233021   \n",
       "3500                                        NCT03382795   \n",
       "3501                         10.1016/j.jtho.2018.08.603   \n",
       "3502                         10.1016/j.jtho.2021.08.117   \n",
       "3503                                           33077354   \n",
       "3504                         10.1016/j.jtho.2021.08.383   \n",
       "3505  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3506  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3507                  10.1200/JCO.2020.38.18_suppl.LBA5   \n",
       "3508                                           29151359   \n",
       "3509                                           29864379   \n",
       "3510  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3511  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3512  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3513  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3514  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3515                                           15329413   \n",
       "3516                                           15329413   \n",
       "3517                                           15118073   \n",
       "3518                                           21642865   \n",
       "3519                                           31809241   \n",
       "3520                                        NCT05653752   \n",
       "3521                                        NCT05555212   \n",
       "3522                                        NCT05223595   \n",
       "3523                                        NCT05166616   \n",
       "3524                                        NCT04970043   \n",
       "3525                                        NCT04780568   \n",
       "3526                                        NCT04541407   \n",
       "3527                10.1200/JCO.2021.39.15_suppl.e21073   \n",
       "3528                                        NCT03333343   \n",
       "3529                                        NCT03333343   \n",
       "3530                                        NCT03516214   \n",
       "3531                                        NCT03333343   \n",
       "3532                                           32139298   \n",
       "3533                                        NCT00381654   \n",
       "3534                                           32139298   \n",
       "3535                                           32139298   \n",
       "3536                                        NCT03333343   \n",
       "3537                                        NCT03333343   \n",
       "3538               10.1200/JCO.2016.34.15_suppl.e20559    \n",
       "3539                                           29056570   \n",
       "3540                       10.1016/j.annonc.2020.08.684   \n",
       "3541                                           34590052   \n",
       "3542                                        NCT02503722   \n",
       "3543                                           27083334   \n",
       "3544                                        NCT05601973   \n",
       "3545                                        NCT00988169   \n",
       "3546                                        NCT05498389   \n",
       "3547                                        NCT05334277   \n",
       "3548                                        NCT05334277   \n",
       "3549                                        NCT05167851   \n",
       "3550                                        NCT05153408   \n",
       "3551                                        NCT05153408   \n",
       "3552                                        NCT05153408   \n",
       "3553                                        NCT05132985   \n",
       "3554                                        NCT05104788   \n",
       "3555                                        NCT05258279   \n",
       "3556                                        NCT05017025   \n",
       "3557                                        NCT05498428   \n",
       "3558                                        NCT05299125   \n",
       "3559                                        NCT05011487   \n",
       "3560                                        NCT05007938   \n",
       "3561                                        NCT04922138   \n",
       "3562                                        NCT04895930   \n",
       "3563                                        NCT04824079   \n",
       "3564                  10.1200/JCO.2018.36.15_suppl.8544   \n",
       "3565                                        NCT04755738   \n",
       "3566                                        NCT05078931   \n",
       "3567                                        NCT05281406   \n",
       "3568                                        NCT05498428   \n",
       "3569                                        NCT04099836   \n",
       "3570                                        NCT03799094   \n",
       "3571                                        NCT04358562   \n",
       "3572                                        NCT03994393   \n",
       "3573                                        NCT03446417   \n",
       "3574                                        NCT03396185   \n",
       "3575                                        NCT03544814   \n",
       "3576                10.1200/JCO.2020.38.15_suppl.e21618   \n",
       "3577                                        NCT03769103   \n",
       "3578                      10.1016/j.annonc.2020.08.1656   \n",
       "3579                  10.1200/JCO.2021.39.15_suppl.9030   \n",
       "3580                                        NCT02737774   \n",
       "3581                                        NCT03151161   \n",
       "3582                        10.1016/j.jtho.2021.01.1093   \n",
       "3583                                           25695221   \n",
       "3584                                        NCT02930954   \n",
       "3585                                        NCT03410043   \n",
       "3586                                        NCT03392246   \n",
       "3587                                        NCT03341494   \n",
       "3588                                           26898607   \n",
       "3589                                        NCT04512430   \n",
       "3590                                        NCT03050437   \n",
       "3591                                        NCT03909334   \n",
       "3592                          10.1093/annonc/mdz437.004   \n",
       "3593                                        NCT05334277   \n",
       "3594                                        NCT05165355   \n",
       "3595                                        NCT05079022   \n",
       "3596                                        NCT04965831   \n",
       "3597                                        NCT04982900   \n",
       "3598                                        NCT05379803   \n",
       "3599  https://www.onclive.com/view/tdm-1-osimertinib...   \n",
       "3600                                        NCT03292133   \n",
       "3601                      10.1016/j.annonc.2020.08.1598   \n",
       "3602                      10.1016/j.annonc.2020.08.1598   \n",
       "3603                                           27686971   \n",
       "3604                  10.1200/JCO.2020.38.15_suppl.9507   \n",
       "3605                 10.1200/JCO.2018.36.15_suppl.9012    \n",
       "3606                                        NCT03486496   \n",
       "3607                  10.1200/JCO.2022.40.16_suppl.9107   \n",
       "3608                                        NCT01532089   \n",
       "3609                                        NCT03457337   \n",
       "3610                                        NCT03831932   \n",
       "3611                                           27448761   \n",
       "3612                                        NCT01819428   \n",
       "3613                                           20479403   \n",
       "3614                                           20215545   \n",
       "3615                                        NCT05463224   \n",
       "3616                                        NCT03046992   \n",
       "3617                                        NCT02444819   \n",
       "3618  https://oncologypro.esmo.org/meeting-resources...   \n",
       "3619                                        NCT02616393   \n",
       "3620                                        NCT02616393   \n",
       "3621                                        NCT02616393   \n",
       "3622                                           22011666   \n",
       "3623                                           22722787   \n",
       "3624                                        NCT04591002   \n",
       "3625                                        NCT03769103   \n",
       "3626                                        NCT03586453   \n",
       "3627                                        NCT04027647   \n",
       "3628                                        NCT05514314   \n",
       "3629                                           35862035   \n",
       "3630                                        NCT03349203   \n",
       "3631                                        NCT03749213   \n",
       "3632                                        NCT03399669   \n",
       "3633                                        NCT02347839   \n",
       "3634                  10.1200/JCO.2017.35.15_suppl.9035   \n",
       "3635                         10.1186/s12885-021-07861-1   \n",
       "3636                                           20493771   \n",
       "3637                                        NCT04988295   \n",
       "3638                                        NCT04988295   \n",
       "3639                                        NCT04923906   \n",
       "3640                                        NCT04874844   \n",
       "3641                         10.1016/j.jtho.2022.07.769   \n",
       "3642                                        NCT04487080   \n",
       "3643                                        NCT04487080   \n",
       "3644                                        NCT05388669   \n",
       "3645                                        NCT04487080   \n",
       "3646                                        NCT04500717   \n",
       "3647                                        NCT04500704   \n",
       "3648                                        NCT04058704   \n",
       "3649                                        NCT04028778   \n",
       "3650                                        NCT03521154   \n",
       "3651                                        NCT05338970   \n",
       "3652                                           23782814   \n",
       "3653                                        NCT02929693   \n",
       "3654                                           34033974   \n",
       "3655                                        NCT02588261   \n",
       "3656                                        NCT02588261   \n",
       "3657                                        NCT04951635   \n",
       "3658                  10.1200/JCO.2021.39.15_suppl.9013   \n",
       "3659                                        NCT04143607   \n",
       "3660                                           35662408   \n",
       "3661                                        NCT03653546   \n",
       "3662                                        NCT03856697   \n",
       "3663  https://oncologypro.esmo.org/meeting-resources...   \n",
       "3664  https://oncologypro.esmo.org/meeting-resources...   \n",
       "3665                                        NCT02442349   \n",
       "3666                                        NCT02518802   \n",
       "3667                                        NCT03381066   \n",
       "3668  https://www.boehringer-ingelheim.us/press-rele...   \n",
       "3669                                        NCT03529084   \n",
       "3670                                        NCT01487174   \n",
       "3671                                        NCT05120349   \n",
       "3672                                        NCT04351555   \n",
       "3673                                        NCT04035486   \n",
       "3674                                           34280355   \n",
       "3675                                           23948351   \n",
       "3676                               10.1200/JCO.21.01729   \n",
       "3677                                           28103612   \n",
       "3678                                        NCT04511533   \n",
       "3679                                        NCT03634059   \n",
       "3680                                        NCT03634059   \n",
       "3681                                        NCT03766490   \n",
       "3682                                        NCT03381430   \n",
       "3684                         10.1016/j.jtho.2021.10.024   \n",
       "3685                                        NCT04952168   \n",
       "3686                                        NCT04905550   \n",
       "3687                                        NCT02442349   \n",
       "3688                                        NCT04687241   \n",
       "3689                                        NCT04971187   \n",
       "3692                                        NCT02716116   \n",
       "3693                                           29483495   \n",
       "3694  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3695  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3696                                           24353160   \n",
       "3697  https://www.jto.org/article/S1556-0864(17)3288...   \n",
       "3698                      10.1016/j.annonc.2021.08.1815   \n",
       "3699                                        NCT05241873   \n",
       "3700                                        NCT04448379   \n",
       "3701                                        NCT04858958   \n",
       "3702                                        NCT04958967   \n",
       "3703                                        NCT02369484   \n",
       "3704                                        NCT05435274   \n",
       "3705                                        NCT05132777   \n",
       "3706                                        NCT02716116   \n",
       "3707                                        NCT05045404   \n",
       "3708                                        NCT05498428   \n",
       "3709                                           35101045   \n",
       "3710                                        NCT04063462   \n",
       "3711                           10.1016/annonc/annonc325   \n",
       "3712                  10.1200/JCO.2021.39.15_suppl.9077   \n",
       "3713                  10.1200/JCO.2021.39.15_suppl.9008   \n",
       "3714                                        NCT02716116   \n",
       "3715                                        NCT04576208   \n",
       "3716                       10.1016/j.annonc.2022.02.030   \n",
       "3717                                        NCT03574402   \n",
       "3718                                        NCT01922583   \n",
       "3719                                        NCT05466149   \n",
       "3720                  10.1200/JCO.2021.39.15_suppl.9112   \n",
       "3721                                           34140248   \n",
       "3722  https://oncologypro.esmo.org/meeting-resources...   \n",
       "3723                                        NCT04402008   \n",
       "3724                                        NCT04044170   \n",
       "3725                                        NCT03318939   \n",
       "3726                         10.1016/j.jtho.2018.08.243   \n",
       "3727                                        NCT03191149   \n",
       "3728                          10.1093/annonc/mdz260.051   \n",
       "3729                                        NCT05378763   \n",
       "3730                                        NCT04538664   \n",
       "3731                                        NCT04447118   \n",
       "3732                                        NCT05668988   \n",
       "3733                                        NCT04129502   \n",
       "3734                                        NCT03178552   \n",
       "3735                                        NCT05607550   \n",
       "3736                                        NCT05513664   \n",
       "3737                                        NCT05559645   \n",
       "3738  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3739                                           28184913   \n",
       "3740                                           15118073   \n",
       "3741                                           20479403   \n",
       "3742                                           26051236   \n",
       "3743                                           34540680   \n",
       "3744                                        NCT03434418   \n",
       "3745                                        NCT05267288   \n",
       "3746                                        NCT05168566   \n",
       "3747                                        NCT05215951   \n",
       "3748                                        NCT05548348   \n",
       "3749                                        NCT05546866   \n",
       "3750                 10.1200/JCO.2018.36.15_suppl.9050    \n",
       "3751                                        NCT04951648   \n",
       "3752                                        NCT04988607   \n",
       "3753                                        NCT05271916   \n",
       "3754                                           27507876   \n",
       "3755                                        NCT05263947   \n",
       "3756                                           33317922   \n",
       "3757                                        NCT04816214   \n",
       "3758                                           33317922   \n",
       "3759  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3760                 10.1200/JCO.2018.36.15_suppl.9050    \n",
       "3761                                           26051236   \n",
       "3762  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3763                 10.1200/JCO.2018.36.15_suppl.9050    \n",
       "3764                                           26051236   \n",
       "3765                                           17045698   \n",
       "3767                                           25923549   \n",
       "3768                                           22071596   \n",
       "3769                                           24035188   \n",
       "3770                                        NCT04479306   \n",
       "3771                                        NCT05555212   \n",
       "3772                                        NCT05489731   \n",
       "3773                                        NCT04479306   \n",
       "3774                                        NCT03618043   \n",
       "3775                                        NCT03603262   \n",
       "3776                                           35274722   \n",
       "3777                                        NCT03053219   \n",
       "3778                                           32139298   \n",
       "3779                                           32139298   \n",
       "3780                                           31319994   \n",
       "3781                                           32139298   \n",
       "3782                                        NCT02323126   \n",
       "3783                                           33046516   \n",
       "3784                                        NCT02789345   \n",
       "3785                          10.1093/annonc/mdz437.002   \n",
       "3786                                           28954786   \n",
       "3787                                           30032814   \n",
       "3788                                           29110849   \n",
       "3789                                        NCT04510415   \n",
       "3790                                           25923549   \n",
       "3791                                        NCT05498389   \n",
       "3792                                        NCT05003037   \n",
       "3793                                        NCT04970693   \n",
       "3794                                        NCT04592666   \n",
       "3795                                        NCT04438902   \n",
       "3796                                        NCT03446417   \n",
       "3797                     10.1158/1538-7445.AM2021-CT170   \n",
       "3798                                        NCT03574402   \n",
       "3799                                        NCT04764214   \n",
       "3800                                        NCT03410043   \n",
       "3801                                        NCT01922583   \n",
       "3802                                        NCT01449461   \n",
       "3803  https://ascopubs.org/doi/abs/10.1200/JCO.2017....   \n",
       "3804  https://meetinglibrary.asco.org/record/123487/...   \n",
       "3805                                        NCT02917993   \n",
       "3806                                           30915273   \n",
       "3807                                        NCT03455829   \n",
       "3808                                        NCT03532698   \n",
       "3809                                        NCT03543683   \n",
       "3810                                        NCT02971501   \n",
       "3811                       10.1016/j.annonc.2021.11.010   \n",
       "3812                                           36049654   \n",
       "3813  https://www.jto.org/article/S1556-0864(16)3290...   \n",
       "3814                                           25923550   \n",
       "3815                                           23490650   \n",
       "3816                         10.1016/j.jtho.2022.05.011   \n",
       "3817                  10.1200/JCO.2020.38.15_suppl.9602   \n",
       "3818                                           27613527   \n",
       "3819                                        NCT03300115   \n",
       "3820                                        NCT01819428   \n",
       "3821                                           17761977   \n",
       "3822                  10.1200/JCO.2019.37.15_suppl.9037   \n",
       "3823                                        NCT03228277   \n",
       "3824                          10.1093/annonc/mdx671.001   \n",
       "3825                                        NCT02444819   \n",
       "3826  https://www.boehringer-ingelheim.com/press-rel...   \n",
       "3827                                        NCT05536505   \n",
       "3828                                        NCT04563871   \n",
       "3829                                           35156036   \n",
       "3830                                        NCT02824952   \n",
       "3831                       10.1016/j.jtocrr.2020.100099   \n",
       "3832                                           32669708   \n",
       "3833                                        NCT03394118   \n",
       "3834                                        NCT02094261   \n",
       "3835                                        NCT02442349   \n",
       "3836  https://www.clinicaltrialsregister.eu/ctr-sear...   \n",
       "3837                                        NCT02856893   \n",
       "3838                                           32200138   \n",
       "3839                                           32634610   \n",
       "3840                                           30763730   \n",
       "3841                              10.1093/annonc/mdw140   \n",
       "3842                                        NCT04870190   \n",
       "3843  https://www.hopkinsmedicine.org/singapore/_dow...   \n",
       "3844  https://www.boehringer-ingelheim.us/press-rele...   \n",
       "3845                                           32634610   \n",
       "3846                                        NCT02474355   \n",
       "3847                                           32817079   \n",
       "3848                                           29858027   \n",
       "3849                                        NCT03853551   \n",
       "3850                                        NCT05377788   \n",
       "3851                                           33052556   \n",
       "3852                                        NCT01982955   \n",
       "3853                                        NCT04862780   \n",
       "3854                                        NCT04785742   \n",
       "3855                       10.1016/j.annonc.2022.02.030   \n",
       "3856                                        NCT04841811   \n",
       "3857                                        NCT05498389   \n",
       "3858                                        NCT05430802   \n",
       "3859                                        NCT05068024   \n",
       "3860                                        NCT04487093   \n",
       "3861                                        NCT04338243   \n",
       "3862                                        NCT04413201   \n",
       "3863                                        NCT05559645   \n",
       "3864                                           32027846   \n",
       "3994  https://www.accessdata.fda.gov/drugsatfda_docs...   \n",
       "3995                                           21111508   \n",
       "3996                                        NCT03711422   \n",
       "3997                                        NCT05503888   \n",
       "3998                                        NCT05497076   \n",
       "3999                                        NCT05401110   \n",
       "4000                         10.1016/j.jtho.2017.09.010   \n",
       "4001                                        NCT05256290   \n",
       "4002                                        NCT05195619   \n",
       "4003                                        NCT05168423   \n",
       "4004                                        NCT05099172   \n",
       "4005                                        NCT05099172   \n",
       "4006                                        NCT05099172   \n",
       "4007                                        NCT05060796   \n",
       "4008                                        NCT04982926   \n",
       "4009                                        NCT04944069   \n",
       "4010                                        NCT04772235   \n",
       "4011                                        NCT04762199   \n",
       "4012                                        NCT05621525   \n",
       "4013                                        NCT04528836   \n",
       "4014                                        NCT02609776   \n",
       "4015                                        NCT04429542   \n",
       "4016                                        NCT04429542   \n",
       "4017                                        NCT04397926   \n",
       "4018                                        NCT04085315   \n",
       "4019                                        NCT04204473   \n",
       "4020                                        NCT03827070   \n",
       "4021                                        NCT03846310   \n",
       "4022                                        NCT03846310   \n",
       "4023                                        NCT04001777   \n",
       "4024                                        NCT03891615   \n",
       "4025                                        NCT04141644   \n",
       "4026                                        NCT04077463   \n",
       "4027                                        NCT03436056   \n",
       "4028                                        NCT03535363   \n",
       "4029                      10.1016/S0959-8049(20)31083-2   \n",
       "4030                                        NCT03326752   \n",
       "4031                                        NCT03567642   \n",
       "4032                                        NCT02411591   \n",
       "4033                                        NCT02374645   \n",
       "4034                10.1200/JCO.2019.37.15_suppl.e20611   \n",
       "4035                  10.1200/jco.2013.31.15_suppl.8107   \n",
       "4036                                        NCT00903734   \n",
       "4037                                        NCT00903734   \n",
       "4038                                        NCT00903734   \n",
       "4039                                           33012782   \n",
       "4040                                           33012782   \n",
       "4041                        10.1016/j.jtho.2017.09.1294   \n",
       "4042                                        NCT02342353   \n",
       "4043                                        NCT01998126   \n",
       "4044                                        NCT02924233   \n",
       "4045                                           16533873   \n",
       "4046                                        NCT01859026   \n",
       "4047                                        NCT03054038   \n",
       "4048                                        NCT03755102   \n",
       "4049                                        NCT03810807   \n",
       "4050                                           30880334   \n",
       "4051                                        NCT03082300   \n",
       "4052                                        NCT04455594   \n",
       "4053                                        NCT03255083   \n",
       "4054                                           16364494   \n",
       "4055                                        NCT03755102   \n",
       "4056                                           36426287   \n",
       "4057                                        NCT05636267   \n",
       "4058                                        NCT05636267   \n",
       "4059                                        NCT05552781   \n",
       "4060                                        NCT05519293   \n",
       "4061                                        NCT05442060   \n",
       "4062                                        NCT05393466   \n",
       "4063                                        NCT05351788   \n",
       "4064                                        NCT05298176   \n",
       "4065                                        NCT05284994   \n",
       "4066                                        NCT05283226   \n",
       "4067                                        NCT05244213   \n",
       "4068                                        NCT05215548   \n",
       "4069                                        NCT05215925   \n",
       "4070                                        NCT05215925   \n",
       "4071                                        NCT05215925   \n",
       "4072                                        NCT05209256   \n",
       "4073                                        NCT05099549   \n",
       "4074                                        NCT05089916   \n",
       "4075                                        NCT05044897   \n",
       "4076                                        NCT04989322   \n",
       "4077                                        NCT04989322   \n",
       "4078                                        NCT04959981   \n",
       "4079                                        NCT04978753   \n",
       "4080                                        NCT01487265   \n",
       "4081                                           27843623   \n",
       "4082                                        NCT02098954   \n",
       "4083                  10.1200/JCO.2021.39.15_suppl.9095   \n",
       "4084                                        NCT04872634   \n",
       "4085                                        NCT04872634   \n",
       "4086                                        NCT05636267   \n",
       "4087                                        NCT04820023   \n",
       "4088                                        NCT04820023   \n",
       "4089                                        NCT04838548   \n",
       "4090                                        NCT04743505   \n",
       "4091                                        NCT03256136   \n",
       "4092                                        NCT04545710   \n",
       "4093                                        NCT04335292   \n",
       "4094                                        NCT04517526   \n",
       "4095                                        NCT04285671   \n",
       "4096                                        NCT04470076   \n",
       "4097                                        NCT04486833   \n",
       "4098                                        NCT04965090   \n",
       "4099                                        NCT04410796   \n",
       "4100  https://oncologypro.esmo.org/meeting-resources...   \n",
       "4101                                        NCT03904823   \n",
       "4102                                        NCT05146219   \n",
       "4103                                        NCT03811054   \n",
       "4104                                        NCT03797391   \n",
       "4105                10.1200/JCO.2022.40.16_suppl.e21140   \n",
       "4106                                        NCT04029350   \n",
       "4107                                        NCT03989115   \n",
       "4108                                        NCT03989115   \n",
       "4109                                        NCT03574402   \n",
       "4110                                        NCT04120454   \n",
       "4111                                        NCT04077255   \n",
       "4112                                        NCT04908956   \n",
       "4113                                        NCT03667820   \n",
       "4114                                        NCT03765775   \n",
       "4115                                           35248866   \n",
       "4116                                        NCT03402464   \n",
       "4117                                        NCT03574402   \n",
       "4118                       10.1016/j.annonc.2022.02.016   \n",
       "4119                                        NCT03450330   \n",
       "4120                                        NCT04519983   \n",
       "4121                                        NCT03497767   \n",
       "4122                         10.1016/j.jtho.2019.08.499   \n",
       "4123                  10.1200/JCO.2020.38.15_suppl.9583   \n",
       "4124                                        NCT03758677   \n",
       "4125                                        NCT03709706   \n",
       "4126                                        NCT03709706   \n",
       "4127                                        NCT03574402   \n",
       "4128                                        NCT03094169   \n",
       "4129                                        NCT03153358   \n",
       "4130                                        NCT03754530   \n",
       "4131                                        NCT03170960   \n",
       "4132                                        NCT00265317   \n",
       "4133                                        NCT04619563   \n",
       "4134                                        NCT03944772   \n",
       "4135                                        NCT03940703   \n",
       "4136                                        NCT03940703   \n",
       "4137                                        NCT03944772   \n",
       "4138                                        NCT00842712   \n",
       "4139                                        NCT00117962   \n",
       "4140                                           29050231   \n",
       "4141                                           29888109   \n",
       "4142                                           26774201   \n",
       "4143                                        NCT02580708   \n",
       "4144                                        NCT03418532   \n",
       "4145                                        NCT00492206   \n",
       "4146                                        NCT01294306   \n",
       "4147                                        NCT02704767   \n",
       "4148                                        NCT00444678   \n",
       "4149                           10.1016/annonc/annonc367   \n",
       "4150                                        NCT04245085   \n",
       "4151                                        NCT04538378   \n",
       "4152                 10.1200/jco.2012.30.15_suppl.7550    \n",
       "4153  https://www.chi-med.com/wp-content/uploads/201...   \n",
       "4154                                           29528793   \n",
       "4155                                        NCT00979212   \n",
       "4156                  10.1200/jco.2013.31.15_suppl.8062   \n",
       "4157                                           26094080   \n",
       "4158                                        NCT01038037   \n",
       "4159  https://www.healio.com/hematology-oncology/lun...   \n",
       "4160                                           20978446   \n",
       "4161                  10.1200/jco.2012.30.15_suppl.7544   \n",
       "4162                                        NCT00126581   \n",
       "4163                                        NCT02947386   \n",
       "4164                  10.1200/JCO.2019.37.15_suppl.9035   \n",
       "4165                                           26033830   \n",
       "4166                                10.1200/PO.20.00315   \n",
       "4167                  10.1200/JCO.2018.36.15_suppl.9097   \n",
       "4168                                        NCT04811001   \n",
       "4169                                        NCT03944772   \n",
       "4170                                           32463456   \n",
       "4171                                        NCT01167244   \n",
       "4172                                        NCT05662813   \n",
       "4173                                        NCT04882345   \n",
       "4174                                        NCT04423185   \n",
       "4175                                        NCT04685070   \n",
       "4176                                        NCT04808752   \n",
       "4177                                        NCT04553887   \n",
       "4178                                        NCT04354961   \n",
       "4179                                        NCT05469022   \n",
       "4180                                        NCT05465343   \n",
       "4181                     10.1158/1538-7445.AM2021-CT163   \n",
       "4182                     10.1158/1538-7445.AM2021-CT163   \n",
       "4183                                        NCT03944772   \n",
       "4184                                        NCT03574402   \n",
       "4185                  10.1200/JCO.2019.37.15_suppl.9079   \n",
       "4186                 10.1200/jco.2014.32.15_suppl.8088    \n",
       "4187                                           27448761   \n",
       "4188                                           17761977   \n",
       "4189                                        NCT05338619   \n",
       "4190                                        NCT05277701   \n",
       "4191                                        NCT04075396   \n",
       "4192                                        NCT00067548   \n",
       "4193                  10.1200/JCO.2021.39.15_suppl.9095   \n",
       "4194                                           24075125   \n",
       "4195                                           23689430   \n",
       "4196                                        NCT05526755   \n",
       "4197                                        NCT03804580   \n",
       "4198                                        NCT03865511   \n",
       "4199                                        NCT03460275   \n",
       "4200                                           35156036   \n",
       "4201                                        NCT03239340   \n",
       "4202                                        NCT00818441   \n",
       "4203                                        NCT04423185   \n",
       "4204                                        NCT04339829   \n",
       "4205                                        NCT04504071   \n",
       "4206                                        NCT00344773   \n",
       "4207                                        NCT00411047   \n",
       "4208                                        NCT02804776   \n",
       "4209                                           25667274   \n",
       "4210                                        NCT00087412   \n",
       "4211                                        NCT02183883   \n",
       "4212                                        NCT04201756   \n",
       "4213                                        NCT03256136   \n",
       "4214                                        NCT02193282   \n",
       "4215                                        NCT05445791   \n",
       "4216                                        NCT05382728   \n",
       "4217                                        NCT04194203   \n",
       "4218                                        NCT05132413   \n",
       "4219                                        NCT05132413   \n",
       "4220                                        NCT05493501   \n",
       "4221                                        NCT05184712   \n",
       "4222                                        NCT04762459   \n",
       "4223                                        NCT04765059   \n",
       "4224                                        NCT04351555   \n",
       "4225                         10.1038/s41392-021-00751-9   \n",
       "4226                       10.1016/j.annonc.2021.10.007   \n",
       "4227                       10.1016/j.annonc.2021.10.007   \n",
       "4228                                        NCT04239833   \n",
       "4229                                        NCT04206072   \n",
       "4230                                        NCT03515837   \n",
       "4231                                        NCT03727867   \n",
       "4232                                        NCT04797806   \n",
       "4233                                        NCT03008109   \n",
       "4234                                        NCT03203590   \n",
       "4235                                        NCT00558103   \n",
       "4236                                        NCT00558103   \n",
       "4237                                        NCT02882984   \n",
       "4238                                        NCT02882984   \n",
       "4239                                        NCT02387086   \n",
       "4240                                           26159065   \n",
       "4241                      10.1016/j.lungcan.2020.06.016   \n",
       "4242                                        NCT02031744   \n",
       "4243                                           16043829   \n",
       "4244                                        NCT05104281   \n",
       "4245                                        NCT03866499   \n",
       "4246                                        NCT02186301   \n",
       "4247                                        NCT05493501   \n",
       "4248                                        NCT04762459   \n",
       "4249                                        NCT04853342   \n",
       "4250                 10.1200/JCO.2018.36.15_suppl.9006    \n",
       "4251                                        NCT04248829   \n",
       "4252                                           25057173   \n",
       "4253                                        NCT03656393   \n",
       "4254                                           22674612   \n",
       "4255                                           18779611   \n",
       "4256                                           33332190   \n",
       "4257                                        NCT04401059   \n",
       "4258                                        NCT03969823   \n",
       "4259                                        NCT04552613   \n",
       "4260                                        NCT03983811   \n",
       "4261                                        NCT05559645   \n",
       "4262                                        NCT04007835   \n",
       "4263                                        NCT03916913   \n",
       "4264                                           31486833   \n",
       "4265                                        NCT04778800   \n",
       "4266                                        NCT04737382   \n",
       "4323                                        NCT02098954   \n",
       "4327                                        NCT02098954   \n",
       "4328                  10.1200/jco.2015.33.15_suppl.2587   \n",
       "4329                                        NCT05120960   \n",
       "4330                                        NCT03778229   \n",
       "4331                                        NCT05642572   \n",
       "4332                                        NCT03940703   \n",
       "4333                                           30156984   \n",
       "4334                                        NCT05642572   \n",
       "4335                                        NCT03940703   \n",
       "4336                                        NCT05163249   \n",
       "4337                                        NCT04606771   \n",
       "4338                                           27937096   \n",
       "4339                                        NCT05015608   \n",
       "4340  https://www.clinicaltrialsregister.eu/ctr-sear...   \n",
       "4342                                        NCT04695847   \n",
       "4343                                        NCT02098954   \n",
       "4344                                        NCT05507606   \n",
       "4346                                           19318484   \n",
       "4347                                        NCT05347628   \n",
       "4348                                        NCT03807778   \n",
       "4349                                        NCT05364073   \n",
       "4350                                        NCT03974022   \n",
       "6176                                           26003007   \n",
       "6177                                        NCT02856425   \n",
       "6178                                        NCT02193152   \n",
       "6179               10.1200/JCO.2020.38.15_suppl.e21694    \n",
       "6180                  10.1200/JCO.2021.39.15_suppl.9095   \n",
       "6181                                           30297175   \n",
       "6182                                        NCT01824901   \n",
       "6183                                        NCT03520842   \n",
       "6184                                        NCT00367679   \n",
       "6185                                        NCT01948141   \n",
       "6186                                           27315356   \n",
       "6187                    10.1200/jco.2016.34.4_suppl.616   \n",
       "6188                                        NCT02231164   \n",
       "6189                                           26074395   \n",
       "6229                                        NCT02699606   \n",
       "6230                                        NCT05287386   \n",
       "6231                                        NCT05253807   \n",
       "6232                10.1200/JCO.2019.37.15_suppl.e20661   \n",
       "6233                                        NCT05210946   \n",
       "\n",
       "                                PRIMARY_OUTCOME_MEASURE  \n",
       "28                            Progression free survival  \n",
       "29                            Progression free survival  \n",
       "30                            Progression free survival  \n",
       "31                      Maximum tolerated dose/toxicity  \n",
       "32                      Maximum tolerated dose/toxicity  \n",
       "33                                Overall Response Rate  \n",
       "34                            Progression free survival  \n",
       "35                                Overall Response Rate  \n",
       "3457                              Overall Response Rate  \n",
       "3458                              Overall Response Rate  \n",
       "3459                    Maximum tolerated dose/toxicity  \n",
       "3460                              Overall Response Rate  \n",
       "3461                              Overall Response Rate  \n",
       "3462                              Overall Response Rate  \n",
       "3463                              Overall Response Rate  \n",
       "3464                              Overall Response Rate  \n",
       "3465                              Overall Response Rate  \n",
       "3468                                            Unknown  \n",
       "3469                                            Unknown  \n",
       "3470                                            Unknown  \n",
       "3471                                            Unknown  \n",
       "3472                              Overall Response Rate  \n",
       "3473                              Overall Response Rate  \n",
       "3474                          Progression free survival  \n",
       "3475                    Maximum tolerated dose/toxicity  \n",
       "3476                    Maximum tolerated dose/toxicity  \n",
       "3477                    Maximum tolerated dose/toxicity  \n",
       "3478                    Maximum tolerated dose/toxicity  \n",
       "3479                                    Absorption rate  \n",
       "3480        Disease control rate, Clinical benefit rate  \n",
       "3481                          Progression free survival  \n",
       "3482                          Progression free survival  \n",
       "3483                              Overall Response Rate  \n",
       "3484                                 MTD, ORR, Toxicity  \n",
       "3485                              Overall Response Rate  \n",
       "3486                          Progression free survival  \n",
       "3487                    Maximum tolerated dose/toxicity  \n",
       "3488                    Maximum tolerated dose/toxicity  \n",
       "3489                    Maximum tolerated dose/toxicity  \n",
       "3490                              Overall Response Rate  \n",
       "3491                    Maximum tolerated dose/toxicity  \n",
       "3492                    Maximum tolerated dose/toxicity  \n",
       "3493  Disease free survival, relapse free survival, ...  \n",
       "3494                              Overall Response Rate  \n",
       "3495                              Overall Response Rate  \n",
       "3496                              Overall Response Rate  \n",
       "3497                          Progression free survival  \n",
       "3498                              Overall Response Rate  \n",
       "3499                              Overall Response Rate  \n",
       "3500                              Overall Response Rate  \n",
       "3501                          Progression free survival  \n",
       "3502                    Maximum tolerated dose/toxicity  \n",
       "3503                              Overall Response Rate  \n",
       "3504  Complete response, Pathological complete response  \n",
       "3505                          Progression free survival  \n",
       "3506                          Progression free survival  \n",
       "3507  Disease free survival, relapse free survival, ...  \n",
       "3508                          Progression free survival  \n",
       "3509                          Progression free survival  \n",
       "3510                          Progression free survival  \n",
       "3511                              Overall Response Rate  \n",
       "3512                                        Not defined  \n",
       "3513                          Progression free survival  \n",
       "3514                          Progression free survival  \n",
       "3515                                            Unknown  \n",
       "3516                                            Unknown  \n",
       "3517                                            Unknown  \n",
       "3518                                            Unknown  \n",
       "3519                    Maximum tolerated dose/toxicity  \n",
       "3520                    Maximum tolerated dose/toxicity  \n",
       "3521                              Overall Response Rate  \n",
       "3522                    Maximum tolerated dose/toxicity  \n",
       "3523                    Maximum tolerated dose/toxicity  \n",
       "3524                          Progression free survival  \n",
       "3525                    Maximum tolerated dose/toxicity  \n",
       "3526                    Maximum tolerated dose/toxicity  \n",
       "3527                              Overall Response Rate  \n",
       "3528                              Overall Response Rate  \n",
       "3529                              Overall Response Rate  \n",
       "3530                    Maximum tolerated dose/toxicity  \n",
       "3531                              Overall Response Rate  \n",
       "3532                    Maximum tolerated dose/toxicity  \n",
       "3533                    Maximum tolerated dose/toxicity  \n",
       "3534                    Maximum tolerated dose/toxicity  \n",
       "3535                    Maximum tolerated dose/toxicity  \n",
       "3536                              Overall Response Rate  \n",
       "3537                              Overall Response Rate  \n",
       "3538                    Maximum tolerated dose/toxicity  \n",
       "3539                    Maximum tolerated dose/toxicity  \n",
       "3540                    Maximum tolerated dose/toxicity  \n",
       "3541                                 MTD, ORR, Toxicity  \n",
       "3542                    Maximum tolerated dose/toxicity  \n",
       "3543                                       PFS, TTP, OS  \n",
       "3544                              Overall Response Rate  \n",
       "3545                              Overall Response Rate  \n",
       "3546                              Overall Response Rate  \n",
       "3547                          Progression free survival  \n",
       "3548                          Progression free survival  \n",
       "3549                          Progression free survival  \n",
       "3550                              Overall Response Rate  \n",
       "3551                              Overall Response Rate  \n",
       "3552                              Overall Response Rate  \n",
       "3553                          Major pathologic response  \n",
       "3554                          Major pathologic response  \n",
       "3555                              Overall Response Rate  \n",
       "3556                    Maximum tolerated dose/toxicity  \n",
       "3557                              Overall Response Rate  \n",
       "3558                          Progression free survival  \n",
       "3559                          Lymph node clearance rate  \n",
       "3560                              Overall Response Rate  \n",
       "3561  Disease free survival, relapse free survival, ...  \n",
       "3562                              Overall Response Rate  \n",
       "3563                              Overall Response Rate  \n",
       "3564                                      Response rate  \n",
       "3565                          Progression free survival  \n",
       "3566                          Progression free survival  \n",
       "3567                          Progression free survival  \n",
       "3568                              Overall Response Rate  \n",
       "3569                              Overall Response Rate  \n",
       "3570                          Progression free survival  \n",
       "3571                          Progression free survival  \n",
       "3572                              Overall Response Rate  \n",
       "3573                    Maximum tolerated dose/toxicity  \n",
       "3574  Disease free survival, relapse free survival, ...  \n",
       "3575                          Progression free survival  \n",
       "3576                              Overall Response Rate  \n",
       "3577                          Progression free survival  \n",
       "3578                          Progression free survival  \n",
       "3579                          Progression free survival  \n",
       "3580                          Progression free survival  \n",
       "3581                                  Clinical activity  \n",
       "3582                          Progression free survival  \n",
       "3583                                            Unknown  \n",
       "3584                          Progression free survival  \n",
       "3585                          Progression free survival  \n",
       "3586                              Best overall response  \n",
       "3587                          Progression free survival  \n",
       "3588                                      Response rate  \n",
       "3589                          Major pathologic response  \n",
       "3590                          Progression free survival  \n",
       "3591                          Progression free survival  \n",
       "3592                              Overall Response Rate  \n",
       "3593                          Progression free survival  \n",
       "3594  Disease free survival, relapse free survival, ...  \n",
       "3595                                 Clearance of ctDNA  \n",
       "3596                              Overall Response Rate  \n",
       "3597                                      Response rate  \n",
       "3598                          Progression free survival  \n",
       "3599                    Maximum tolerated dose/toxicity  \n",
       "3600                          Progression free survival  \n",
       "3601                              Overall Response Rate  \n",
       "3602                              Overall Response Rate  \n",
       "3603                                            Unknown  \n",
       "3604                    Maximum tolerated dose/toxicity  \n",
       "3605                    Maximum tolerated dose/toxicity  \n",
       "3606                          Progression free survival  \n",
       "3607                          Progression free survival  \n",
       "3608                          Progression free survival  \n",
       "3609                          Progression free survival  \n",
       "3610                              Overall Response Rate  \n",
       "3611                              Overall Response Rate  \n",
       "3612                              Overall Response Rate  \n",
       "3613                              Overall Response Rate  \n",
       "3614                              Overall Response Rate  \n",
       "3615                          Progression free survival  \n",
       "3616                              Overall Response Rate  \n",
       "3617                              Overall Response Rate  \n",
       "3618                              Overall Response Rate  \n",
       "3619                              Overall Response Rate  \n",
       "3620                              Overall Response Rate  \n",
       "3621                              Overall Response Rate  \n",
       "3622                                      Response rate  \n",
       "3623                                      Response rate  \n",
       "3624                                  Clinical activity  \n",
       "3625                          Progression free survival  \n",
       "3626                                Biomarker discovery  \n",
       "3627                          Progression free survival  \n",
       "3628  Disease free survival, relapse free survival, ...  \n",
       "3629                              Overall Response Rate  \n",
       "3630                              Overall Response Rate  \n",
       "3631                              Overall Response Rate  \n",
       "3632                                Time to progression  \n",
       "3633                                     Resection rate  \n",
       "3634        Disease control rate, Clinical benefit rate  \n",
       "3635                              Overall Response Rate  \n",
       "3636                          Progression free survival  \n",
       "3637                          Progression free survival  \n",
       "3638                          Progression free survival  \n",
       "3639                          Progression free survival  \n",
       "3640                          Progression free survival  \n",
       "3641                          Progression free survival  \n",
       "3642                          Progression free survival  \n",
       "3643                          Progression free survival  \n",
       "3644                                           PFS, ORR  \n",
       "3645                          Progression free survival  \n",
       "3646                          Progression free survival  \n",
       "3647                          Progression free survival  \n",
       "3648                                   Overall survival  \n",
       "3649                          Progression free survival  \n",
       "3650                          Progression free survival  \n",
       "3651                          Progression free survival  \n",
       "3652                          Progression free survival  \n",
       "3653                          Progression free survival  \n",
       "3654                          Progression free survival  \n",
       "3655                          Progression free survival  \n",
       "3656                              Overall Response Rate  \n",
       "3657                          Progression free survival  \n",
       "3658                          Progression free survival  \n",
       "3659                          Progression free survival  \n",
       "3660                          Progression free survival  \n",
       "3661                          Progression free survival  \n",
       "3662                          Progression free survival  \n",
       "3663                          Progression free survival  \n",
       "3664                          Progression free survival  \n",
       "3665                                            OS, PFS  \n",
       "3666  Disease free survival, relapse free survival, ...  \n",
       "3667  Disease free survival, relapse free survival, ...  \n",
       "3668                                            Unknown  \n",
       "3669                          Progression free survival  \n",
       "3670                                   Overall survival  \n",
       "3671  Disease free survival, relapse free survival, ...  \n",
       "3672                          Major pathologic response  \n",
       "3673                          Progression free survival  \n",
       "3674  Disease free survival, relapse free survival, ...  \n",
       "3675                          Progression free survival  \n",
       "3676  Disease free survival, relapse free survival, ...  \n",
       "3677                          Progression free survival  \n",
       "3678                    Maximum tolerated dose/toxicity  \n",
       "3679                          Progression free survival  \n",
       "3680                          Progression free survival  \n",
       "3681                          Progression free survival  \n",
       "3682  Disease free survival, relapse free survival, ...  \n",
       "3684                              Overall Response Rate  \n",
       "3685                                   Overall survival  \n",
       "3686                          Progression free survival  \n",
       "3687                                            OS, PFS  \n",
       "3688  Disease free survival, relapse free survival, ...  \n",
       "3689                          Progression free survival  \n",
       "3692                              Overall Response Rate  \n",
       "3693                                            Unknown  \n",
       "3694                              Overall Response Rate  \n",
       "3695                              Overall Response Rate  \n",
       "3696                                            Unknown  \n",
       "3697                                            Unknown  \n",
       "3698                              Overall Response Rate  \n",
       "3699                              Overall Response Rate  \n",
       "3700                    Maximum tolerated dose/toxicity  \n",
       "3701                              Overall Response Rate  \n",
       "3702                              Overall Response Rate  \n",
       "3703        Disease control rate, Clinical benefit rate  \n",
       "3704                              Overall Response Rate  \n",
       "3705                              Overall Response Rate  \n",
       "3706                              Overall Response Rate  \n",
       "3707                          Progression free survival  \n",
       "3708                              Overall Response Rate  \n",
       "3709                                                NaN  \n",
       "3710                              Overall Response Rate  \n",
       "3711                              Overall Response Rate  \n",
       "3712                              Overall Response Rate  \n",
       "3713                              Overall Response Rate  \n",
       "3714                              Overall Response Rate  \n",
       "3715                    Maximum tolerated dose/toxicity  \n",
       "3716                          Progression free survival  \n",
       "3717                              Overall Response Rate  \n",
       "3718                              Overall Response Rate  \n",
       "3719                              Overall Response Rate  \n",
       "3720        Disease control rate, Clinical benefit rate  \n",
       "3721                    Maximum tolerated dose/toxicity  \n",
       "3722                              Overall Response Rate  \n",
       "3723                              Overall Response Rate  \n",
       "3724                              Overall Response Rate  \n",
       "3725                              Overall Response Rate  \n",
       "3726                              Overall Response Rate  \n",
       "3727                              Overall Response Rate  \n",
       "3728                              Overall Response Rate  \n",
       "3729                          Progression free survival  \n",
       "3730                          Progression free survival  \n",
       "3731                          Progression free survival  \n",
       "3732                          Progression free survival  \n",
       "3733                          Progression free survival  \n",
       "3734                              Overall Response Rate  \n",
       "3735                          Progression free survival  \n",
       "3736                              Overall Response Rate  \n",
       "3737                          Progression free survival  \n",
       "3738                                        Not defined  \n",
       "3739                                            Unknown  \n",
       "3740                                            Unknown  \n",
       "3741                              Overall Response Rate  \n",
       "3742                                            Unknown  \n",
       "3743                                                NaN  \n",
       "3744                              Overall Response Rate  \n",
       "3745                          Progression free survival  \n",
       "3746                              Overall Response Rate  \n",
       "3747                              Overall Response Rate  \n",
       "3748                              Overall Response Rate  \n",
       "3749  Disease free survival, relapse free survival, ...  \n",
       "3750                              Overall Response Rate  \n",
       "3751                          Progression free survival  \n",
       "3752                          Progression free survival  \n",
       "3753                          Progression free survival  \n",
       "3754                          Progression free survival  \n",
       "3755                          Progression free survival  \n",
       "3756                          Progression free survival  \n",
       "3757                          Progression free survival  \n",
       "3758                          Progression free survival  \n",
       "3759                                        Not defined  \n",
       "3760                              Overall Response Rate  \n",
       "3761                                            Unknown  \n",
       "3762                                        Not defined  \n",
       "3763                              Overall Response Rate  \n",
       "3764                                            Unknown  \n",
       "3765                                            Unknown  \n",
       "3767                          Progression free survival  \n",
       "3768                                            Unknown  \n",
       "3769                                            Unknown  \n",
       "3770                    Maximum tolerated dose/toxicity  \n",
       "3771                              Overall Response Rate  \n",
       "3772                    Maximum tolerated dose/toxicity  \n",
       "3773                    Maximum tolerated dose/toxicity  \n",
       "3774                    Maximum tolerated dose/toxicity  \n",
       "3775                    Maximum tolerated dose/toxicity  \n",
       "3776                    Maximum tolerated dose/toxicity  \n",
       "3777                              Overall Response Rate  \n",
       "3778                    Maximum tolerated dose/toxicity  \n",
       "3779                    Maximum tolerated dose/toxicity  \n",
       "3780                    Maximum tolerated dose/toxicity  \n",
       "3781                    Maximum tolerated dose/toxicity  \n",
       "3782                          Progression free survival  \n",
       "3783                    Maximum tolerated dose/toxicity  \n",
       "3784                    Maximum tolerated dose/toxicity  \n",
       "3785                    Maximum tolerated dose/toxicity  \n",
       "3786                    Maximum tolerated dose/toxicity  \n",
       "3787                              Overall Response Rate  \n",
       "3788                    Maximum tolerated dose/toxicity  \n",
       "3789                              Overall Response Rate  \n",
       "3790                              Overall Response Rate  \n",
       "3791                              Overall Response Rate  \n",
       "3792                          Progression free survival  \n",
       "3793                          Progression free survival  \n",
       "3794                          Progression free survival  \n",
       "3795                          Progression free survival  \n",
       "3796                    Maximum tolerated dose/toxicity  \n",
       "3797                              Overall Response Rate  \n",
       "3798                              Overall Response Rate  \n",
       "3799                          Progression free survival  \n",
       "3800                          Progression free survival  \n",
       "3801                              Overall Response Rate  \n",
       "3802                              Overall Response Rate  \n",
       "3803                          Progression free survival  \n",
       "3804                              Overall Response Rate  \n",
       "3805                              Overall Response Rate  \n",
       "3806                              Overall Response Rate  \n",
       "3807                    Maximum tolerated dose/toxicity  \n",
       "3808                              Overall Response Rate  \n",
       "3809                          Progression free survival  \n",
       "3810                          Progression free survival  \n",
       "3811                          Progression free survival  \n",
       "3812                              Overall Response Rate  \n",
       "3813                              Overall Response Rate  \n",
       "3814                              Overall Response Rate  \n",
       "3815                    Maximum tolerated dose/toxicity  \n",
       "3816                              Overall Response Rate  \n",
       "3817                              Overall Response Rate  \n",
       "3818                              Overall Response Rate  \n",
       "3819                              Overall Response Rate  \n",
       "3820                              Overall Response Rate  \n",
       "3821                                  Clinical activity  \n",
       "3822                              Overall Response Rate  \n",
       "3823                              Overall Response Rate  \n",
       "3824                              Overall Response Rate  \n",
       "3825                              Overall Response Rate  \n",
       "3826                    Maximum tolerated dose/toxicity  \n",
       "3827  Disease free survival, relapse free survival, ...  \n",
       "3828                                   Overall survival  \n",
       "3829                              Overall Response Rate  \n",
       "3830                              Overall Response Rate  \n",
       "3831                              Overall Response Rate  \n",
       "3832                                      ORR, PFS, DOR  \n",
       "3833                              Overall Response Rate  \n",
       "3834                              Overall Response Rate  \n",
       "3835                              Overall Response Rate  \n",
       "3836                              Overall Response Rate  \n",
       "3837                          Progression free survival  \n",
       "3838                              Overall Response Rate  \n",
       "3839                              Overall Response Rate  \n",
       "3840                    Maximum tolerated dose/toxicity  \n",
       "3841                          Progression free survival  \n",
       "3842                          Progression free survival  \n",
       "3843                                            Unknown  \n",
       "3844                          Progression free survival  \n",
       "3845                                   Overall survival  \n",
       "3846                                   Overall survival  \n",
       "3847                          Progression free survival  \n",
       "3848                          Progression free survival  \n",
       "3849                    Maximum tolerated dose/toxicity  \n",
       "3850                          Progression free survival  \n",
       "3851                    Maximum tolerated dose/toxicity  \n",
       "3852                          Progression free survival  \n",
       "3853                              Overall Response Rate  \n",
       "3854                    Maximum tolerated dose/toxicity  \n",
       "3855                          Progression free survival  \n",
       "3856                                           ORR, EFS  \n",
       "3857                              Overall Response Rate  \n",
       "3858                              Overall Response Rate  \n",
       "3859                    Maximum tolerated dose/toxicity  \n",
       "3860                    Maximum tolerated dose/toxicity  \n",
       "3861                              Overall Response Rate  \n",
       "3862  Disease free survival, relapse free survival, ...  \n",
       "3863                          Progression free survival  \n",
       "3864                    Maximum tolerated dose/toxicity  \n",
       "3994                                   Overall survival  \n",
       "3995                                            Unknown  \n",
       "3996                                            OS, PFS  \n",
       "3997                          Progression free survival  \n",
       "3998                              Overall Response Rate  \n",
       "3999                    Maximum tolerated dose/toxicity  \n",
       "4000                    Maximum tolerated dose/toxicity  \n",
       "4001                    Maximum tolerated dose/toxicity  \n",
       "4002                    Maximum tolerated dose/toxicity  \n",
       "4003                    Maximum tolerated dose/toxicity  \n",
       "4004                    Maximum tolerated dose/toxicity  \n",
       "4005                    Maximum tolerated dose/toxicity  \n",
       "4006                    Maximum tolerated dose/toxicity  \n",
       "4007                    Maximum tolerated dose/toxicity  \n",
       "4008                              Overall Response Rate  \n",
       "4009                                   Overall survival  \n",
       "4010                    Maximum tolerated dose/toxicity  \n",
       "4011                    Maximum tolerated dose/toxicity  \n",
       "4012                                           ORR, DOR  \n",
       "4013                    Maximum tolerated dose/toxicity  \n",
       "4014                              Overall Response Rate  \n",
       "4015                    Maximum tolerated dose/toxicity  \n",
       "4016                    Maximum tolerated dose/toxicity  \n",
       "4017                    Maximum tolerated dose/toxicity  \n",
       "4018                    Maximum tolerated dose/toxicity  \n",
       "4019                              Overall Response Rate  \n",
       "4020                                  Clinical activity  \n",
       "4021                    Maximum tolerated dose/toxicity  \n",
       "4022                    Maximum tolerated dose/toxicity  \n",
       "4023                    Maximum tolerated dose/toxicity  \n",
       "4024                    Maximum tolerated dose/toxicity  \n",
       "4025                    Maximum tolerated dose/toxicity  \n",
       "4026                                      ORR, PFS, DOR  \n",
       "4027                    Maximum tolerated dose/toxicity  \n",
       "4028                    Maximum tolerated dose/toxicity  \n",
       "4029                    Maximum tolerated dose/toxicity  \n",
       "4030                    Maximum tolerated dose/toxicity  \n",
       "4031                    Maximum tolerated dose/toxicity  \n",
       "4032                    Maximum tolerated dose/toxicity  \n",
       "4033                    Maximum tolerated dose/toxicity  \n",
       "4034                    Maximum tolerated dose/toxicity  \n",
       "4035                    Maximum tolerated dose/toxicity  \n",
       "4036                    Maximum tolerated dose/toxicity  \n",
       "4037                    Maximum tolerated dose/toxicity  \n",
       "4038                    Maximum tolerated dose/toxicity  \n",
       "4039                    Maximum tolerated dose/toxicity  \n",
       "4040                    Maximum tolerated dose/toxicity  \n",
       "4041                    Maximum tolerated dose/toxicity  \n",
       "4042                    Maximum tolerated dose/toxicity  \n",
       "4043                    Maximum tolerated dose/toxicity  \n",
       "4044                    Maximum tolerated dose/toxicity  \n",
       "4045                                            Unknown  \n",
       "4046                    Maximum tolerated dose/toxicity  \n",
       "4047                    Maximum tolerated dose/toxicity  \n",
       "4048                              Overall Response Rate  \n",
       "4049                    Maximum tolerated dose/toxicity  \n",
       "4050                    Maximum tolerated dose/toxicity  \n",
       "4051                    Maximum tolerated dose/toxicity  \n",
       "4052                              Overall Response Rate  \n",
       "4053                    Maximum tolerated dose/toxicity  \n",
       "4054                                            Unknown  \n",
       "4055                              Overall Response Rate  \n",
       "4056                              Overall Response Rate  \n",
       "4057                              Overall Response Rate  \n",
       "4058                              Overall Response Rate  \n",
       "4059                              Overall Response Rate  \n",
       "4060                              Overall Response Rate  \n",
       "4061                          Progression free survival  \n",
       "4062                              Overall Response Rate  \n",
       "4063                              Overall Response Rate  \n",
       "4064        Disease control rate, Clinical benefit rate  \n",
       "4065                              Overall Response Rate  \n",
       "4066                              Overall Response Rate  \n",
       "4067  Complete response, Pathological complete response  \n",
       "4068                          Progression free survival  \n",
       "4069                              Overall Response Rate  \n",
       "4070                              Overall Response Rate  \n",
       "4071                              Overall Response Rate  \n",
       "4072                    Maximum tolerated dose/toxicity  \n",
       "4073                              Overall Response Rate  \n",
       "4074                    Maximum tolerated dose/toxicity  \n",
       "4075                    Maximum tolerated dose/toxicity  \n",
       "4076                              Overall Response Rate  \n",
       "4077                              Overall Response Rate  \n",
       "4078                    Maximum tolerated dose/toxicity  \n",
       "4079                          Progression free survival  \n",
       "4080                          Progression free survival  \n",
       "4081                              Overall Response Rate  \n",
       "4082                          Progression free survival  \n",
       "4083                          Progression free survival  \n",
       "4084                    Maximum tolerated dose/toxicity  \n",
       "4085                    Maximum tolerated dose/toxicity  \n",
       "4086                              Overall Response Rate  \n",
       "4087                              Overall Response Rate  \n",
       "4088                              Overall Response Rate  \n",
       "4089                              Overall Response Rate  \n",
       "4090                          Progression free survival  \n",
       "4091                              Overall Response Rate  \n",
       "4092                          Progression free survival  \n",
       "4093                              Overall Response Rate  \n",
       "4094                                            OS, PFS  \n",
       "4095                              Overall Response Rate  \n",
       "4096                              Overall Response Rate  \n",
       "4097                          Progression free survival  \n",
       "4098                              Overall Response Rate  \n",
       "4099                          Progression free survival  \n",
       "4100                          Progression free survival  \n",
       "4101                              Overall Response Rate  \n",
       "4102                         Intracranial Response Rate  \n",
       "4103                              Overall Response Rate  \n",
       "4104                                            OS, PFS  \n",
       "4105                              Overall Response Rate  \n",
       "4106                          Progression free survival  \n",
       "4107                    Maximum tolerated dose/toxicity  \n",
       "4108                    Maximum tolerated dose/toxicity  \n",
       "4109                                      Response rate  \n",
       "4110                              Overall Response Rate  \n",
       "4111                              Overall Response Rate  \n",
       "4112                          Progression free survival  \n",
       "4113                          Progression free survival  \n",
       "4114                          Progression free survival  \n",
       "4115                    Maximum tolerated dose/toxicity  \n",
       "4116                                            OS, PFS  \n",
       "4117                              Overall Response Rate  \n",
       "4118                              Overall Response Rate  \n",
       "4119                    Maximum tolerated dose/toxicity  \n",
       "4120                              Overall Response Rate  \n",
       "4121                          Progression free survival  \n",
       "4122                          Progression free survival  \n",
       "4123                              Overall Response Rate  \n",
       "4124                          Progression free survival  \n",
       "4125                              Overall Response Rate  \n",
       "4126                              Overall Response Rate  \n",
       "4127                                      Response rate  \n",
       "4128                                  Clinical activity  \n",
       "4129                          Progression free survival  \n",
       "4130                          Progression free survival  \n",
       "4131                              Overall Response Rate  \n",
       "4132                          Progression free survival  \n",
       "4133                          Progression free survival  \n",
       "4134                              Overall Response Rate  \n",
       "4135                              Overall Response Rate  \n",
       "4136                              Overall Response Rate  \n",
       "4137                              Overall Response Rate  \n",
       "4138                          Progression free survival  \n",
       "4139                                   Overall survival  \n",
       "4140                              Overall Response Rate  \n",
       "4141                    Maximum tolerated dose/toxicity  \n",
       "4142                          Progression free survival  \n",
       "4143                                            Unknown  \n",
       "4144                              Overall Response Rate  \n",
       "4145                                   Overall survival  \n",
       "4146                                           DCR, ORR  \n",
       "4147                          Progression free survival  \n",
       "4148                                      Response rate  \n",
       "4149                              Overall Response Rate  \n",
       "4150                          Progression free survival  \n",
       "4151                              Best overall response  \n",
       "4152                          Progression free survival  \n",
       "4153                                            Unknown  \n",
       "4154                          Progression free survival  \n",
       "4155                                  Clinical activity  \n",
       "4156                                Time to progression  \n",
       "4157                          Progression free survival  \n",
       "4158                              Overall Response Rate  \n",
       "4159                              Overall Response Rate  \n",
       "4160                              Overall Response Rate  \n",
       "4161                          Progression free survival  \n",
       "4162                          Progression free survival  \n",
       "4163                              Overall Response Rate  \n",
       "4164                          Progression free survival  \n",
       "4165                          Progression free survival  \n",
       "4166                              Overall Response Rate  \n",
       "4167                          Progression free survival  \n",
       "4168                                   Overall survival  \n",
       "4169                              Overall Response Rate  \n",
       "4170                          Progression free survival  \n",
       "4171                              Overall Response Rate  \n",
       "4172                              Overall Response Rate  \n",
       "4173                    Maximum tolerated dose/toxicity  \n",
       "4174                              Overall Response Rate  \n",
       "4175                              Overall Response Rate  \n",
       "4176                          Progression free survival  \n",
       "4177                              Overall Response Rate  \n",
       "4178                          Progression free survival  \n",
       "4179                              Overall Response Rate  \n",
       "4180                                           PFS, ORR  \n",
       "4181                              Overall Response Rate  \n",
       "4182                              Overall Response Rate  \n",
       "4183                              Overall Response Rate  \n",
       "4184                                      Response rate  \n",
       "4185                                Time to progression  \n",
       "4186                          Progression free survival  \n",
       "4187                              Overall Response Rate  \n",
       "4188                                  Clinical activity  \n",
       "4189                          Progression free survival  \n",
       "4190                              Overall Response Rate  \n",
       "4191                    Maximum tolerated dose/toxicity  \n",
       "4192                                        Not defined  \n",
       "4193                          Progression free survival  \n",
       "4194                          Progression free survival  \n",
       "4195                          Progression free survival  \n",
       "4196  Disease free survival, relapse free survival, ...  \n",
       "4197                              Overall Response Rate  \n",
       "4198                                Biomarker discovery  \n",
       "4199                                  Clinical activity  \n",
       "4200                              Overall Response Rate  \n",
       "4201                                            Unknown  \n",
       "4202                          Progression free survival  \n",
       "4203                              Overall Response Rate  \n",
       "4204                          Progression free survival  \n",
       "4205                              Overall Response Rate  \n",
       "4206                              Overall Response Rate  \n",
       "4207                              Overall Response Rate  \n",
       "4208                                      Tumour volume  \n",
       "4209                                      Response rate  \n",
       "4210                                   Overall survival  \n",
       "4211                          Progression free survival  \n",
       "4212                              Overall Response Rate  \n",
       "4213                              Overall Response Rate  \n",
       "4214                                   Overall survival  \n",
       "4215                          Progression free survival  \n",
       "4216                          Progression free survival  \n",
       "4217                          Progression free survival  \n",
       "4218                          Progression free survival  \n",
       "4219                          Progression free survival  \n",
       "4220                          Progression free survival  \n",
       "4221                          Progression free survival  \n",
       "4222  Disease free survival, relapse free survival, ...  \n",
       "4223                          Progression free survival  \n",
       "4224                          Major pathologic response  \n",
       "4225                              Overall Response Rate  \n",
       "4226                          Progression free survival  \n",
       "4227                          Progression free survival  \n",
       "4228                          Progression free survival  \n",
       "4229                          Progression free survival  \n",
       "4230                                            OS, PFS  \n",
       "4231                          Progression free survival  \n",
       "4232                          Progression free survival  \n",
       "4233                          Progression free survival  \n",
       "4234  Disease free survival, relapse free survival, ...  \n",
       "4235                              Overall Response Rate  \n",
       "4236                              Overall Response Rate  \n",
       "4237                          Progression free survival  \n",
       "4238                          Progression free survival  \n",
       "4239                          Progression free survival  \n",
       "4240                          Progression free survival  \n",
       "4241                                   Overall survival  \n",
       "4242                                   Overall survival  \n",
       "4243                                            Unknown  \n",
       "4244                          Progression free survival  \n",
       "4245                          Progression free survival  \n",
       "4246                          Progression free survival  \n",
       "4247                          Progression free survival  \n",
       "4248  Disease free survival, relapse free survival, ...  \n",
       "4249  Disease free survival, relapse free survival, ...  \n",
       "4250                          Progression free survival  \n",
       "4251                          Progression free survival  \n",
       "4252                          Progression free survival  \n",
       "4253  Disease free survival, relapse free survival, ...  \n",
       "4254                          Progression free survival  \n",
       "4255                                   Overall survival  \n",
       "4256                          Progression free survival  \n",
       "4257                          Progression free survival  \n",
       "4258                          Progression free survival  \n",
       "4259                                            OS, PFS  \n",
       "4260  Disease free survival, relapse free survival, ...  \n",
       "4261                          Progression free survival  \n",
       "4262                          Progression free survival  \n",
       "4263                          Progression free survival  \n",
       "4264                          Progression free survival  \n",
       "4265                          Progression free survival  \n",
       "4266                                Biomarker discovery  \n",
       "4323                          Progression free survival  \n",
       "4327                          Progression free survival  \n",
       "4328                    Maximum tolerated dose/toxicity  \n",
       "4329                    Maximum tolerated dose/toxicity  \n",
       "4330                              Overall Response Rate  \n",
       "4331                          Progression free survival  \n",
       "4332                              Overall Response Rate  \n",
       "4333                                                NaN  \n",
       "4334                          Progression free survival  \n",
       "4335                              Overall Response Rate  \n",
       "4336                              Overall Response Rate  \n",
       "4337                              Overall Response Rate  \n",
       "4338                                   Overall survival  \n",
       "4339                          Progression free survival  \n",
       "4340                          Progression free survival  \n",
       "4342                                           ORR, DOR  \n",
       "4343                          Progression free survival  \n",
       "4344                              Overall Response Rate  \n",
       "4346                    Maximum tolerated dose/toxicity  \n",
       "4347                    Maximum tolerated dose/toxicity  \n",
       "4348                              Overall Response Rate  \n",
       "4349                    Maximum tolerated dose/toxicity  \n",
       "4350                              Overall Response Rate  \n",
       "6176                    Maximum tolerated dose/toxicity  \n",
       "6177                    Maximum tolerated dose/toxicity  \n",
       "6178                              Overall Response Rate  \n",
       "6179                              Overall Response Rate  \n",
       "6180                          Progression free survival  \n",
       "6181                                            Unknown  \n",
       "6182                    Maximum tolerated dose/toxicity  \n",
       "6183                          Progression free survival  \n",
       "6184                                      Tumour volume  \n",
       "6185                          Progression free survival  \n",
       "6186                                      Response rate  \n",
       "6187                                            Unknown  \n",
       "6188        Disease control rate, Clinical benefit rate  \n",
       "6189                                   Overall survival  \n",
       "6229                              Overall Response Rate  \n",
       "6230                              Overall Response Rate  \n",
       "6231                              Overall Response Rate  \n",
       "6232                          Progression free survival  \n",
       "6233                              Overall Response Rate  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Parse Actionability Data file\n",
    "data = pd.read_csv('/Users/Kaitlyn/Desktop/ActionabilityData.tsv', sep='\\t', index_col=False, dtype='unicode') #read input file\n",
    "\n",
    "#Parsing data within the dataframe based on search terms\n",
    "#including \"and logic\" as per HW9 review comments\n",
    "df = data[(data['GENE'].isin(['EGFR', 'FGFR1','ErbB-1'])) & (data['DISEASE'] == 'lung / carcinoma / non small cell carcinoma')]\n",
    "\n",
    "#Include desired columns\n",
    "df = df[['GENE', 'MUTATION_REMARK', 'DISEASE', 'ACTIONABILITY_RANK', 'DRUG_COMBINATION', 'SOURCE', 'PRIMARY_OUTCOME_MEASURE']]\n",
    "df.to_csv(\"/Users/Kaitlyn/Desktop/DataOutput1.csv\", sep='\\t',encoding='utf-8') #write parsed data to csv output file\n",
    "\n",
    "with pd.option_context('display.max_rows', None, 'display.max_columns', None, 'display.precision', 3): #set parameters for dataframe to show all rows\n",
    "    display(df) #display all rows of dataframe"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9ad8f1a3",
   "metadata": {},
   "source": [
    "### 3.\tCreate a scatterplot based on the GENE & MUTATION_REMARK.  2 points"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "84b4b873",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:xlabel='GENE', ylabel='MUTATION_REMARK'>"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Scatter plot for gene and Mutation remark\n",
    "df.plot.scatter(x = 'GENE', y = 'MUTATION_REMARK') \n",
    "#prints scatter plot with MUTATION_REMARK on y axis and GENE on x axis for easier viewing of labels\n",
    "#No hits for ErbB-1 search came up, only showing EGFR and FGFR1"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a2f59d35",
   "metadata": {},
   "source": [
    "### 4.\tCreate a scatterplot based on the ACTIONABILITY_RANK of '1' where the DRUG_COMBINATION and PRIMARY_OUTCOME are visualized. The plot includes only the following  PRIMARY_OUTCOME measures 2 points:\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;$ 1.\tProgression free survival.\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;$ 2.\tDisease free survival.\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;$ 3.\tOverall survival."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "1c5d8c25",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ACTIONABILITY_RANK</th>\n",
       "      <th>DRUG_COMBINATION</th>\n",
       "      <th>PRIMARY_OUTCOME_MEASURE</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3505</th>\n",
       "      <td>1</td>\n",
       "      <td>Afatinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3506</th>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib + Ramucirumab</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3507</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3508</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3509</th>\n",
       "      <td>1</td>\n",
       "      <td>Dacomitinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3510</th>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3513</th>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3514</th>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3524</th>\n",
       "      <td>1</td>\n",
       "      <td>Camrelizumab + Carboplatin + Pemetrexed</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3547</th>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib + Bevacizumab + Carboplatin + Pemet...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3548</th>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib + Carboplatin + Pemetrexed</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3549</th>\n",
       "      <td>1</td>\n",
       "      <td>Lazertinib + Stereotactic Body Radiation Therapy</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3558</th>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Carboplatin + Lazertinib + Pemet...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3561</th>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3565</th>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib + Microwave ablation</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3566</th>\n",
       "      <td>1</td>\n",
       "      <td>Lenvatinib + Pembrolizumab</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3567</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Pemetrexed + Platinum-based chem...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3570</th>\n",
       "      <td>1</td>\n",
       "      <td>Ascorbic acid + Tyrosine Kinase Inhibitor</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3571</th>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Gefitinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3574</th>\n",
       "      <td>1</td>\n",
       "      <td>Chemotherapy + Icotinib</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3575</th>\n",
       "      <td>1</td>\n",
       "      <td>Cisplatin + Icotinib + Pemetrexed</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3577</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Stereotactic radiotherapy</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3578</th>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Icotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3579</th>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Tyrosine Kinase Inhibitor</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3580</th>\n",
       "      <td>1</td>\n",
       "      <td>Carboplatin + Icotinib + Pemetrexed</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3582</th>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Carboplatin + Pemetrexed</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3584</th>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Gefitinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3585</th>\n",
       "      <td>1</td>\n",
       "      <td>Local Consolidation Therapy + Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3587</th>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Thalidomide</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3590</th>\n",
       "      <td>1</td>\n",
       "      <td>Cisplatin + Pemetrexed</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3591</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Ramucirumab</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3593</th>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3594</th>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3598</th>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3600</th>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Nazartinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3606</th>\n",
       "      <td>1</td>\n",
       "      <td>Berberine + Gefitinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3607</th>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Erlotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3608</th>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Erlotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3609</th>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Tegafur-gimeracil-oteracil potassium</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3615</th>\n",
       "      <td>1</td>\n",
       "      <td>Lazertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3625</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3627</th>\n",
       "      <td>1</td>\n",
       "      <td>Dacomitinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3628</th>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3636</th>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3637</th>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Carboplatin + Pemetrexed</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3638</th>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Carboplatin + Lazertinib + Pemet...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3639</th>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib + Chemotherapy</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3640</th>\n",
       "      <td>1</td>\n",
       "      <td>EGFR-TKI + JY025</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3641</th>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib or Erlotinib + Niacinamaide</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3642</th>\n",
       "      <td>1</td>\n",
       "      <td>Lazertinib + Placebo</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3643</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib + Placebo</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3645</th>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Lazertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3646</th>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib + Carboplatin + Pemetrexed</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3647</th>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib + Carboplatin + Pemetrexed</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3648</th>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib + Stereotactic radiotherapy</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3649</th>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Gefitinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3650</th>\n",
       "      <td>1</td>\n",
       "      <td>Chemotherapy + Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3651</th>\n",
       "      <td>1</td>\n",
       "      <td>Patritumab deruxtecan</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3652</th>\n",
       "      <td>1</td>\n",
       "      <td>Chemotherapy + Erlotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3653</th>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Yiqi-yangyin-jiedu Decoction</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3654</th>\n",
       "      <td>1</td>\n",
       "      <td>Apatinib + Gefitinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3655</th>\n",
       "      <td>1</td>\n",
       "      <td>Naquotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3657</th>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3658</th>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3659</th>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3660</th>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3661</th>\n",
       "      <td>1</td>\n",
       "      <td>Zorifertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3662</th>\n",
       "      <td>1</td>\n",
       "      <td>Abivertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3663</th>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Erlotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3664</th>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Erlotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3666</th>\n",
       "      <td>1</td>\n",
       "      <td>Cisplatin + Gefitinib + Pemetrexed</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3667</th>\n",
       "      <td>1</td>\n",
       "      <td>Cisplatin + Gefitinib + Pemetrexed</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3669</th>\n",
       "      <td>1</td>\n",
       "      <td>Nazartinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3670</th>\n",
       "      <td>1</td>\n",
       "      <td>Tesevatinib</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3671</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3673</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3674</th>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3675</th>\n",
       "      <td>1</td>\n",
       "      <td>Icotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3676</th>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3677</th>\n",
       "      <td>1</td>\n",
       "      <td>Erlotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3679</th>\n",
       "      <td>1</td>\n",
       "      <td>Apatinib + Erlotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3680</th>\n",
       "      <td>1</td>\n",
       "      <td>Apatinib + Icotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3681</th>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Gefitinib + Icotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3682</th>\n",
       "      <td>1</td>\n",
       "      <td>Gefitinib + Radiotherapy</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3707</th>\n",
       "      <td>1</td>\n",
       "      <td>Poziotinib + Ramucirumab</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3716</th>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Sintilimab</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3729</th>\n",
       "      <td>1</td>\n",
       "      <td>Poziotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3730</th>\n",
       "      <td>1</td>\n",
       "      <td>Amivantamab + Carboplatin + Pemetrexed</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3731</th>\n",
       "      <td>1</td>\n",
       "      <td>Pyrotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3732</th>\n",
       "      <td>1</td>\n",
       "      <td>DZD9008</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3733</th>\n",
       "      <td>1</td>\n",
       "      <td>Mobocertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3735</th>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3737</th>\n",
       "      <td>1</td>\n",
       "      <td>DZD9008</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3767</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3782</th>\n",
       "      <td>1</td>\n",
       "      <td>Nazartinib + Nivolumab</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3792</th>\n",
       "      <td>1</td>\n",
       "      <td>Carboplatin + Pemetrexed + Sulfatinib + Toripa...</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3793</th>\n",
       "      <td>1</td>\n",
       "      <td>Alflutinib + Radiotherapy</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3794</th>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib + Carboplatin + Pemetrexed</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3795</th>\n",
       "      <td>1</td>\n",
       "      <td>Anlotinib + Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3799</th>\n",
       "      <td>1</td>\n",
       "      <td>Interleukin-2 + WT1-sensitized allogenic T cells</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3800</th>\n",
       "      <td>1</td>\n",
       "      <td>Local Consolidation Therapy + Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3803</th>\n",
       "      <td>1</td>\n",
       "      <td>Emibetuzumab + Erlotinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3809</th>\n",
       "      <td>1</td>\n",
       "      <td>Aspirin + Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3810</th>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3811</th>\n",
       "      <td>1</td>\n",
       "      <td>Bevacizumab + Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3827</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Disease free survival, relapse free survival, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3828</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3837</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3841</th>\n",
       "      <td>1</td>\n",
       "      <td>Rociletinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3842</th>\n",
       "      <td>1</td>\n",
       "      <td>Almonertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3844</th>\n",
       "      <td>1</td>\n",
       "      <td>Olmutinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3845</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3846</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Overall survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3847</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3848</th>\n",
       "      <td>1</td>\n",
       "      <td>Osimertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3850</th>\n",
       "      <td>1</td>\n",
       "      <td>Lazertinib</td>\n",
       "      <td>Progression free survival</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     ACTIONABILITY_RANK                                   DRUG_COMBINATION  \\\n",
       "3505                  1                                           Afatinib   \n",
       "3506                  1                            Erlotinib + Ramucirumab   \n",
       "3507                  1                                        Osimertinib   \n",
       "3508                  1                                        Osimertinib   \n",
       "3509                  1                                        Dacomitinib   \n",
       "3510                  1                                          Gefitinib   \n",
       "3513                  1                                          Erlotinib   \n",
       "3514                  1                                          Erlotinib   \n",
       "3524                  1            Camrelizumab + Carboplatin + Pemetrexed   \n",
       "3547                  1  Alflutinib + Bevacizumab + Carboplatin + Pemet...   \n",
       "3548                  1              Alflutinib + Carboplatin + Pemetrexed   \n",
       "3549                  1   Lazertinib + Stereotactic Body Radiation Therapy   \n",
       "3558                  1  Amivantamab + Carboplatin + Lazertinib + Pemet...   \n",
       "3561                  1                                       Almonertinib   \n",
       "3565                  1                  Almonertinib + Microwave ablation   \n",
       "3566                  1                         Lenvatinib + Pembrolizumab   \n",
       "3567                  1  Osimertinib + Pemetrexed + Platinum-based chem...   \n",
       "3570                  1          Ascorbic acid + Tyrosine Kinase Inhibitor   \n",
       "3571                  1                              Anlotinib + Gefitinib   \n",
       "3574                  1                            Chemotherapy + Icotinib   \n",
       "3575                  1                  Cisplatin + Icotinib + Pemetrexed   \n",
       "3577                  1            Osimertinib + Stereotactic radiotherapy   \n",
       "3578                  1                               Anlotinib + Icotinib   \n",
       "3579                  1              Anlotinib + Tyrosine Kinase Inhibitor   \n",
       "3580                  1                Carboplatin + Icotinib + Pemetrexed   \n",
       "3582                  1               Anlotinib + Carboplatin + Pemetrexed   \n",
       "3584                  1                            Bevacizumab + Gefitinib   \n",
       "3585                  1          Local Consolidation Therapy + Osimertinib   \n",
       "3587                  1                            Gefitinib + Thalidomide   \n",
       "3590                  1                             Cisplatin + Pemetrexed   \n",
       "3591                  1                          Osimertinib + Ramucirumab   \n",
       "3593                  1                                         Alflutinib   \n",
       "3594                  1                                         Alflutinib   \n",
       "3598                  1                                         Alflutinib   \n",
       "3600                  1                             Gefitinib + Nazartinib   \n",
       "3606                  1                              Berberine + Gefitinib   \n",
       "3607                  1                            Bevacizumab + Erlotinib   \n",
       "3608                  1                            Bevacizumab + Erlotinib   \n",
       "3609                  1   Gefitinib + Tegafur-gimeracil-oteracil potassium   \n",
       "3615                  1                                         Lazertinib   \n",
       "3625                  1                                        Osimertinib   \n",
       "3627                  1                                        Dacomitinib   \n",
       "3628                  1                                           Icotinib   \n",
       "3636                  1                                          Erlotinib   \n",
       "3637                  1             Amivantamab + Carboplatin + Pemetrexed   \n",
       "3638                  1  Amivantamab + Carboplatin + Lazertinib + Pemet...   \n",
       "3639                  1                        Almonertinib + Chemotherapy   \n",
       "3640                  1                                   EGFR-TKI + JY025   \n",
       "3641                  1              Gefitinib or Erlotinib + Niacinamaide   \n",
       "3642                  1                               Lazertinib + Placebo   \n",
       "3643                  1                              Osimertinib + Placebo   \n",
       "3645                  1                           Amivantamab + Lazertinib   \n",
       "3646                  1            Almonertinib + Carboplatin + Pemetrexed   \n",
       "3647                  1            Almonertinib + Carboplatin + Pemetrexed   \n",
       "3648                  1               Icotinib + Stereotactic radiotherapy   \n",
       "3649                  1                              Anlotinib + Gefitinib   \n",
       "3650                  1                         Chemotherapy + Osimertinib   \n",
       "3651                  1                              Patritumab deruxtecan   \n",
       "3652                  1                           Chemotherapy + Erlotinib   \n",
       "3653                  1           Gefitinib + Yiqi-yangyin-jiedu Decoction   \n",
       "3654                  1                               Apatinib + Gefitinib   \n",
       "3655                  1                                         Naquotinib   \n",
       "3657                  1                                       Almonertinib   \n",
       "3658                  1                                       Almonertinib   \n",
       "3659                  1                                         Alflutinib   \n",
       "3660                  1                                         Alflutinib   \n",
       "3661                  1                                       Zorifertinib   \n",
       "3662                  1                                        Abivertinib   \n",
       "3663                  1                            Bevacizumab + Erlotinib   \n",
       "3664                  1                            Bevacizumab + Erlotinib   \n",
       "3666                  1                 Cisplatin + Gefitinib + Pemetrexed   \n",
       "3667                  1                 Cisplatin + Gefitinib + Pemetrexed   \n",
       "3669                  1                                         Nazartinib   \n",
       "3670                  1                                        Tesevatinib   \n",
       "3671                  1                                        Osimertinib   \n",
       "3673                  1                                        Osimertinib   \n",
       "3674                  1                                           Icotinib   \n",
       "3675                  1                                           Icotinib   \n",
       "3676                  1                                          Gefitinib   \n",
       "3677                  1                                          Erlotinib   \n",
       "3679                  1                               Apatinib + Erlotinib   \n",
       "3680                  1                                Apatinib + Icotinib   \n",
       "3681                  1                   Anlotinib + Gefitinib + Icotinib   \n",
       "3682                  1                           Gefitinib + Radiotherapy   \n",
       "3707                  1                           Poziotinib + Ramucirumab   \n",
       "3716                  1                             Anlotinib + Sintilimab   \n",
       "3729                  1                                         Poziotinib   \n",
       "3730                  1             Amivantamab + Carboplatin + Pemetrexed   \n",
       "3731                  1                                          Pyrotinib   \n",
       "3732                  1                                            DZD9008   \n",
       "3733                  1                                       Mobocertinib   \n",
       "3735                  1                                         Alflutinib   \n",
       "3737                  1                                            DZD9008   \n",
       "3767                  1                                        Osimertinib   \n",
       "3782                  1                             Nazartinib + Nivolumab   \n",
       "3792                  1  Carboplatin + Pemetrexed + Sulfatinib + Toripa...   \n",
       "3793                  1                          Alflutinib + Radiotherapy   \n",
       "3794                  1            Almonertinib + Carboplatin + Pemetrexed   \n",
       "3795                  1                            Anlotinib + Osimertinib   \n",
       "3799                  1   Interleukin-2 + WT1-sensitized allogenic T cells   \n",
       "3800                  1          Local Consolidation Therapy + Osimertinib   \n",
       "3803                  1                           Emibetuzumab + Erlotinib   \n",
       "3809                  1                              Aspirin + Osimertinib   \n",
       "3810                  1                          Bevacizumab + Osimertinib   \n",
       "3811                  1                          Bevacizumab + Osimertinib   \n",
       "3827                  1                                        Osimertinib   \n",
       "3828                  1                                        Osimertinib   \n",
       "3837                  1                                        Osimertinib   \n",
       "3841                  1                                        Rociletinib   \n",
       "3842                  1                                       Almonertinib   \n",
       "3844                  1                                          Olmutinib   \n",
       "3845                  1                                        Osimertinib   \n",
       "3846                  1                                        Osimertinib   \n",
       "3847                  1                                        Osimertinib   \n",
       "3848                  1                                        Osimertinib   \n",
       "3850                  1                                         Lazertinib   \n",
       "\n",
       "                                PRIMARY_OUTCOME_MEASURE  \n",
       "3505                          Progression free survival  \n",
       "3506                          Progression free survival  \n",
       "3507  Disease free survival, relapse free survival, ...  \n",
       "3508                          Progression free survival  \n",
       "3509                          Progression free survival  \n",
       "3510                          Progression free survival  \n",
       "3513                          Progression free survival  \n",
       "3514                          Progression free survival  \n",
       "3524                          Progression free survival  \n",
       "3547                          Progression free survival  \n",
       "3548                          Progression free survival  \n",
       "3549                          Progression free survival  \n",
       "3558                          Progression free survival  \n",
       "3561  Disease free survival, relapse free survival, ...  \n",
       "3565                          Progression free survival  \n",
       "3566                          Progression free survival  \n",
       "3567                          Progression free survival  \n",
       "3570                          Progression free survival  \n",
       "3571                          Progression free survival  \n",
       "3574  Disease free survival, relapse free survival, ...  \n",
       "3575                          Progression free survival  \n",
       "3577                          Progression free survival  \n",
       "3578                          Progression free survival  \n",
       "3579                          Progression free survival  \n",
       "3580                          Progression free survival  \n",
       "3582                          Progression free survival  \n",
       "3584                          Progression free survival  \n",
       "3585                          Progression free survival  \n",
       "3587                          Progression free survival  \n",
       "3590                          Progression free survival  \n",
       "3591                          Progression free survival  \n",
       "3593                          Progression free survival  \n",
       "3594  Disease free survival, relapse free survival, ...  \n",
       "3598                          Progression free survival  \n",
       "3600                          Progression free survival  \n",
       "3606                          Progression free survival  \n",
       "3607                          Progression free survival  \n",
       "3608                          Progression free survival  \n",
       "3609                          Progression free survival  \n",
       "3615                          Progression free survival  \n",
       "3625                          Progression free survival  \n",
       "3627                          Progression free survival  \n",
       "3628  Disease free survival, relapse free survival, ...  \n",
       "3636                          Progression free survival  \n",
       "3637                          Progression free survival  \n",
       "3638                          Progression free survival  \n",
       "3639                          Progression free survival  \n",
       "3640                          Progression free survival  \n",
       "3641                          Progression free survival  \n",
       "3642                          Progression free survival  \n",
       "3643                          Progression free survival  \n",
       "3645                          Progression free survival  \n",
       "3646                          Progression free survival  \n",
       "3647                          Progression free survival  \n",
       "3648                                   Overall survival  \n",
       "3649                          Progression free survival  \n",
       "3650                          Progression free survival  \n",
       "3651                          Progression free survival  \n",
       "3652                          Progression free survival  \n",
       "3653                          Progression free survival  \n",
       "3654                          Progression free survival  \n",
       "3655                          Progression free survival  \n",
       "3657                          Progression free survival  \n",
       "3658                          Progression free survival  \n",
       "3659                          Progression free survival  \n",
       "3660                          Progression free survival  \n",
       "3661                          Progression free survival  \n",
       "3662                          Progression free survival  \n",
       "3663                          Progression free survival  \n",
       "3664                          Progression free survival  \n",
       "3666  Disease free survival, relapse free survival, ...  \n",
       "3667  Disease free survival, relapse free survival, ...  \n",
       "3669                          Progression free survival  \n",
       "3670                                   Overall survival  \n",
       "3671  Disease free survival, relapse free survival, ...  \n",
       "3673                          Progression free survival  \n",
       "3674  Disease free survival, relapse free survival, ...  \n",
       "3675                          Progression free survival  \n",
       "3676  Disease free survival, relapse free survival, ...  \n",
       "3677                          Progression free survival  \n",
       "3679                          Progression free survival  \n",
       "3680                          Progression free survival  \n",
       "3681                          Progression free survival  \n",
       "3682  Disease free survival, relapse free survival, ...  \n",
       "3707                          Progression free survival  \n",
       "3716                          Progression free survival  \n",
       "3729                          Progression free survival  \n",
       "3730                          Progression free survival  \n",
       "3731                          Progression free survival  \n",
       "3732                          Progression free survival  \n",
       "3733                          Progression free survival  \n",
       "3735                          Progression free survival  \n",
       "3737                          Progression free survival  \n",
       "3767                          Progression free survival  \n",
       "3782                          Progression free survival  \n",
       "3792                          Progression free survival  \n",
       "3793                          Progression free survival  \n",
       "3794                          Progression free survival  \n",
       "3795                          Progression free survival  \n",
       "3799                          Progression free survival  \n",
       "3800                          Progression free survival  \n",
       "3803                          Progression free survival  \n",
       "3809                          Progression free survival  \n",
       "3810                          Progression free survival  \n",
       "3811                          Progression free survival  \n",
       "3827  Disease free survival, relapse free survival, ...  \n",
       "3828                                   Overall survival  \n",
       "3837                          Progression free survival  \n",
       "3841                          Progression free survival  \n",
       "3842                          Progression free survival  \n",
       "3844                          Progression free survival  \n",
       "3845                                   Overall survival  \n",
       "3846                                   Overall survival  \n",
       "3847                          Progression free survival  \n",
       "3848                          Progression free survival  \n",
       "3850                          Progression free survival  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#use original actionability file for re-parsing considering parameters above\n",
    "data = pd.read_csv('/Users/Kaitlyn/Desktop/ActionabilityData.tsv', sep='\\t', index_col=False, dtype='unicode') \n",
    "\n",
    "#include new parameters with old parameters when parsing\n",
    "#Disease free survival never occurs alone. Had to include full outcome measure in parsing and plotting here.\n",
    "#changed to use \"and logic\" here like in parsing for data above after recieving hw9 feedback.\n",
    "df2 = data[(data['GENE'].isin(['ErbB-1','EGFR', 'FGFR1'])) & (data['DISEASE'] == 'lung / carcinoma / non small cell carcinoma')& data['ACTIONABILITY_RANK'].isin(['1']) & data['PRIMARY_OUTCOME_MEASURE'].isin(['Progression free survival','Disease free survival, relapse free survival, regression free survival, recurrence free survival', 'Overall survival'])]\n",
    "\n",
    "#Include desired columns, limited here for easy reference\n",
    "df2 = df2[['ACTIONABILITY_RANK', 'DRUG_COMBINATION', 'PRIMARY_OUTCOME_MEASURE']]\n",
    "df2.to_csv(\"/Users/Kaitlyn/Desktop/DataOutput2.csv\", sep='\\t',encoding='utf-8')\n",
    "\n",
    "\n",
    "with pd.option_context('display.max_rows', None, 'display.max_columns', None, 'display.precision', 3): #set parameters for dataframe to show all rows\n",
    "    display(df2) #display all rows of dataframe"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "0b803f39",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:xlabel='PRIMARY_OUTCOME_MEASURE', ylabel='DRUG_COMBINATION'>"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Make the scatter plot of primary outcome vs drug combo, disease free survival includes other names, never occurs alone.\n",
    "df2= pd.read_csv('/Users/Kaitlyn/Desktop/DataOutput2.csv', sep= '\\t', engine= 'python')\n",
    "df2.plot.scatter(x = 'PRIMARY_OUTCOME_MEASURE', y = 'DRUG_COMBINATION') "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "782d619a",
   "metadata": {},
   "source": [
    "# Part IV: Write up. 5 points\n",
    "### •\tReturn as a jupyter notebook.\n",
    "### •\tExplain the reasoning behind each analysis. Why would you run an MSA on a group of proteins that are targets for non small cell carcinoma? Add it as markup to the jupyter notebook. \n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;$ Answer: The MSA between these proteins that are targets for non small cell carcinoma is to identify any sequence similarity between genes or proteins that may contribute to this disease. If there are highly conserved regions between multiple sequences, this may suggest that a particular functional property is shared between these proteins which is relevant to the disease. This could be significant for understanding the disease's function and pathway. From this multiple sequence alignment, we can see that many of our proteins do not have sequence similarity (no matches denoted by only '-' or a zero in the right-most column). However, we do have several alignments between 24-50 amino acid residues conserved. For example, NP_001402802.1, NP_001402801.1, NP_001402800.1, and NP_006258.3 all have the same 34 amino acid residues conserved, which suggests similarity in function between these four proteins. While this is not the only alignment we see in our output, it is the first example of a conserved region between sequences and can give us a better understanding of the protein's association with the disease. "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9b665ae7",
   "metadata": {},
   "source": [
    "\n",
    "### •\tIn your own words, what's the reasoning by running the uniprot analysis.\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;$ Answer: The UniProt analysis was run so that we can see, along with our proteins of interest, a list of proteins associated with our POIs. These associated proteins include chimeric or fusion proteins with our POIs. Also included are feedback inhibitor proteins which may perform regulatory or inhibitory functions to the target genes and could be significant in understanding the disease pathway. Included in this list is their sequence lengths. Using the sequence lengths of the fasta seqs, we can observe a histogram comparing these lengths between search results. This comparison of sequence lengths can give us a look at the diversity in associated proteins, finding outliers in the group, and determining better characterization of the genes associated with the disease.\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "fa7f935d",
   "metadata": {},
   "source": [
    "\n",
    "### •\tWhat will the COSMIC ACTIONABILITY file analysis tell us? What's the purpose behind the analysis.\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;$ Answer: It seems that the COSMIC Actionability file comes from the COSMIC database (Catalogue of Somatic Mutations in Cancer), which provides us information about our search terms including drug treatment, associated diseases, mutations, etc. The analysis we were able to run from this data set in our first scatter plot shows us the relationship between genes matching our search terms and their associated mutations. Then when we look at the second scatter plot, we see the effect of the drug treatments has on the mutated genes. As all of the results in this search are associated with the same disease, it can give us a better understanding of how certain mutated genes react to drug treatment, which can highlight areas of interest within the wild type sequences.  \n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "23d05bd3",
   "metadata": {},
   "source": [
    "\n",
    "### •\tProvide a summary.\n",
    "### $\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;\\;$ Summary: In this assignment, we looked at the genes ErbB-1, EGFR, and FGFR1 in association with our disease of interest, lung/carcinoma/non small cell carcinoma. Through our initial search, we were able to find 580 relevant proteins and compared their sequences through a multiple sequence alignment. Through futher analysis of the conserved regions in our MSA, as discussed above, we can better understand the function of these regions in the sequence, and how these proteins are related to eachother and to the disease. Using the UniProt analysis, we are able to compare the sequence lengths using similar search parameters as part 1, and compared the lengths between the fasta sequences obtained. We then parsed through the provided Actionability file using a more narrow set of search parameters. This allowed us to look more directly at the theraputic relationship between drug treatment, gene mutation, and outcome of treatment related to the same disease. \n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d87c67c5",
   "metadata": {},
   "source": [
    "\n",
    "### •\tReferences are easily obtained by running a pubmed search. Limit the return info to 20 references.\n",
    "### •\tLoad them into the references as a dataframe.\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "ba4e6af6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PubMed Reference</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PMID- 35870050 OWN - NLM STAT- MEDLINE DCOM- ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>PMID- 30201491 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>PMID- 30123084 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>PMID- 28630215 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>PMID- 23329143 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>PMID- 20422052 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>PMID- 18665077 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>PMID- 17363592 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>PMID- 17200012 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>PMID- 16452204 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>PMID- 12660168 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>PMID- 11445008 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>PMID- 10572038 OWN - NLM STAT- MEDLINE DCOM- 2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>PMID- 9883842 OWN - NLM STAT- MEDLINE DCOM- 19...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>PMID- 9523234 OWN - NLM STAT- MEDLINE DCOM- 19...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>PMID- 9491372 OWN - NLM STAT- MEDLINE DCOM- 19...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>PMID- 9211733 OWN - NLM STAT- MEDLINE DCOM- 19...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>PMID- 8950485 OWN - NLM STAT- MEDLINE DCOM- 19...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>PMID- 8881516 OWN - NLM STAT- MEDLINE DCOM- 19...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>PMID- 1379591 OWN - NLM STAT- MEDLINE DCOM- 19...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     PubMed Reference\n",
       "0    PMID- 35870050 OWN - NLM STAT- MEDLINE DCOM- ...\n",
       "1   PMID- 30201491 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "2   PMID- 30123084 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "3   PMID- 28630215 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "4   PMID- 23329143 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "5   PMID- 20422052 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "6   PMID- 18665077 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "7   PMID- 17363592 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "8   PMID- 17200012 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "9   PMID- 16452204 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "10  PMID- 12660168 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "11  PMID- 11445008 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "12  PMID- 10572038 OWN - NLM STAT- MEDLINE DCOM- 2...\n",
       "13  PMID- 9883842 OWN - NLM STAT- MEDLINE DCOM- 19...\n",
       "14  PMID- 9523234 OWN - NLM STAT- MEDLINE DCOM- 19...\n",
       "15  PMID- 9491372 OWN - NLM STAT- MEDLINE DCOM- 19...\n",
       "16  PMID- 9211733 OWN - NLM STAT- MEDLINE DCOM- 19...\n",
       "17  PMID- 8950485 OWN - NLM STAT- MEDLINE DCOM- 19...\n",
       "18  PMID- 8881516 OWN - NLM STAT- MEDLINE DCOM- 19...\n",
       "19  PMID- 1379591 OWN - NLM STAT- MEDLINE DCOM- 19..."
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from Bio import Entrez \n",
    "import pandas as pd\n",
    "from io import StringIO\n",
    "\n",
    "def Pubmed_search(query, retmax=20):  #function for esearch and efetch, query term set below.   \n",
    "    Entrez.email = \"knt2039@nyu.edu\" #start Entrez session using biopython\n",
    "    \n",
    "    search = Entrez.esearch(db=\"pubmed\", term=query, retmax=20) #use esearch, parameters set so searches pubmed database for search terms, maximum output of 20 IDs\n",
    "    record = Entrez.read(search) #read the search \n",
    "    IDList = record['IdList'] #create ID list from search\n",
    "    \n",
    "    fetch = Entrez.efetch(db='pubmed', id=IDList, rettype='medline', retmode='text') #fetch based on IDList\n",
    "    records = fetch.read() #read the fetch\n",
    "    fetch.close()\n",
    "    \n",
    "    return records\n",
    "\n",
    "query = \"HUMAN[ORGN]ErbB-1\" and \"HUMAN[ORGN]EGFR\" and \"HUMAN[ORGN]FGFR1\" #set search term\n",
    "\n",
    "Pubmed = Pubmed_search(query, retmax=20) #rename function so it prints out all 20 sources\n",
    "#print(References)\n",
    "\n",
    "\n",
    "References = Pubmed.split('\\n\\n') #split at newlines\n",
    "df = pd.DataFrame(References, columns=[\"PubMed Reference\"])#printed out a dataframe filled with a bunch of '\\n'\n",
    "\n",
    "df[\"PubMed Reference\"] = df[\"PubMed Reference\"].str.replace('\\n', ' ') #replace newlines with space\n",
    "df \n",
    "#0-19 rows gives 20 PubMed sources"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
